













This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
 
This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
When referring to this work, full bibliographic details including the author, title, 
awarding institution and date of the thesis must be given. 
 
 
An investigation into pathogenic 
mechanisms leading to neuro-glial-vascular 
damage and cognitive decline in a mouse 









Joshua Beverley MSc BSc (Hons) 
Doctor of Philosophy 
2020 
 iii 
Table of Contents 
Declaration ........................................................................................................................ xi 
Acknowledgements ............................................................................................................. 2 
Abstract ............................................................................................................................... 3 
Lay Summary ..................................................................................................................... 5 
List of Figures .................................................................................................................... 7 
List of Tables .................................................................................................................... 10 
List of Abbreviations ........................................................................................................ 11 
Chapter 1 .......................................................................................................................... 13 
Introduction ........................................................................................................ 13 
1.1 Overview ................................................................................................................ 13 
1.2 The cerebral blood supply ..................................................................................... 15 
1.3 Cerebrovascular control mechanisms ................................................................... 18 
1.3.1 Cerebrovascular autoregulation ....................................................................... 19 
1.3.2 Neurovascular coupling .................................................................................... 19 
1.3.3 Cerebrovascular pulsation ................................................................................ 20 
1.4 Vascular cognitive impairment .............................................................................. 21 
1.5 Cerebrovascular disease ........................................................................................ 21 
1.5.1 Large vessel disease .......................................................................................... 24 
1.5.2 Small vessel disease .......................................................................................... 24 
1.5.3 Neuroimaging features of cerebrovascular disease ......................................... 25 
1.5.4 Cerebrovascular disease pathology .................................................................. 25 
1.6 Vascular risk factors and underlying cerebrovascular causes of VCI ..................... 26 
1.7 Chronic cerebral hypoperfusion as a key mechanism leading to white matter 
damage and cognitive impairment ......................................................................................... 27 
1.7.1 Carotid artery stenosis: A leading cause of chronic cerebral hypoperfusion ... 28 
1.8 Experimental models to study VCI......................................................................... 28 
1.8.1 Bilateral common carotid artery stenosis ......................................................... 29 
1.8.2 BCAS mediated neuropathological changes ..................................................... 30 
1.8.3 BCAS mediated cognitive impairments ............................................................ 31 
1.8.4 The interplay between BCAS and comorbidities .............................................. 32 
1.8.5 BCAS coupled to amyloidosis ............................................................................ 32 
 iv 
1.9 Potential pathophysiological mechanisms underlying white matter damage and 
cognitive impairment ............................................................................................................... 33 
1.9.1 Neuroinflammation ........................................................................................... 33 
1.9.2 Genetic models and intravital imaging aid microglial research ......................... 33 
1.9.3 Microglia under normal homeostatic conditions .............................................. 34 
1.9.4 Microglial structural and functional alterations under pathological conditions
 ………………………………………………………………………………………………………………………37 
1.9.5 Evidence for microglial involvement in human VCI and other chronic 
degenerative diseases ......................................................................................................... 39 
1.9.6 BCAS models: The contribution of microglia to white matter disease and 
cognitive impairment .......................................................................................................... 40 
1.9.7 Pharmacological targeting microglial within BCAS and chronic degenerative 
disease models .................................................................................................................... 40 
1.10 Potential pathophysiological mechanisms underlying white matter damage and 
cognitive impairment ............................................................................................................... 41 
1.10.1 Cerebrovascular dysfunction and microvascular inflammation ...................... 41 
1.10.2 Microvascular inflammation ............................................................................ 42 
1.10.3 Evidence for cerebrovascular dysfunction and microvascular inflammation in 
human VCI and other chronic degenerative diseases ......................................................... 43 
1.10.4 BCAS model: Evidence for cerebrovascular dysfunction and microvascular 
inflammation ....................................................................................................................... 44 
1.11 Summary ................................................................................................................ 45 
1.12 Hypothesis .............................................................................................................. 46 
1.13 Aims ........................................................................................................................ 46 
Chapter 2 .......................................................................................................................... 47 
Materials and Methods ........................................................................................ 47 
2.1 Animals ................................................................................................................... 47 
2.1.1 C57BL/6J mice ................................................................................................... 47 
2.1.2 Cx3Cr1eGFP/eGFP mice ............................................................................................ 47 
2.1.3 App23 mice ........................................................................................................ 48 
2.1.4 Cx3Cr1eGFP/+ and Cx3Cr1eGFP/+ App23+/- mice ......................................................... 48 
2.1.5 DNA extraction for genotyping .......................................................................... 48 
2.1.6 Cx3Cr1eGFP/+ genotyping ...................................................................................... 48 
2.1.7 App23 genotyping ............................................................................................. 48 
2.2 Bilateral common carotid artery stenosis surgery ................................................. 51 
2.3 Laser speckle imaging of resting cerebral blood flow ............................................ 52 
2.3.1 Laser speckle imaging analysis .......................................................................... 54 
2.3.2 Laser speckle imaging of neurovascular coupling responses ........................... 55 
2.3.3 Laser speckle neurovascular coupling image analysis ...................................... 56 
2.4 Cranial window surgery in preparation for multiphoton microscopy ................... 56 
2.5 Multiphoton microscopy ....................................................................................... 57 
2.5.1 In vivo assessment of microglial structure........................................................ 58 
2.5.2 In vivo assessment of microglial process dynamics .......................................... 60 
2.5.3 In vivo cerebral RBC velocity measurement via line scan analysis ................... 61 
2.5.4 In vivo assessment of vascular pulsation .......................................................... 64 
2.5.5 In vivo assessment of leukocyte trafficking behaviours ................................... 67 
2.6 Behavioural testing ................................................................................................ 67 
2.6.1 Barnes maze ..................................................................................................... 67 
2.6.2 Acclimatisation phase ....................................................................................... 69 
2.6.3 Training phase .................................................................................................. 69 
2.6.4 72-hour probe ................................................................................................... 70 
2.6.5 Reminder phase ................................................................................................ 70 
2.6.6 Reversal phase .................................................................................................. 70 
2.6.7 Reversal 72-hour probe .................................................................................... 70 
2.6.8 Barnes maze exclusion criteria ......................................................................... 71 
2.7 Substance administration ...................................................................................... 71 
2.7.1 GW2580 administration ................................................................................... 71 
2.7.2 5-Bromo-2’-deoxyuridine (BrdU) administration ............................................. 71 
2.8 Tissue collection and processing ........................................................................... 71 
2.8.1 Rapid brain extraction ...................................................................................... 71 
2.8.2 Transcardial perfusion and brain extraction ..................................................... 72 
2.8.3 Paraffin processing ........................................................................................... 72 
2.8.4 Microtome sectioning ....................................................................................... 73 
2.8.5 Processing for freezing and cyrosectioning ...................................................... 73 
2.9 Flow cytometry ...................................................................................................... 73 
2.10 RNA extraction and cDNA synthesis ...................................................................... 74 
2.11 Quantitative (q)-PCR .............................................................................................. 74 
2.12 Immunohistochemical staining.............................................................................. 75 
2.12.1 Immunohistochemical DAB staining ............................................................... 75 
2.12.2 Immunofluorescent labelling .......................................................................... 76 
2.12.3 Tyramide Immunofluorescent labelling .......................................................... 76 
2.12.4 Preparation for Cx3Cr1eGFP cell counts ............................................................. 77 
2.12.5 Immunohistochemical staining controls......................................................... 77 
 vi 
2.13 Imaging acquisition and analysis of immunohistochemical staining ...................... 78 
2.13.1 Imaging acquisition .......................................................................................... 78 
2.13.2 Image analysis ................................................................................................. 78 
2.13.3 Exclusion criteria.............................................................................................. 79 
2.14 Statistical analysis ................................................................................................... 79 
Chapter 3 .......................................................................................................................... 80 
Investigating the role of microglial proliferation in the development of white matter 
damage and cognitive impairment following BCAS .................................................... 80 
3.1 Introduction ................................................................................................................ 80 
3.1.1 Hypothesis .............................................................................................................. 82 
3.1.2 Aims ........................................................................................................................ 82 
3.2 Materials and Methods ............................................................................................... 83 
3.2.1 Experimental Mice ............................................................................................. 83 
3.2.2 Bilateral common carotid artery stenosis .......................................................... 84 
3.2.3 Laser speckle imaging assessment of resting cortical blood flow ...................... 84 
3.2.4 GW2580 administration ..................................................................................... 84 
3.2.5 5-Bromo-2’-deoxyuridine (BrdU) administration ............................................... 84 
3.2.6 Barnes maze behavioural testing ....................................................................... 85 
3.2.7 Tissue collection and processing ........................................................................ 85 
3.2.8 Flow cytometry and cell sorting ......................................................................... 85 
3.2.9 RNA extraction and cDNA synthesis ................................................................... 85 
3.2.10 Quantitative (q)-PCR .......................................................................................... 86 
3.2.11 Immunohistochemistry ...................................................................................... 86 
3.2.12 Image acquisition and analysis ........................................................................... 86 
3.2.13 Statistical analysis .............................................................................................. 86 
3.2.14 Experimental contributions ................................................................................ 87 
3.3 Results ......................................................................................................................... 88 
3.3.1 BCAS induces a significant and sustained reduction in cerebral blood flow ...... 88 
3.3.2 Microglial expansion dominates the early inflammatory response following 
BCAS…………………………………………………………………………………………………………………………………… 90 
3.3.3 BCAS induces microglial expansion following 1-week of reduced cerebral blood 
flow……………………………………………………………………………………………………………………………………. 92 
3.3.4 Microglial expansion following BCAS is associated with a significant increase in 
local proliferation ..................................................................................................................... 94 
3.3.5 CSF1R inhibition has no impact on the magnitude of cerebral blood flow 
reductions following BCAS ....................................................................................................... 98 
3.3.6 CSF1R inhibition following BCAS prevents microglial expansion .................... 101 
3.3.7 Modest levels of microglial proliferation at 6-weeks following BCAS blocked 
through CSF1R inhibition ...................................................................................................... 104 
3.3.8 CSF1R inhibition protects against white matter damage following BCAS ....... 108 
3.3.9 BCAS induced impairments in spatial learning are completely restored through 
CSF1R inhibition .................................................................................................................... 110 
3.3.10 Cognitive flexibility is unaltered following BCAS ............................................. 115 
3.3.11 CSF1R inhibition protects against increased microglial lysosomal expression 
following BCAS ...................................................................................................................... 118 
3.4 Discussion ................................................................................................................ 123 
3.4.1 Resting cerebral blood flow is significantly reduced following BCAS and 
unaltered by GW2580 treatment .......................................................................................... 123 
3.4.2 Microglia dominate the early inflammatory response following BCAS........... 124 
3.4.3 Microglial expansion following BCAS is driven by local proliferation ............. 126 
3.4.4 GW2580 treatment prevents microglial expansion following BCAS ............... 128 
3.4.5 GW2580 treatment prevents white matter integrity disruption following BCAS
 …………………………………………………………………………………………………………………….130 
3.4.6 GW2580 treatment rescues spatial learning impairments following BCAS .... 132 
3.4.7 GW2580 treatment prevents BCAS mediated increases in microglial lysosomal 
expression within the corpus callosum ................................................................................. 134 
3.4.8 Study limitations and future directions ........................................................... 136 
3.5 Conclusion ................................................................................................................ 140 
Chapter 4 ........................................................................................................................ 141 
Investigating structural and functional microglial changes in response to BCAS with 
the use of intravital imaging .................................................................................... 141 
4.1 Introduction ............................................................................................................. 141 
4.1.1 Hypothesis ........................................................................................................... 143 
4.1.2 Aims ..................................................................................................................... 143 
4.2 Materials and Methods ............................................................................................ 144 
4.2.1 Experimental mice ........................................................................................... 144 
4.2.2 Bilateral common carotid artery stenosis ....................................................... 145 
4.2.3 Craniotomy and cranial window surgery in preparation for multiphoton 
microscopy……………………………………………………………………………………………………………………….. 145 
4.2.4 Laser speckle imaging assessment of resting cortical blood flow ................... 145 
4.2.5 Laser speckle assessment of neurovascular coupling responses .................... 145 
4.2.6 Multiphoton microscopy ................................................................................. 146 
 viii 
4.2.7 In vivo assessment of microglial structure .......................................................146 
4.2.8 In vivo assessment of microglial process dynamics .........................................146 
4.2.9 Barnes maze behavioural testing .....................................................................146 
4.2.10 Tissue collection and processing ......................................................................147 
4.2.11 Flow cytometry and cell sorting .......................................................................147 
4.2.12 RNA extraction and cDNA synthesis .................................................................147 
4.2.13 Quantitative (q)-PCR ........................................................................................147 
4.2.14 Image acquisition and analysis .........................................................................148 
4.2.15 Statistical analysis ............................................................................................148 
4.2.16 Experimental contributions ..............................................................................149 
4.3 Results .......................................................................................................................150 
4.3.1 BCAS induces a significant and sustained reduction in cerebral blood flow 
within Cx3Cr1eGFP/+ mice ..........................................................................................................150 
4.3.2 Microglial structure is unaltered following BCAS within Cx3Cr1eGFP/+ mice ......151 
4.3.3 Microglial process dynamics are unaltered following BCAS within Cx3Cr1eGFP/+ 
mice…………………………………………………………………………………………………………………………………. 154 
4.3.4 Microglial density is unaltered following BCAS within Cx3Cr1eGFP/+ mice ..........156 
4.3.5 Neurovascular coupling responses are unaltered following BCAS within 
Cx3Cr1eGFP/+ mice .....................................................................................................................158 
4.3.6 Spatial memory is impaired following BCAS within Cx3Cr1eGFP/+ mice ..............160 
4.3.7 Microglial density remains unaltered following BCAS within Cx3Cr1eGFP/+App23 
mice…………………………………………………………………………………………………………………………………. 164 
4.3.8 Neurovascular coupling responses are impaired following BCAS within 
Cx3Cr1eGFP/+App23 mice...........................................................................................................168 
4.3.9 Microglial structure and process motility are unaffected within 
Cx3Cr1eGFP/+App23 mice following BCAS .................................................................................170 
4.3.10 Spatial learning and memory are impaired within Cx3Cr1eGFP/+App23 mice, with 
no additional BCAS mediated deficit .....................................................................................173 
4.3.11 eGFP insertion leads to reduced Cx3Cr1 receptor expression within Cx3Cr1eGFP/+ 
mice…………………………………………………………………………………………………………………………………. 178 
4.4 Discussion .................................................................................................................180 
4.4.1 Microglial density is unaltered following BCAS within Cx3Cr1eGFP/+ mice ..........180 
4.4.2 Microglial structure and surveillance functions are unaltered following BCAS 
within Cx3Cr1eGFP/+ mice ..........................................................................................................182 
4.4.3 BCAS elicits significant and sustained reductions in cerebral blood flow within 
Cx3Cr1eGFP/+ mice .....................................................................................................................184 
4.4.4 Neurovascular coupling response are unaltered following BCAS within 
Cx3Cr1eGFP/+ mice .................................................................................................................... 185 
4.4.5 Spatial memory is impaired within Cx3Cr1eGFP/+ mice following BCAS ............. 185 
4.4.6 Microglial density remains unaltered following BCAS within Cx3Cr1eGFP/+App23 
mice…………………………………………………………………………………………………………………………………. 187 
4.4.7 Impaired neurovascular coupling responses following BCAS within 
Cx3Cr1eGFP/+App23 mice .......................................................................................................... 187 
4.4.8 Impaired spatial learning and memory within Cx3Cr1eGFP/+App23 mice, with no 
clear additional BCAS mediated impairment ........................................................................ 189 
4.4.9 Study limitations and future directions ........................................................... 189 
4.5 Conclusion ................................................................................................................ 192 
Chapter 5 ........................................................................................................................ 193 
Investigating dynamic alterations within the cerebrovasculature in response to BCAS 
with the use of intravital imaging ............................................................................. 193 
5.1 Introduction ............................................................................................................. 193 
5.1.1 Hypothesis ........................................................................................................... 195 
5.1.2 Aims ..................................................................................................................... 195 
5.2 Materials and Methods ............................................................................................ 196 
5.2.1 Experimental mice ........................................................................................... 196 
5.2.2 Bilateral common carotid artery stenosis ....................................................... 196 
5.2.3 Craniotomy and cranial window surgery in preparation for multiphoton 
microscopy………………………………………………………………………………………………………………………..197 
5.2.4 Laser speckle imaging to measure cortical cerebral blood flow ..................... 197 
5.2.5 Multiphoton microscopy ................................................................................. 197 
5.2.6 In vivo cerebral RBC velocity measurement via line scan analysis .................. 197 
5.2.7 In vivo vascular pulsation measurement via line scan analysis ....................... 198 
5.2.8 In vivo assessment of leukocyte trafficking behaviours .................................. 198 
5.2.9 Statistical analysis............................................................................................ 198 
5.2.10 Experimental contributions ............................................................................. 199 
5.3 Results ...................................................................................................................... 200 
5.3.1 Cerebral blood flow is significantly and persistently reduced following BCAS
 …………………………………………………………………………………………………………………….200 
5.3.2 RBC velocity can be accurately and reliable measured in vivo via multiphoton 
microscopy …………………………………………………………………………………………………………………….202 
5.3.3 RBC velocity is significantly reduced following BCAS ...................................... 204 
5.3.4 Arterial pulsation is significantly impaired following BCAS ............................. 206 
 x 
5.3.5 Leukocyte trafficking is significantly increased following BCAS .......................209 
5.4 Discussion .................................................................................................................212 
5.4.1 BCAS mediated cortical blood flow reductions can be detected globally as well 
as at the single vessel resolution ...........................................................................................212 
5.4.2 BCAS leads to impaired arterial pulsation ........................................................213 
5.4.3 BCAS leads to increased leukocyte trafficking, indicative of endothelial 
activation…………………………………………………………………………………………………………………………..214 
5.4.4 Study limitations and future directions............................................................216 
5.5 Conclusion .................................................................................................................218 
Chapter 6 ........................................................................................................................ 219 
General Discussion ............................................................................................. 219 
6.1 CSF1R as a target for therapeutic intervention ....................................................219 
6.2 Microglial heterogeneity ......................................................................................221 
6.3 Cx3Cr1eGFP reporter mice: A reliable model to assess microglial function in health 
and disease?...........................................................................................................................221 
6.4 Co-morbid models: Essential for the discovery of clinically relevant mechanisms? 
………………………………………………………………………………………………………………………………………….222 
6.5 BCAS: A more accurate model of human VCI than originally anticipated ............223 
6.6 Final Conclusions ..................................................................................................224 
References ....................................................................................................................... 225 




I declare that this thesis has been composed solely by myself and has not been submitted 
for any previous degree or qualification. The work described within this thesis comprises my 
own original work except where otherwise stated in the text. All external sources of data and 





   2 
Acknowledgements 
Firstly, I would like to thank Professor Karen Horsburgh for giving me the opportunity to 
carry out my thesis within her lab, and for always pushing me to work as hard and diligently 
as possible to produce the very best science I was capable of. I want to thank you for all the 
hours you spared to help guide me through my PhD as well as for your understanding and 
support when it came to my personal life.  
Next, I want to thank everybody within the Horsburgh lab, as this truly would not have 
been the same experience without such a friendly, gifted, and supportive team. I especially 
want to thank Dr Juraj Koudelka who has consistently been there to offer help, support, and 
guidance throughout, not just by PhD, but also my masters. Your endless optimism and 
positive outlook were always helpful, even in the 12-hour multiphoton imaging days. Dr 
Emma Sigfridsson also deserves a special mention as we were together for almost my entire 
time within the lab. You were always a friendly face open to answering my silly questions 
during hours of animal work, which really helped to pass the time. I also want to thank Dr 
Jessica Duncombe who took so much time out to help me during the formative years of my 
training. Thanks also to Dr Mosi Li, Dr Jemma Pilcher, Dr Akihiro Kitamura, Dr Edel 
Hennessy, and Dr Jill Fowler for helping support my work and always being open to answering 
my questions and teaching me new things. I would also like to thank Dr Katie Askew and Dr 
Gaia Brezzo who brought new energy and expert opinions to the lab and provided great support 
for the final stages of my PhD.  Thank you also to Dr Barry McColl for being my secondary 
supervisor and always being a friendly, approachable person to discuss my research. Thanks 
also to Dr Stefan Szymkowiak for always being so generous with your time. A huge thank you 
goes to the animal unit staff members Duncan, Keith, Will, and Jon who always made my life 
so much easier.  
I also want to thank my family, mum, dad, and Oliver for always supporting me and 
believing in me. Your love and support mean everything to me, and I really would not be 
where I am today without it.  
I of course must thank Helix. Being in lockdown writing my thesis with you 24/7 has been 
challenging but stopping to play and cuddle you has helped me through.  
Lastly, I want thank Zoë. You have shown immeasurable levels of patience, understanding, 
and love throughout this process and I will be forever grateful. I can only imagine how tedious 
it was for you to hear me complain about writing my thesis for so long, but you never showed 
that and were always there to support me and keep me going. I would not have been able to 
do it without you. 




Vascular cognitive impairment (VCI) refers to the contribution of cerebrovascular disease 
to a spectrum of cognitive impairments, ranging from subjective cognitive decline to dementia. 
Compromised cerebral blood flow (CBF) has been heavily implicated in the pathogenesis of 
cerebrovascular disease, however, the key underlying mechanisms remain to be fully 
elucidated.  
Bilateral common carotid artery stenosis (BCAS) is a surgical method in which micro-coils 
are applied permanently to both carotid arteries to reduce CBF. The BCAS mouse model 
recapitulates many of the pathological and functional hallmarks of VCI, making it a valuable 
experimental model. A prominent feature of the BCAS model is a robust increase in white 
matter microglial numbers, which are significantly associated with cognitive impairments.  
The first aim of this thesis was to test the hypothesis that microglial proliferation directly 
leads to white matter damage and cognitive impairment following BCAS. BCAS surgery was 
found to elicit a significant and persistent reduction in CBF, alongside increased microglial 
proliferation. Pharmacological inhibition of microglial proliferation, through GW2580 
treatment, prevented microglial proliferation, reduced microglial lysosomal expression, 
preserved white matter integrity, and restored spatial learning deficits. 
The second aim was to investigate, using the Cx3Cr1eGFP microglial reporter line and 
intravital multiphoton imaging, structural and functional changes within microglial cells 
following BCAS. The additional pathogenic effects of amyloidosis as a co-morbidity using 
the transgenic App23 mouse model were also assessed. Microglial structure and process 
motility were found to be unaltered, at 1-week following BCAS, within both Cx3Cr1eGFP/+ and 
Cx3Cr1eGFP/+App23 mice. Following 3-months of BCAS, microglial density was found to be 
unaltered, alongside intact neurovascular coupling responses and spatial learning, although, 
spatial memory was impaired within Cx3Cr1eGFP/+ mice. Microglial density was also found to 
be unchanged within Cx3Cr1eGFP/+App23 mice following 3-months of BCAS. Neurovascular 
coupling, however, was significantly impaired within Cx3Cr1eGFP/+App23 mice following 
BCAS surgery. Spatial learning and memory deficits were found within Cx3Cr1eGFP/+App23 
mice alone, with no additional BCAS mediated deficit. As a means of explaining the lack of 
microglial response within the Cx3Cr1eGFP/+ mice, qPCR analysis was carried out and 
confirmed a ≈5-fold reduction in Cx3Cr1 receptor expression.  
Considerable evidence has implicated cerebrovascular dysfunction as a pivotal mechanism 
in the pathophysiology of VCI and dementia. The studies in chapter 3 aimed to test the 
hypothesis that BCAS causes vascular dysfunction leading to the onset of neuro-glial-vascular 
damage. Multiphoton imaging of C57BL/6J wild-type mice found significantly reduced RBC 
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velocity alongside impaired arterial pulsation, and increased leukocyte trafficking, 1-month 
following BCAS surgery.  
In conclusion, the work described within this thesis demonstrates that microglial 
proliferation plays a causative role in white matter damage and cognitive decline following 
BCAS, and that this can be successfully targeted to reverse pathological damage and functional 
deficits. Furthermore, Cx3Cr1 receptor signalling was found to play a significant role in the 
regulation of microglial responses following BCAS. Finally, BCAS was found to not simply 
be a model of reduced CBF, with impairments in arterial pulsation and increased endothelial 







Dementia is a term used to describe a range of human conditions that predominantly occur 
at old age and are characterised by significant memory deterioration. Reductions in the amount 
of blood reaching the brain has been highlighted as an early feature of dementia progression. 
Reduced brain blood flow is thought to lead to memory impairments through damage to the 
brains wiring or white matter, which carries signals from one region of the brain to another. In 
the present thesis an animal model of reduced brain blood flow was used to help uncover the 
key mechanisms contributing to damage and memory impairments. Previous investigations 
using this model have highlighted inflammation and blood vessel dysfunction as key potential 
mechanisms. 
Inflammation describes the body’s natural defence against damage and infection. Within 
the brain, the microglial cell represents the primary mediator of inflammation. In response to 
acute injury or infection, microglial cells multiply to remove harmful molecules by engulfing 
them or releasing pro-inflammatory signals. Under chronic disease conditions, however, these 
microglial responses become uncontrolled, causing the excessive release of pro-inflammatory 
signals leading to damage. This thesis firstly explores the contribution of microglial 
multiplication to damage and memory impairments following chronic reductions in blood flow 
to the brain. Pharmacologically blocking microglial multiplication was shown to protect the 
brains wiring and prevent memory deterioration, within mice, when blood flow to the brain is 
reduced. The thesis then went on to use specialised microscopes to allow microglial cells to 
be studied within the brain of live mice following blood flow reductions. Microglial cells were 
found to be completely unaffected in response reduced brain blood flow. These findings were 
surprising considering the extensive evidence of microglial changes following blood flow 
reductions. To allow microglial cells to be visible using the specialised microscope, mice were 
genetically engineered so that microglial cells emit colour. Interestingly, in the process of 
attaching colour to these cells a component of the microglial cell was replaced. This 
component therefore appears to be crucial to the microglial response to reduced brain blood 
flow. In the final section of this thesis the techniques previously developed, to assess microglia 
within live mice, were reapplied to the study of the brains blood vessels following reduced 
brain blood flow. The brains blood vessels are not simply inactive tubes that hold blood and 
oxygen, they are dynamic vessels that perform key actions that help maintain healthy blood 
flow throughout the brain. Results demonstrate that reduced blood flow leads to increased 
blood vessel stress as well as impairments within a key blood vessel function. 
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Overall, the work presented within this thesis demonstrates that microglial multiplication 
is fundamental to damage and memory impairments following reduced brain blood flow in 
mice, and that targeting, or disruption of this response can have a beneficial impact. 
Furthermore, altered blood vessel function and stress were also observed following reduced 
brain blood flow, indicating additional mechanisms which could be driving disease 
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1.1  Overview 
Dementia is characterised by the progressive and unfaltering deterioration of cognitive 
capacities, leading ultimately to a loss of independence and a need for constant care (Iadecola 
et al., 2019). In 2018, worldwide dementia cases were estimated to be 50 million, with 
projections indicating a rise to 152 million by 2050, driven predominantly by the advancing 
age of the population (Alzheimer’s Disease International, 2018). Despite these alarming 
figures, no disease-altering treatment is currently available, and the cause of late onset 
dementias are not fully understood. Cerebrovascular disease represents the second most 
common cause, after Alzheimer’s disease (AD), of age-related cognitive decline and dementia 
(R. N. Kalaria, 2016). Vascular cognitive impairment (VCI) results from all causes of 
cerebrovascular disease and is a term used to characterise a whole spectrum of cognitive 
impairments, ranging from mild to severe deficits, ultimately leading to dementia (Farooq & 
Gorelick, 2013). Vascular contributions to other dementia subtypes, most notably AD, are 
increasingly apparent, indicating potentially overlapping pathogenic mechanisms (R. N. 
Kalaria, 2016; Kapasi, DeCarli, & Schneider, 2017). Vascular risk factors such as ageing, 
hypertension and diabetes have been associated with an increased risk for VCI and dementia 
(P. B. Gorelick & Nyenhuis, 2013; M. Ihara & Yamamoto, 2016). It has been proposed that 
vascular risk factors alter vascular haemodynamic responses leading to detrimental effects on 
endothelial cell function. Endothelial dysfunction has been shown to impede cerebral 
haemodynamic changes and impair neurovascular coupling mechanisms, leading to both 
transient and chronic cerebral hypoperfusion, further exacerbating vascular pathology (Di 
Marco et al., 2015; Poggesi, Pasi, Pescini, Pantoni, & Inzitari, 2016; Joanna M. Wardlaw, 
Colin Smith, & Martin Dichgans, 2013). Such evidence has highlighted chronic cerebral 
hypoperfusion as a major contributor to cognitive decline and cerebrovascular pathology 
leading to VCI and dementia. Chronic cerebral hypoperfusion describes a sustained reduction 
in cerebral blood flow (CBF), that has been demonstrated to be present before the onset of 
cognitive decline (Ruitenberg et al., 2005). Disrupted CBF has been identified as a reliable 
predictor of dementia progression (Alsop, Dai, Grossman, & Detre, 2010; Chao et al., 2010), 
with the magnitude of CBF reductions correlating with the severity of cognitive impairment 
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(de Eulate et al., 2017). Reductions in CBF have also been closely related to white matter 
damage (Barker et al., 2014), with areas of impaired cerebrovascular reactivity found to 
proceed and therefore predict the appearance of white matter lesions (Sam et al., 2016). 
The mechanisms by which chronic cerebral hypoperfusion leads to neuro-glial-vascular 
damage and cognitive impairments are not yet fully understood, however, animal models have 
provided a pathological system by which these mechanisms can be uncovered and targeted. 
Bilateral common carotid artery stenosis (BCAS) surgery is a well-established model of 
chronic cerebral hypoperfusion, that recapitulates many of the pathological features of VCI 
such as neuro-glial-vascular damage and cognitive impairments (Duncombe, Kitamura, et al., 
2017). Microglial proliferation and activation, as well cerebrovascular dysfunction, have been 
highlighted as key potential mechanisms leading to neuro-glial-vascular damage and cognitive 
impairment following BCAS (Duncombe, Kitamura, et al., 2017). White matter microglial 
expansion is a commonly observed feature following BCAS, and has been correlated with 
increased white matter damage (Holland et al., 2011; McQueen et al., 2014; Reimer et al., 
2011; Shibata, Ohtani R Fau - Ihara, Ihara M Fau - Tomimoto, & Tomimoto, 2004; Wakita, 
Tomimoto H Fau - Akiguchi, Akiguchi I Fau - Kimura, & Kimura, 1994) and cognitive 
impairments (Kitamura et al., 2017). Broad acting anti-inflammatory pharmacological 
approaches, found to improve white matter integrity and cognition following BCAS, were also 
associated with a reduction in microglial expansion (Fowler et al., 2017; Kitamura et al., 2017; 
Manso et al., 2017). To date however, direct proof of the causal contribution of microglial 
proliferation to BCAS mediated damage, has yet to be uncovered.  
Microarray analysis, conducted 3 days following BCAS surgery, demonstrated significant 
alterations within endothelial related genes, alongside the increased expression of pro-
inflammatory associated genes (Reimer et al., 2011). Markers of endothelial activation were 
also found to increase progressively following BCAS, alongside increasing white matter 
damage and the onset of cognitive impairment (Kitamura et al., 2017). Despite extensive 
clinical and pre-clinical evidence to implicate cerebrovascular dysfunction in the pathogenesis 
of VCI, further research is still required to evaluate additional cerebrovascular mechanisms, 
such as vascular pulsation and leukocyte trafficking, that may by relevant to the onset and 
progression of VCI. 
The work described within this thesis was designed to test the hypothesis that microglial 
driven neuroinflammation, as well as cerebrovascular dysfunction, compromise the structure 
and function of white matter tracts, leading to impaired cognition following BCAS. The 
studies herein describe the investigation of microglial proliferation in the onset of white matter 
damage and cognitive impairments following BCAS. Furthermore, intravital multiphoton 
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imaging approaches were employed to allow for the in vivo evaluation of microglial, as well 
as cerebrovascular mechanisms, implicated in the onset and progression of disease within a 
BCAS mouse model of VCI.  
 
1.2  The cerebral blood supply 
The fundamental contribution of the cerebral vasculature to the broad spectrum of 
pathologies that underlie VCI, highlights the significance of healthy vascular structure and 
function to brain health. The brain is an extremely energy demanding organ, requiring 
approximately 15% of the bodies cardiac output despite only representing 2% of the bodies 
total mass (Williams & Leggett, 1989). This coupled to the fact that the brain has a very limited 
capacity for storing fuel reserves means that it is highly reliant on an efficient and effective 
supply of blood, delivering oxygen and energy substrates, in order to support neuronal activity 
(Hossmann, 1994; Ii et al., 2020).  
The brain’s vascular supply is delivered through the left and right internal carotid and 
vertebral arteries (Figure 1.1A), which merge to form a structure known as the circle of Willis 
which is situated at the base of the brain (Figure 1.1B/C) (Hossmann, 2006). Anterior middle 
and posterior cerebral arteries exit the circle of Willis and project along the brains surface, 
across the subarachnoid space, eventually branching to give rise to leptomeningeal arteries 
(Iadecola, 2013). The leptomeningeal arteries branch into smaller vessels that are able to 
penetrate deep into the brains parenchyma in the form of arteries and arterioles (Iadecola & 
Nedergaard, 2007). Arteries and arterioles contain an endothelial cell layer that forms the inner 
lining of the vessel which is surrounded by one or more layers of smooth muscle, suppling the 
contractile force to enable the diameter of the vessel to be altered (Jones, 1970). Penetrating 
vessels are separated from the brain by a basement membrane that delimits the perivascular 
(Virchow-Robin) space, which stores cerebrospinal fluid (Dyrna, Hanske S Fau - Krueger, 
Krueger M Fau - Bechmann, & Bechmann, 2013). On the adjacent side of the perivascular 
spaces, astrocytes join to generate the glia limitans membrane (Girouard & Iadecola, 2006).  
As vessels penetrate deeper into the brain, perivascular spaces disappear allowing 
astrocytic end-feet to make direct contact with the basal lamina to form intracerebral arterioles. 
Intracerebral arterioles become progressively smaller, lose their smooth muscle layer, and 
eventually give rise to a vast capillary network, which is supported by the contractile effects 
of pericytes to direct blood flow throughout the parenchyma. The organisation of the cerebral 
vasculature means that region specific variations in blood supply exist, due to heterogeneity 
in capillary density directed by regional blood flow and metabolic demands (Ward & 
Lamanna, 2004). For example, white matter regions are predominantly supplied by capillaries 
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situated at the end of the vascular supply chain. Such vascular organisation results in white 
matter receiving approximately 1/3 of the blood flow supplying the grey matter, this alongside 
a lack of collateral blood supply renders white matter particularly susceptible to CBF 
alterations (Harris & Attwell, 2012). 
The vascular organisation of the brain means that the vessels supplying the majority of the 
CBF are located outside the brain’s parenchyma. As a consequence, elaborate vascular 
signalling mechanisms, such as cerebrovascular autoregulation and functional hyperaemia, are 
essential to coordinate diameter changes of arterioles within the intracerebral microvasculature 
(Bagher & Segal, 2011; Iadecola, 2004; E. A. Winkler et al., 2019). An added complication of 
this vascular arrangement is that penetrating arteries and venules, unlike the larger 
leptomeningeal vessels, do not have compensatory anastomotic branches, and therefore single 
occlusions can be sufficient to cause small ischemic lesions (microinfarcts) (Blinder et al., 
2013; Nguyen, Nishimura, Fetcho, Iadecola, & Schaffer, 2011; Nishimura, Rosidi, Iadecola, 
& Schaffer, 2010; Shih et al., 2013). Deep white matter regions are particularly vulnerable to 
reductions in CBF as they are supplied by arterioles exiting the cortical network, a region on 
the border of the non-overlapping territories of the anterior and middle cerebral arteries 
(Brown & Thore, 2011; De Reuck, 1971). It is therefore essential that the health of the neuro-
glial-vascular unit and cerebral vasculature is maintained to ensure that ischemic conditions 





Figure 1.1 Cerebrovascular anatomy. (A) Left and right internal carotid artery supplying 
blood flow to the brain, as seen by angiography (Chandra, Li, Stone, Geng, & Ding, 2017). (B) 
CBF is delivered through the left and right internal carotid and vertebral arteries, which merge 
to form a structure known as the circle of Willis which is situated at the base of the brain and 
can be seen within the centre of the image. Vessels branch off from the circle of Willis to form 
small blood vessels that deliver blood throughout the brain. (C) Illustration of the vessels that 
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form the circle of Willis. Images B and C adapted from 
https://www.scienceabc.com/humans/circle-of-willis-anatomy-diagram-and-functions.html.  
 
1.3  Cerebrovascular control mechanisms 
The regulation of CBF to the brain is a challenging proposition, as not only does CBF need 
to be sufficient to meet the high metabolic demands of the brain, it also must be highly dynamic 
to match rapid changes in neuronal activity. Alongside these factors CBF can also be effected 
by intracranial pressure and peripheral changes in blood pressure making the moment to 
moment control of CBF crucial to avoid both hypoperfusion and hyperperfusion within the 
brain (Toth, Tarantini, Csiszar, & Ungvari, 2017). The supply of blood throughout the brain 
is tightly controlled through the coordinated action of a collection of different cell types, 
collectively known as the neuro-glial-vascular unit (Figure 1.2). The neuro-glial-vascular unit 
is comprised of neurons, astrocytes, oligodendrocytes, microglia, perivascular macrophages 
and microvascular endothelial cells which act in unison to match CBF to the energy demands 
of the tissue (Lok et al., 2007). Interruption in the supply of CBF to areas of the brain can lead 
to brain dysfunction and if present over a prolonged period of time even cell death (Kunz & 
Iadecola, 2009). To combat these varied conditions, cerebral blood vessels possess adaptive 
mechanisms to ensure that blood flow is always matched to neuronal activity and that this 




Figure 1.2 The neuro-glial-vascular unit. Cartoon illustration of the neuro-glial-vascular 
unit, which functions in unison to maintain homeostatic conditions within the brain. Image 
created with software from BioRender.com. 
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1.3.1 Cerebrovascular autoregulation 
Cerebrovascular autoregulation describes a mechanism by which CBF pressure is 
maintained at a relatively stable state, despite changes in systemic blood pressure (Iadecola & 
Davisson, 2008; Paulson, Strandgaard S Fau - Edvinsson, & Edvinsson, 1990). Arterial 
pressure can vary drastically throughout the day, depending on the level of physical exertion, 
and therefore it is essential that the cerebrovasculature is not exposed to potentially harmful 
fluctuations in arterial pressure (Mancia, Parati G Fau - Albini, Albini F Fau - Villani, & 
Villani, 1988). Due to the ability of vascular smooth muscle cells to contract and relax 
(myogenic tone) in response to intravascular pressure, CBF can be maintained at a relatively 
consistent level despite varied levels of arterial pressure (Iadecola, 2013). Cerebral 
autoregulation can be subdivided into two processes that act on a continuum in response to 
changing systemic blood pressure. Firstly, dynamic cerebral autoregulation describes the 
vasculatures ability to respond to very fast changes in perfusion pressure, which is brought 
about through altered vascular resistance. Secondary, static cerebral autoregulation describes 
changes to vascular resistance to counteract longer term, more stable, changes in perfusion 
pressure. The overall result of these processes is that systemic blood pressure changes are 
counteracted within the vasculature of the brain to prevent excessive changes in vascular 
pressure (Toth et al., 2017). 
 
1.3.2 Neurovascular coupling 
Another essential adaptive response carried out by the cerebral vasculature is known as 
neurovascular coupling. Neurovascular coupling, or functional hyperemia, describes a process 
by which the supply of blood flow to a region of the brain is matched to its level of neuronal 
activity and therefore metabolic demand (Iadecola & Nedergaard, 2007). It has been 
extensively shown that neuronal activity can promote rapid, within seconds, increases in CBF 
that are region specific (Cox, Woolsey Ta Fau - Rovainen, & Rovainen, 1993; Ngai, Ko Kr 
Fau - Morii, Morii S Fau - Winn, & Winn, 1988; Silva, Lee Sp Fau - Iadecola, Iadecola C Fau 
- Kim, & Kim, 2000). It is thought that neuronal activity signals arterioles within the 
surrounding area, as well as more distal arteries, to relax causing an increase in blood supply 
specifically to that area (Kleinfeld, Mitra, Helmchen, & Denk, 1998; Takano et al., 2006). 
Various components of the neuro-glial-vascular unit have been shown to have a crucial role in 
these processes. For example astrocytes, whose end-feet processes are in direct contact with 
cerebral vessels, have been shown to link synaptic activity to cerebrovascular cells to enable 
an increase in CBF (Iadecola & Nedergaard, 2007). Accumulating evidence also suggests that 
vascular dilation can be mediated through vasoactive agents that are secreted by components 
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of the neuro-glial-vascular unit including neurons, astrocytes and endothelial cells (Iadecola 
& Davisson, 2008). These vasoactive agents include vasodilators such as nitric oxide (NO), 
prostacyclin and bradykinin (Iadecola & Nedergaard, 2007) as well as vasoconstrictors such 
as endothelin and endothelium-derived constriction factor (Andresen, Shafi Ni Fau - Bryan, & 
Bryan, 2006). The coordinated action of the neuro-glial-vascular unit is essential to match 
CBF to neuronal activity (neurovascular coupling) and therefore the health of each component 
is essential to prevent the harmful effects of hypoperfusion within the brain.  
 
1.3.3 Cerebrovascular pulsation 
Homeostatic processes within the brain, such as the maintenance of CBF and interstitial 
fluid equilibrium, rely on the tight regulation of intracranial pressure (ICP) and fluid flow 
(Wagshul, Eide, & Madsen, 2011). The mean ICP and flow are the most important factors in 
sustaining these processes, however, systemic variations in pressure and flow also play a 
fundamental role in maintaining tissue homeostasis. The predominant pulsatile force comes 
from variations in blood pressure over the cardiac cycle, although, other pulsatory forces, such 
as respiratory and vasomotor induced oscillations, can also have a significant effect on both 
ICP and flow (Wagshul et al., 2011). Vasomotor induced vascular oscillations, also known as 
cerebrovascular pulsatility, refers to spontaneous arteriole smooth muscle cell contractions 
which have recently become of interest to cerebrovascular disease due to their proposed role 
in the brains waste clearance mechanisms (Jeffrey J. Iliff et al., 2013b). Perivascular spaces 
are compartments that surround surface and penetrating blood vessels within the brain, which 
contain either interstitial fluid (ISF) or cerebrospinal fluid (CSF). A key function of these 
compartments is to facilitate the exchange of ISF and CSF, in a process known as paravascular 
drainage (Abbott, 2004). Paravascular drainage pathways facilitate the clearance of interstitial 
solutes and waste products from the brain’s parenchyma (Abbott, 2004; Cserr Hf Fau - Ostrach 
& Ostrach, 1974; Ichimura, Fraser Pa Fau - Cserr, & Cserr, 1991; S. Yamada, DePasquale M 
Fau - Patlak, Patlak Cs Fau - Cserr, & Cserr, 1991). Multiphoton imaging approaches have 
demonstrated that a large proportion of subarachnoid CSF re-enters the brain along the 
paravascular pathways surrounding penetrating arteries, flowing into the terminal capillary 
beds where exchange with ISF can occur throughout the brain (Iliff et al., 2012; Xie et al., 
2013). Cerebral arterial pulsatility has been identified as a key driver of paravascular CSF 
influx and therefore plays a crucial role in facilitating waste clearance from the brain 
parenchyma, thus has the potential to contribute significantly to the onset and progression of 




1.4    Vascular cognitive impairment 
Vascular cognitive impairment (VCI) refers to the contribution of vascular pathology to a 
spectrum of cognitive impairments, ranging from subjective cognitive decline and mild 
cognitive impairment to dementia (Farooq & Gorelick, 2013; van der Flier et al., 2018). VCI 
has been shown to be a causative mechanism within both Vascular dementia (VaD) and AD, 
and is associated with increased morbidity, disability and a poorer quality of life (Fitzpatrick, 
Kuller Lh Fau - Lopez, Lopez Ol Fau - Kawas, Kawas Ch Fau - Jagust, & Jagust, 2005; Hill, 
Fillit H Fau - Shah, Shah Sn Fau - del Valle, del Valle Mc Fau - Futterman, & Futterman, 
2005; Knopman, Rocca Wa Fau - Cha, Cha Rh Fau - Edland, Edland Sd Fau - Kokmen, & 
Kokmen, 2003). Patients with VCI typically display mental slowness and have problems with 
executive functions, such as planning, initiation, decision making, hypothesis generation, 
organising, monitoring behaviour and cognitive flexibility (Iadecola et al., 2019; van der Flier 
et al., 2018). Major VCI is clinically defined as a deficit within at least 1 of these cognitive 
domains that is significant enough to impair daily living, alongside neuroimaging evidence of 
cerebrovascular disease (Iadecola et al., 2019; Skrobot et al., 2018).  
 
1.5    Cerebrovascular disease 
Cerebrovascular disease describes the underlying neuropathology of VCI, and 
encompasses a very heterogenous collection of pathologies that can accumulate within a single 
human brain (Figure 1.3) (Levit, Hachinski, & Whitehead, 2020). Clinical-pathological studies 
demonstrate a role for cerebrovascular disease, not only as a primary cause of cognitive 
decline, but also as an agonist for the expression of dementia resulting from other causes, 
including AD and neurodegeneration (Philip B. Gorelick et al., 2011; Schneider, Arvanitakis 
Z Fau - Bang, Bang W Fau - Bennett, & Bennett, 2007; Toledo et al., 2013). Cerebrovascular 
disease encompasses large and small vessel disease, however, the breadth of cerebrovascular 
disease, alongside the resulting clinical manifestations, remain topics of ongoing research 
(Jellinger, 2013; Raj N. Kalaria, 2016; Kalaria et al., 2004). Within hereditary cerebrovascular 
conditions known to result in VCI, such as cerebral autosomal dominant arteriopathy with 
subcortical infarcts and leukoencephalopathy (CADASIL) (Jellinger, 2013) and Moya Moya 
disease (Yamashita M Fau - Oka, Oka K Fau - Tanaka, & Tanaka, 1983), both large and small 
vessel disease can be found throughout the brain in a diffuse and multifocal distribution 
(Figure 1.3A). Alterations within the large and small cerebral vasculature have also been 
shown to be key contributors to cognitive impairment resulting from other pathologies, 
including AD (Iadecola et al., 2019). Such observations have led to the more commonly held 
view that sporadic, old age, dementias occur due to a combination of cerebrovascular disease 
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and AD (de la Torre, 2002). Indeed, evaluations of dementia patients at autopsy identified that 
vascular pathology was present within up to 75% of cases, highlighting the significant 
occurrence of mixed dementia at old age (Pathological correlates of late-onset dementia in a 
multicentre, community-based population in England and Wales. Neuropathology Group of 
the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS), 2001). 
Additional evaluations of AD patients, the most common form of late onset dementia, 
demonstrated cerebral vascular pathology in up to 80% of cases (Toledo et al., 2013). It is, 
therefore, becoming increasingly apparent that cerebrovascular dysfunction has an important 
role to play in the progression of cognitive impairment observed in ageing, VCI and AD 






Figure 1.3 Major mechanisms leading to vascular cognitive impairment. (A) Vascular 
associated causes of VCI. (B) Brain parenchymal lesions resulting from VCI. (C) Fluid-
attenuated inversion recovery (FLAIR) image showing extensive white matter hyperintensities 
(white arrows) and a lacune (white arrowhead). All images adapted from (Dichgans & Leys, 
2017). 
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1.5.1 Large vessel disease 
Alterations within the large and small cerebral vasculature have been highlighted as key 
mechanisms underpinning cerebrovascular disease and contributing to cognitive impairment 
(Iadecola et al., 2019). Large and small vessel forms of cerebrovascular disease are commonly 
found to co-exist within the aged brain. Large vessel disease describes pathologies effecting 
the larger extracranial vessels such as carotid artery stenosis (atherosclerosis), hyalinosis, 
vessel wall thickening, and fibroid necrosis (Li et al., 2018). Changes in the larger arteries 
supplying the brain likely compromises the vessels ability to dilate and constrict in response 
to peripheral blood pressure changes. The loss of cerebrovascular autoregulation leads to 
uncontrolled fluctuations in blood flow reaching the brain, resulting in abnormal tissue 
perfusion. Such blood flow changes leave deep cerebral structures and white matter regions 
particular vulnerable due to a lack of anastomoses and collateral blood flow (R. N. Kalaria, 
2016).  
 
1.5.2 Small vessel disease 
Cerebral small vessel disease (SVD) describes a pathological disorder which is found 
within intracranial vessels including small arteries, arterioles, venules, and capillaries (Raj N. 
Kalaria, 2016). The term SVD, refers not only to intracranial vascular disease, resulting from 
varied pathological and neurological mechanisms, but also the resulting clinical manifestations 
and neuroimaging features (Li et al., 2018). Analysis of SVD pathology, highlights 
abnormalities within arterioles such as arteriolosclerosis, lipohyalinosis, and fibrinoid necrosis 
(Arvanitakis et al., 2017; Vinters et al., 2018). Capillaries and venules can also be found to be 
abnormal in the context of SVD, demonstrating that the pathogenesis of SVD is very complex. 
Cerebral amyloid angiopathy (CAA), is another common feature of cerebrovascular disease 
and describes the deposition of Aβ into the vascular wall of leptomeningeal and cerebral blood 
vessels (Attems, Jellinger K Fau - Thal, Thal Dr Fau - Van Nostrand, & Van Nostrand, 2011). 
Aβ deposits form within the basement membrane or smooth muscle cell layers and can lead to 
vessel wall rupture and haemorrhage, microbleeds, capillary occlusion, blood flow 
disturbances, and microinfarcts (Okamoto et al., 2012; Thal et al., 2009). CAA is most 
commonly observed within AD (Charidimou, Gang Q Fau - Werring, & Werring, 2012), but 
is also often identified within old aged patients in the absence of AD pathology (Cohen, Hedera 
P Fau - Premkumar, Premkumar Dr Fau - Friedland, Friedland Rp Fau - Kalaria, & Kalaria, 
1997). Severe CAA is associated with cerebrovascular lesions that co-exist with AD, such as 
lacunar infarcts, microinfarcts, and haemorrhages (Ellis et al., 1996; Okamoto et al., 2012; 
Olichney et al., 1995). 
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1.5.3 Neuroimaging features of cerebrovascular disease 
To satisfy a clinical diagnosis of VCI, patients need to demonstrate impairment within at 
least 1 cognitive domain, alongside neuroimaging evidence of cerebrovascular disease (Figure 
1.3B) (Iadecola et al., 2019; Skrobot et al., 2018). Magnetic resonance imaging (MRI) has, for 
a number of years, been employed to identify structural alterations associated with 
neurological disorders and is considered the gold standard for the neuroimaging of VCI. The 
characteristic neuroimaging features of cerebrovascular disease include white matter 
hyperintensities, brain atrophy, subcortical infarcts, lacunes, enlarged perivascular spaces, and 
microbleeds (J. M. Wardlaw, C. Smith, & M. Dichgans, 2013). White matter hyperintensities, 
also known as leukoaraisosis, can be observed on T2-weighted MRI scans (Figure 1.3C), and 
are attributed to white matter lesions. White matter hyperintensities are commonly observed 
alongside lacunes and small (<1.5cm) white matter infarcts (Iadecola, 2013; Joanna M. 
Wardlaw, Colin Smith, et al., 2013), and are considered the most important neuroimaging 
feature of VCI, and are vital for the establishment of a clinical diagnosis (E. E. Smith, 2017).  
 
1.5.4 Cerebrovascular disease pathology 
Typical cerebrovascular pathology consist of white matter lesions, lacunes, micro-bleeds, 
superficial siderosis, enlarged perivascular spaces, and microinfarcts (van Veluw et al., 2017; 
Joanna M. Wardlaw, Eric E. Smith, et al., 2013). Less commonly observed ultrastructural 
abnormalities to the microvasculature, include capillary wall deterioration and erythrocyte 
accumulation, basement membrane thickening, pericyte degeneration, and pallor of 
perivascular myelin (Farkas, De Jong Gi Fau - de Vos, de Vos Ra Fau - Jansen Steur, Jansen 
Steur En Fau - Luiten, & Luiten, 2000; R. N. Kalaria, 2016; Lammie, Brannan F Fau - Slattery, 
Slattery J Fau - Warlow, & Warlow, 1997; Schreiber, Bueche, Garz, & Braun, 2013; Y. Yang 
& Rosenberg, 2011). Found individually, such cerebrovascular lesions can be asymptomatic, 
however, increasing numbers of individual lesions, and combinations of different lesion types, 
are associated with cognitive decline and dementia (Debette, Schilling, Duperron, Larsson, & 
Markus, 2019).  
White matter lesions are consider the neuropathological hallmark of VCI and incorporate 
a range of white matter changes including rarefaction, vacuolation, incomplete infarction, 
lacunar infarcts, perivascular spacing, demyelination and axonal degeneration (Iadecola, 
2013). Areas of white matter lesions show reduced vascular density and are associated with 
unstable carotid plaques (Altaf et al., 2006; R. N. Kalaria, 2016). The significance of white 
matter lesions to disease progression has been highted within a range of neuroimaging studies 
which have shown a clear association between white matter alterations and cognitive decline 
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(Joanna M. Wardlaw, Valdés Hernández, & Muñoz-Maniega, 2015). For example, white 
matter lesions detected by MRI were found to be significantly associated with impairments in 
the processing speeds of a large human cohort (de Groot et al., 2000). White matter alterations 
have also been shown to serve as accurate predictors of cognitive decline, with the severity of 
early white matter changes found to correlate with an increased rate of cognitive decline 
(Inzitari et al., 2009). 
Cerebrovascular disease related brain damage, however, is not limited to lesions visible 
through standard neuroimaging techniques, with evidence from more sensitive MRI methods 
revealing alterations within the normally appearing white and grey matter that worsen as 
cerebrovascular disease burden increases (Baykara et al., 2016; Muñoz Maniega et al., 2017). 
The various pathologies of cerebrovascular disease lead to oedema and blood brain barrier 
(BBB) damage, resulting in the uncontrolled movement of fluid and macromolecules into the 
white matter (Giwa et al., 2012; Joanna M. Wardlaw, Colin Smith, et al., 2013). Disease of 
the microvasculature may also be associated with inflammatory processes through endothelial 
cell activation triggering leukocyte and macrophage recruitment (Raj N. Kalaria, 2016). Tissue 
injury because of cerebrovascular disease is commonly observed in both cortical and 
subcortical grey and white matter. The mechanisms by which such vessel abnormalities occur 
and lead to brain damage is still the source of debate. However, increasing evidence would 
suggest an important role for the components of the neuro-glial-vascular unit, such as 
microglia, oligodendrocytes, and astrocytes (J. M. Wardlaw, Smith, & Dichgans, 2019). 
 
1.6    Vascular risk factors and underlying cerebrovascular causes 
of VCI 
Due to the considerable variety of cerebrovascular disease pathologies alongside the co-
existence of AD and other neurodegenerative diseases, ascertaining the genetic and modifiable 
risk factors contributing to VCI is challenging (Philip B. Gorelick et al., 2011). The primary 
risk factor for VCI and dementia is age, with several epidemiological studies also highlighting 
vascular risk factors such as hypertension and diabetes as key causative factors (Raz, Knoefel, 
& Bhaskar, 2016; Ruitenberg et al., 2005). Overlapping vascular risk factors associated with 
VCI and AD further strengthen the evidence for shared vascular pathologies, with estimates 
indicating that ≈50% of AD risk can be explained by cardiovascular risk factors (D. E. Barnes 
& Yaffe, 2011). The mechanisms by which vascular risk factors contribute to VCI are ill-
defined, however, there is considerable evidence to suggest that endothelial dysfunction plays 
a pivotal role (Di Marco et al., 2015; Poggesi A Fau - Pasi, Pasi M Fau - Pescini, Pescini F 
Fau - Pantoni, Pantoni L Fau - Inzitari, & Inzitari, 2016; Joanna M. Wardlaw, Colin Smith, et 
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al., 2013). Evidence from animal and human studies indicates that these vascular risk factors 
may alter vascular haemodynamics, detrimentally impacting cerebrovascular regulation, 
leading to the disruption of crucial regulatory pathways such as endothelium-dependent 
vasodilation, neurovascular coupling and autoregulation (Di Marco et al., 2015; Iadecola & 
Davisson, 2008; Poggesi et al., 2016; J. M. Wardlaw et al., 2013; Joanna M. Wardlaw, Eric E. 
Smith, et al., 2013). Such impairments in cerebral haemodynamics can lead to transient or 
chronic cerebral hypoperfusion which has been shown to exacerbate cerebrovascular disease 
pathologies, such as white matter damage. In addition, it has been proposed that the BBB can 
become compromised early in VCI leading to a chronic hypoxic state and cerebral 
hypoperfusion (Di Marco et al., 2015; Poggesi A Fau - Pasi et al., 2016; Joanna M. Wardlaw, 
Colin Smith, et al., 2013). Such findings have highlighted chronic cerebral hypoperfusion as 
a major contributor to neurodegenerative processes leading to VCI and dementia.  
 
1.7    Chronic cerebral hypoperfusion as a key mechanism leading 
to white matter damage and cognitive impairment 
Chronic cerebral hypoperfusion has been shown to lead to diffuse white matter changes, 
which are strongly related with cognitive impairment (Longstreth et al., 1996; Poggesi A Fau 
- Pantoni et al., 2011). Neuroimaging studies have demonstrated that areas containing white 
matter hyperintensities exhibit reduced CBF (Brickman et al., 2009; Schuff et al., 2009). 
Perfusion deficits have also been identified within normally appearing white matter, which 
have been successfully used to predict the occurrence of future white matter alterations 
(Bernbaum et al., 2015; Promjunyakul et al., 2015). Such findings implicate reduced CBF in 
the onset and progression of white matter hyperintensities, which are known to correlate 
strongly with cognitive impairment (Barker et al., 2014). Furthermore, chronic reductions in 
CBF, has been identified within the prodromal stages of dementia (Ruitenberg et al., 2005) 
before the onset of clinical symptoms, and therefore could represent one of the earliest changes 
in disease progression (Austin et al., 2011). Disrupted CBF has been shown to be a reliable 
predictor of which patients will progress from mild to severe cognitive impairment and 
ultimately dementia (Alsop et al., 2010; Chao et al., 2010) and can identify which patients 
have an increased genetic risk of developing dementia (Thambisetty, Beason-Held L Fau - An, 
An Y Fau - Kraut, Kraut Ma Fau - Resnick, & Resnick, 2010). The magnitude of CBF 
reductions has been shown to correlate to the severity of cognitive impairment (de Eulate et 
al., 2017) with chronically hypoperfused patients displaying increased cognitive deficits in 
comparison to aged matched controls (Ruitenberg et al., 2005). A reduced resting CBF as well 
as reduced CBF responses to brain activation have also been described in multiple 
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neurodegenerative conditions including AD (Iadecola, 2004). Moreover, hemodynamic 
impairment of mean blood flow velocity, pulsatility index, and cerebrovascular reactivity were 
observed within the middle cerebral artery of AD patients. Thus highlighting haemodynamic 
impairment as an early and critical marker of vascular damage within AD (Raz et al., 2016; 
Stefani et al., 2009).  
 
1.7.1 Carotid artery stenosis: A leading cause of chronic 
cerebral hypoperfusion 
Carotid artery stenosis is one of the primary causes of chronic cerebral hypoperfusion, and 
describes the narrowing of the carotid arteries as a result of atherosclerosis, which is associated 
with reduced CBF and declining cognition (Balucani, Viticchi G Fau - Falsetti, Falsetti L Fau 
- Silvestrini, & Silvestrini, 2012). Carotid artery stenosis is also considered an important risk 
factor for white matter disease (Baradaran et al., 2016; Kandiah, Goh, Mak, Marmin, & Ng, 
2012), and is associated with white matter damage and cognitive dysfunction (Jokinen et al., 
2007; Ryberg et al., 2011; Tomimoto et al., 2004). Longitudinal clinical studies demonstrate 
that patients with moderate or severe intracranial stenosis have an accelerated rate of cognitive 
and functional decline relative to those without (Zhu, Wang Y Fau - Li, Li J Fau - Deng, Deng 
J Fau - Zhou, & Zhou, 2014). Carotid-artery occlusion or high-grade stenosis have been shown 
to cause cognitive impairments alone, even in the absence of macroscopic brain lesions 
(Balestrini et al., 2013; Cheng et al., 2012; Johnston et al., 2004). Additional clinical studies 
have also demonstrated that haemodynamic failure following carotid artery occlusion is 
independently associated with cognitive impairment (Marshall et al., 2012).  
Despite substantial mounting evidence of the significance of reduced CBF to the onset and 
progression of VCI (de la Torre, 2000), the mechanisms underlying such damage and 
dysfunction remain largely unknown. Animal models, therefore, represent an important 
avenue by which key pathogenic mechanisms can be identified and the benefit of targeting 
such pathways can be evaluated. 
 
1.8    Experimental models to study VCI 
To enable the study of early pathological mechanisms contributing to VCI, rodent models 
of chronic cerebral hypoperfusion were developed. The first of these were established in rats 
through the occlusion or ligation of both common carotid arteries to elicit a severe, >70%, 
reduction in CBF (Farkas, Luiten Pg Fau - Bari, & Bari, 2007; Farooq & Gorelick, 2013). Such 
models were established in the Wistar and Sprague-Dawley rat strains, which are able to 
tolerate complete blockade of both common carotid arteries due to intact circle of Willis’ 
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allowing for sufficient collateral blood flow (Farkas et al., 2007). Such models were then 
established within mice, however, due to the poor collateral flow through the circle of Willis, 
within C57BL/6J mice, models had to be adapted so that carotid arteries were temporarily, and 
not permanently, occluded to permit survival (G. Yang et al., 1997). Such approaches were 
found to lead to severe, 80-90%, reductions in CBF resulting in transient global ischemia 
(Kitagawa et al., 1998). Concerns over the occlusion models ability to accurately recapitulate 
the milder 20-30% blood flow reductions observed within human VCI, led to the development 
of the bilateral common carotid artery stenosis (BCAS) model in rats (Wakita et al., 1994). 
The BCAS model was then established within mice due to the increased accessibility of 
molecular technologies such as knockout and transgenic lines (Figure 1.4) (Shibata et al., 
2004). BCAS mouse models have gone on to be used extensively within our laboratory and 
others as a tractable and reproducible model of VCI.  
 
1.8.1 Bilateral common carotid artery stenosis 
The BCAS model achieves cerebral hypoperfusion through the application of micro-coils, 
around both the common carotid arteries, resulting in a ≈50% reduction in luminal diameter 
(Shibata et al., 2004). This method takes advantage of a lack of collateral blood flow within 
C57BL/6J mice to elicit a significant and sustained reduction in CBF following surgery 
(Shibata et al., 2004). The most commonly used BCAS model, utilises 2x0.18mm micro-coils 
which achieve a 30-40% reduction in CBF immediately following surgery, with recovery 
overtime within young 3-4 month old mice, leading to an overall 15-20% CBF reduction 
(Holland et al., 2015; McQueen et al., 2014; Shibata et al., 2004). Other micro-coil sizes and 
combinations, such as the 0.16mmx0.18mm mixed coil model, are also used to elicit varying 
severities of CBF reductions (Fowler et al., 2017; Miki et al., 2009). Alongside the varying 
diameter of micro-coils and combinations used, periods of recovery between left and right 
micro-coil attachment can also differ between groups. Due to such a high degree of variability 
between BCAS methods, comparisons between research groups can be difficult. It is therefore 
crucial that blood flow reductions are accurately measured following surgery, as the level of 
cerebral hypoperfusion and not the diameter of the micro-coils is of crucial importance. Laser 
speckle and Doppler flowmetry are two of the most commonly used methods to monitor CBF 
reductions following BCAS surgery. Both imaging methods project visible-to-infrared laser 
beams onto the surface of the skull to detect scatter interference patterns generated by blood 
flow. Such approaches provide, relatively non-invasive, methods by which blood flow 
reductions can be assessed longitudinally flowing BCAS surgery (Postnov, Cheng, Erdener, 
& Boas, 2019). A key limitation of these techniques, however, is that they are constrained by 
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the limited depth of laser penetration that can be achieved, thus restricting blood flow 
assessments to the cortical surface. Arterial spin labelling MRI methods, however, 
demonstrated a ≈50% reduction in cortical and subcortical blood flow 24-hours following 
BCAS surgery, recovering to ≈70-75% of baseline by 1-month (Boehm-Sturm et al., 2017; 
Hattori et al., 2016). Thus, indicating that BCAS surgery elicits widespread blood flow 




Figure 1.4 Bilateral common carotid artery stenosis surgery (BCAS). Representative 
images in green of FITC-perfused common carotid arteries before and after micro-coil 
application (Masafumi Ihara & Tomimoto, 2011). Images appear alongside laser speckle 
representative images of CBF measures before and after mixed coil BCAS surgery.  
 
1.8.2 BCAS mediated neuropathological changes 
As referred to previously, alterations within the brains white matter has been identified as 
a prominent feature of VCI and contributes to the onset and progression of cognitive 
impairments (Prins & Scheltens, 2015). A key feature of the BCAS model is the development 
of white matter damage in the absence of overt ischaemic neuronal perikaryal damage. Early 
investigations, 2-weeks following BCAS surgery, identified white matter rarefaction and 
vacuolation, associated with a prominent glial response (Shibata et al., 2004). Additional 
immunohistochemical evaluations, 1-month following BCAS, highlighted widespread white 
matter damage, as detected by increased  levels of myelin associated glycoprotein (MAG) and 
degraded myelin protein (Holland et al., 2015; Reimer et al., 2011; Shibata et al., 2004; Wakita 
et al., 1994). BCAS has also been shown to lead to the selective disruption of key proteins 
within the paranodal axon-glial junctions, causing a loss of stability and function within 
myelinated axons resulting in impaired white matter function (Reimer et al., 2011). It is 
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important to note, however, that white matter damage and functional impairments are observed 
within the BCAS model in the absence of overt demyelination (McQueen et al., 2014). 
Alterations within the cerebral vasculature, indicative of cerebrovascular disease begin to 
occur at more chronic timepoints following BCAS surgery. Sustained BCAS, >6-months, 
induces morphological changes to small vessels, such as increased thickening, fibrin 
deposition, and fibrosis of capillary walls (Holland et al., 2015). Overt BBB disruption is also 
apparent, 6-months following BCAS surgery, as determined through parenchymal fibrinogen 
deposits and a reduction in tight junction protein claudin-5 (Holland et al., 2015). Other 
studies, in which BCAS induced more significant blood flow reductions and white matter 
damage, report evidence of BBB dysfunction at the much earlier timepoints of 3- and 7-days 
following surgery (Seo et al., 2013). These differences likely reflect the variability in the 
severity of CBF reductions following BCAS surgery that exists between research groups.  
 
1.8.3 BCAS mediated cognitive impairments 
A fundamental aspect of both severe VCI and dementia is the development of cognitive 
deficits. It has previously been proposed that chronic cerebral hypoperfusion directly 
contributes to cognitive decline (de la Torre, 2000). Behavioural investigations, using the 8-
arm radial maze and Y-maze tests, within the BCAS model have mainly reported deficits in 
spatial working memory (Maki et al., 2011; Shibata et al., 2007; Wakita et al., 1994; Washida 
et al., 2010). Following 1-month of BCAS spatial working memory, but not reference memory, 
was impaired indicating a potential selective frontal-subcortical circuitry deficit (Wakita et al., 
1994). Spatial working memory was, however, found to be impaired 4-months following 
BCAS, as assessed through the 9-arm radial maze (Hase et al., 2018). Following chronic 
BCAS, >6-months, both spatial working memory and spatial reference memory were found to 
be impaired, as assessed by the 8-arm radial arm and Morris water mazes (Holland et al., 
2015). Impairments in spatial learning are apparent 6-months following BCAS, as assessed 
via the Barnes maze (Nishio et al., 2010). The Barnes maze is land based version of the Morris 
water maze, which assesses the time taken for each mouse to locate an escape chamber that is 
present within 1 of the 20 available holes (C. A. Barnes, 1979). The advantage of the Barnes 
maze is that the motivation to explore is produced via aversive stimuli, such as bright lights 
and white noise audio. Such methods remove the need for the use of, potentially response 
altering, motivation methods such as dietary restriction as well as eliminating the physical 
stress induced by swimming reliant tasks. The onset of both working and reference memory 
impairments following chronic BCAS, likely reflects the presence of both white and grey 
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matter pathology, including whole brain and hippocampal specific atrophy (Holland et al., 
2015; Nishio et al., 2010).  
 
1.8.4 The interplay between BCAS and comorbidities 
VCI and dementias are very heterogenous conditions, which is reflected at post-mortem by 
the variety of pathological lesions and mixed pathologies that are commonly observed within 
the elderly, such as white matter damage, microinfarcts, microbleeds, and amyloid pathology 
(Kalaria, 2012). Such findings indicate the importance of studying these various pathologies 
in conjunction, to more accurately model human disease conditions.  
 
1.8.5 BCAS coupled to amyloidosis 
It has been demonstrated that neurovascular pathology is present in up to 80% of sporadic 
late-onset AD patients (Toledo et al., 2013). Indicating, that cerebrovascular disease and 
amyloidosis are commonly found in conjunction. Aβ deposition is one of the key pathological 
hallmarks of AD and is proposed to be one of the fundamental drivers of pathophysiology. As 
rodents do not naturally form Aβ deposits, human amyloid precursor protein (APP) mutations 
are most commonly introduced to model amyloidosis in vivo. An example of such a model 
system is the App23 mice model, which was genetically engineered to overexpress human 
APP containing the Swedish KM670/671NL mutation. App23 mice develop both meningeal 
and parenchymal amyloid deposits by 6-months of age and display pathological, cognitive, 
and behavioural changes typical for AD patients (Shang J Fau - Yamashita et al., 2016; 
Sturchler-Pierrat et al., 1997). Previous studies within App23 mice in combination with BCAS 
have demonstrated exacerbated neuronal loss, BBB leakage, as well as worsened AD 
pathology including neurovascular unit disruption, loss of axon-glial integrity and 
cerebrovascular remodelling (Shang J Fau - Yamashita et al., 2016; Zhai Y Fau - Yamashita, 
Yamashita T Fau - Nakano, Nakano Y Fau - Sun, Sun Z Fau - Morihara, et al., 2016).  
BCAS has also been applied to a number of different transgenic APP models, with reports 
of varied effects on amyloid deposits, cerebrovascular pathology and cognition. The C57BL/6-
Tg(Thy1-APPSwDutIowa)BWevn/J mouse model (J. Davis et al., 2004) demonstrated 
increased leptomeningeal Aβ, associated with microinfarcts and impaired microvascular 
function, following BCAS surgery (Okamoto et al., 2012). Transgenic mice with Swedish, 
Dutch and Iowa mutations (Tg-SwDI) demonstrated increased parenchymal levels of soluble 
Aβ peptides (Aβ40/42), APP as well as APP proteolytic products following BCAS surgery 
(Salvadores, Searcy, Holland, & Horsburgh, 2017). Alterations in the pools of APP and 
amyloid peptides following BCAS have also been associated with increased CAA, 
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microinfarct load and haemorrhages (Salvadores et al., 2017). Furthermore, BCAS surgery 
within App Swedish and Indiana mutated mice (AppSw/Ind) exacerbated neuronal loss, 
altered Aβ metabolism and led to impairments in spatial learning, not observed within 
AppSw/Ind mice alone (M. Yamada et al., 2011). 
Despite clear evidence of a harmful synergistic effect of BCAS and amyloidosis, the 
mechanisms by which pathology and function are exacerbated remain unclear. A common 
feature of human AD, transgenic APP models and BCAS models is a pronounced pro-
inflammatory environment, including the activation of microglia and the release of pro-
inflammatory cytokines (Duncombe, Kitamura, et al., 2017; Heneka et al., 2015; Heppner, 
Ransohoff, & Becher, 2015). Such mechanisms, however, require additional study in order 
confirm a causal role in the detrimental synergistic effect of BCAS and amyloidosis.  
 
1.9    Potential pathophysiological mechanisms underlying white 
matter damage and cognitive impairment 
 
1.9.1 Neuroinflammation  
Neuroinflammation describes an endogenous protective response within the brain, 
primarily mediated by microglial cells, which functions to combat infection and limit tissue 
damage caused by invading pathogens, dying cells, and cellular debris (Salter & Stevens, 
2017). Once consider the rudimentary macrophages of the brain, microglial have emerged as 
fundamental players within a variety of central nervous system (CNS) disorders, ranging from 
neurodevelopmental conditions such as autism to neurodegenerative disorders such as VCI 
and dementia. Alongside significant roles within disease conditions, crucial microglial 
functions within the healthy brain have also been reported, with key roles in neurodevelopment 
and homeostatic maintenance (Salter & Stevens, 2017). The emergence of intravital imaging, 
microglial reporter lines, as well as more sophisticated molecular tools, provides new 
opportunities to help uncover the role of microglia in the onset and progression of VCI and 
dementia. 
 
1.9.2 Genetic models and intravital imaging aid microglial 
research 
The study of microglial physical dynamics and biological functions, in both healthy and 
diseased brains, have been the focus of intense scientific activity over recent years. The 
emergence of genetic models alongside more sophisticated neuroimaging methods has 
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uncovered novel microglial functions as well as the redefinition of classical ones (Diego 
Gomez-Nicola & V. Hugh Perry, 2015). A major breakthrough within microglial research 
came following the generation of a transgenic knock-in mouse expressing green fluorescent 
protein (GFP) driven by the myeloid specific chemokine receptor Cx3Cr1. Cx3Cr1eGFP mice 
express green florescent protein within microglia, perivascular macrophages, peripheral 
macrophages, and monocytes (Jung, Aliberti, et al., 2000). The ability to readily visualise 
microglial cells, without the need for immunohistochemistry or specialised staining, alongside 
the development of multiphoton microscopy, provided unprecedented methodologies to assess 
microglial functions in vivo (R. M. Ransohoff & J. El Khoury, 2015). Multiphoton microscopy 
is a minimally invasive imaging method offering high spatial resolution, in the range of 
micrometres, as well as very fast imaging acquisition (Hierro-Bujalance, Bacskai, & Garcia-
Alloza, 2018). Multiphoton microscopy possesses several distinct advantages over other 
commonly used neuroimaging approaches. For example, through the use of low energy near 
infrared light, with excitation limited to a single plane of focus, phototoxicity and tissue 
damage is dramatically reduced, allowing for chronic in vivo imaging over extended periods 
(Hierro-Bujalance et al., 2018). As multiphoton microscopy florescence is limited to a single 
point of focus, absorption and scattering of light is limited, allowing for much deeper imaging, 
with common set ups reaching depths of ≈500µm (Levene, Dombeck Da Fau - Kasischke, 
Kasischke Ka Fau - Molloy, Molloy Rp Fau - Webb, & Webb, 2003). Transgenic microglial 
reporter lines alongside multiphoton imaging have allowed for structural and functioning 
imaging of microglia within the living brain, providing a greater understanding of microglial 
behaviour both under homeostatic and disease conditions. 
 
1.9.3 Microglia under normal homeostatic conditions 
Microglia are the resident myeloid cell population of the CNS parenchyma, acting as active 
sensors of disturbances within their own microenvironment, with the capacity to initiate a 
diverse spectrum of responses to help restore tissue homeostasis (U. K. Hanisch & H. 
Kettenmann, 2007; Kreutzberg, 1996). Microglia have an abundant array of functions under 
normal homeostatic conditions including synaptic organisation, trophic neuronal support 
during development, phagocytosis of apoptotic cells in the developing brain, myelin turnover, 
control of neuronal excitability, phagocytic debris removal as well as brain protection and 
repair (Figure 1.5) (Bachiller et al., 2018). The development of single cell isolation techniques, 
alongside RNA sequencing advancements, have helped to delineate microglial cells from other 
mononuclear phagocytes within the CNS. Analysis of these datasets revealed microglial 
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specific transcripts such as P2ry12, P2ry13, Tmem119, Gpr34, siglech, Trem2, and Cx3Cr1 
(Beutner et al., 2013; Hickman et al., 2013).  
 
 
Figure 1.5 Functional processes carried out by microglia within the healthy brain. 
Under normal homeostatic conditions, microglia carryout a range of significant functions to 
help support and maintain the components of the neuro-glial-vascular unit. Image taken from 
(D. Gomez-Nicola & V. H. Perry, 2015). 
 
 Fate mapping studies have demonstrated that microglia mainly originate within the yolk 
sac, colonising within the neuroepithelium in early embryogenesis, having been derived from 
primitive macrophages (Ginhoux et al., 2010). The microglial population is maintained by the 
self-renewal of proliferating resident cells, and function largely independently of bone-
marrow-derived cells in the healthy brain (D. Gomez-Nicola & V. H. Perry, 2015). Microglial 
proliferation therefore relies on in situ mechanisms to regulate turnover, with little or no 
contribution from circulating progenitor cells (Lawson, Perry Vh Fau - Gordon, & Gordon, 
1992; Prinz & Mildner, 2011). The colony stimulating factor 1 receptor (CSF1R) is a myeloid 
specific class III receptor tyrosine kinase responsible for signalling cascades required for the 
development, survival, recruitment, and proliferation of mononuclear phagocytes such as 
microglia, perivascular macrophages, and peripheral macrophages (Dai et al., 2002; Raivich 
& Kreutzberg, 1994; Rojo et al., 2019). CSF1R has two known ligands, colony stimulating 
factor 1 (CSF-1) and interleukin 34 (IL-34), which are both produced locally within the CNS 
(Easley-Neal, Foreman, Sharma, Zarrin, & Weimer, 2019). IL-34 is predominantly expressed 
by neurons (Greter et al., 2012; Y. Wang et al., 2012), whereas CSF1 is produced by astrocytes, 
oligodendrocytes, and microglia (Cahoy et al., 2008). The importance for CSF1R signalling 
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in microglial survival and proliferation was demonstrated clearly in CSF1R knockout mice 
which show almost a complete lack of microglia at 3-weeks of age, while adult CSF-1 and IL-
34 null mice show regional specific microglia depletion (Ginhoux et al., 2010; Greter et al., 
2012; Kondo & Duncan, 2009; Y. Wang et al., 2012). 
Under healthy conditions microglia position themselves in tightly controlled mosaic 
organisations throughout the brain, independent of cell layers and blood vessels (Lawson, 
Perry Vh Fau - Dri, Dri P Fau - Gordon, & Gordon, 1990). Despite continuity in microglial 
mosaic formations across the brain, microglial cell density and morphology show a high 
degree of regional diversity (D. Gomez-Nicola & V. H. Perry, 2015). For example, microglia 
represent 12% of the total cells within the substantia nigra but only 5% within the corpus 
callosum of rodent brains (Lawson et al., 1990). Such density diversity is also evident in 
human brains with microglial representing 0.3% of cells within the cerebellar grey matter and 
16.9% within the medulla oblongata (Mittelbronn, Dietz K Fau - Schluesener, Schluesener Hj 
Fau - Meyermann, & Meyermann, 2001). Microglial morphological diversity is also region 
dependent, with elongated and orientated cells visible within the white matter which contrasts 
the more abundantly found, radially orientated, morphology observed within the cerebral 
cortex (Lawson et al., 1990). Along with regional specific morphology, microglia also display 
variation in lysosomal content (Majumdar et al., 2007), membrane composition (Button et al., 
2014), electrophysiological properties (De Biase et al., 2017) and gene transcriptome profiles 
(Hammond et al., 2019). Along with regional differences in transcriptomic prolife, microglial 
transcriptome diversity, particularly related to surface proteins and inflammatory markers, has 
been shown to differ between microglia even in close proximity (Jiang-Shieh, Wu Ch Fau - 
Chang, Chang Ml Fau - Shieh, Shieh Jy Fau - Wen, & Wen, 2003; Wu, Chien Hf Fau - Chang, 
Chang Cy Fau - Ling, & Ling, 1997). Generally speaking, however, microglia under normal 
homeostatic conditions show a transcription profile that is dominated by encoding for proteins 
associated with the sensing of endogenous ligands and microbes, referred to as the microglial 
sensome (Hickman et al., 2013). 
Ramified morphology and the limited expression of molecules related to macrophage 
function, are attributed to a ‘resting’ microglial phenotype (U. K. Hanisch & H. Kettenmann, 
2007). The emergence of in vivo multiphoton imaging techniques and transgenic Cx3Cr1eGFP 
reporter lines has demonstrated, however, that resting microglia are not dormant.  
Neuroimaging studies within both mice and zebrafish demonstrated that microglial processes 
are continually extending and retracting within their local environment, whilst maintaining a 
fixed soma position (Davalos et al., 2005; Nimmerjahn, Kirchhoff F Fau - Helmchen, & 
Helmchen, 2005; Wake, Moorhouse Aj Fau - Jinno, Jinno S Fau - Kohsaka, Kohsaka S Fau - 
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Nabekura, & Nabekura, 2009). Time-lapse recordings acquired through multiphoton imaging, 
within Cx3Cr1eGFP mice, demonstrated that microglial processes are continually rebuilt through 
de novo formation and withdrawal of processes, alongside motile filopodium-like protrusions 
(Davalos et al., 2005; Nimmerjahn et al., 2005). Microglial cells take turns scanning shared 
areas, thus ensuring that processes rarely come into contact with one another allowing for the 
mosaic distribution of microglia to effectively cover, and therefore monitor, the local 
environment (Nimmerjahn et al., 2005). It is estimated that through careful organisation, and 
dynamic process movement, that microglia can monitor the entire brain parenchyma every few 
hours (U. K. Hanisch & H. Kettenmann, 2007). The maintenance of this highly dynamic 
process movement is achieved through a diverse array of soluble or membrane-bound factors, 
with neuronal and non-neuronal origin (U.-K. Hanisch & H. Kettenmann, 2007; Kettenmann, 
Hanisch Uk Fau - Noda, Noda M Fau - Verkhratsky, & Verkhratsky, 2011). Examples of such 
factors altering microglial dynamics include ATP and CX3CL1 (Davalos et al., 2005; Liang et 
al., 2009), however the full scope of modulatory systems potentially effecting these processes 
are not fully understood (Diego Gomez-Nicola & V. Hugh Perry, 2015). Microglial 
surveillance functions challenge the view of a ‘resting’ phenotype, as such activities require 
constant morphological alterations alongside biochemical sensing and interpretation of 
environmental cues. The microglial resting state may therefore more accurately reflect a 
defined mode of activation (U. K. Hanisch & H. Kettenmann, 2007). 
 
1.9.4 Microglial structural and functional alterations under 
pathological conditions 
Microglia are often considered the immune cells of the CNS, with the remarkable capacity 
to respond to almost any form of CNS disturbance raging from local changes in homeostasis 
and infection to acute and chronic injury (Richard M. Ransohoff & Joseph El Khoury, 2015). 
Microglia have the ability to sense changes within their local microenvironment through the 
surface expression of varied receptors such as purino- and fractalkine receptors, receptors for 
complement fragments, immunoglobulins, adhesion molecules, and inflammatory stimuli 
(Raivich et al., 1999; van Rossum & Hanisch, 2004).  The microglial response to such changes 
is termed “microglial activation” and describes alterations not only in function but also cell 
morphology (Diego Gomez-Nicola & V. Hugh Perry, 2015). Microglia, following activation, 
have the ability to shift into a range of functional states leading to changes in proliferation 
(Gomez-Nicola, Fransen Nl Fau - Suzzi, Suzzi S Fau - Perry, & Perry, 2013), morphology 
(Cuadros & Navascués, 1998), motility and migration (Mosher & Wyss-Coray, 2014), 
phagocytic activity (Sierra, Abiega, Shahraz, & Neumann, 2013), antigen presentation 
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(McGeer, Itagaki S Fau - Tago, Tago H Fau - McGeer, & McGeer, 1988), and the release of 
inflammatory mediators such as cytokines and chemokines (Kettenmann et al., 2011). 
Microglial activation results in chemotactic reorientations and other non-transcriptional events 
within seconds to minutes following stimulation. Within a few hours a massive induction of 
complex gene sets can be achieved, drastically altering microglial function (U. K. Hanisch & 
H. Kettenmann, 2007). Microglial activation is often accompanied by increased lysosomal and 
phagocytic activity, detected by the immunohistochemical markers lysosome-associated 
membrane protein 2 (Lamp2) and CD68, respectively. Such alterations highlight an increased 
capacity to remove cellular debris which forms a fundamental aspect of microglia’s ability to 
combat infection and disease (Mosher & Wyss-Coray, 2014). Microglial phagocytosis has also 
been shown to be important for the removal of apoptotic debris in the developing and adult 
brain, which has a beneficial effect through the prevention of pro-inflammatory cytokine and 
chemoattractant release (Magnus, Chan A Fau - Grauer, Grauer O Fau - Toyka, Toyka Kv Fau 
- Gold, & Gold, 2001). However, there is evidence to suggest that microglia can actively 
phagocytose endangered, but potentially viable, neurons and therefore can contribute to 
neurodegenerative disease (Fricker et al., 2012; Jonas J. Neher et al., 2013; J. J. Neher et al., 
2011). In addition to the removal of apoptotic or damaged cells, microglia can engulf and 
prune synapses (Schafer et al., 2012), clear axonal and myelin debris (Hosmane et al., 2012; 
Nielsen et al., 2009), and remove potentially toxic proteins such as Aβ (Sierra et al., 2013).  
Such results highlight the potentially detrimental effect of uncontrolled or misdirected 
microglial phagocytosis. 
Traditionally, the study of microglial activation was carried out within animal models of 
disease or through tissue culture approaches, with the bacterial endotoxin lipopolysaccharide 
(LPS) most commonly used to elicit microglial activation. LPS mimics infection by Gram-
negative bacteria, leading to a substantial antimicrobial defence and the activation of microglia 
(U. K. Hanisch & H. Kettenmann, 2007). Such a paradigm led to the view that microglial 
activation is an all or nothing reaction, causing the release of proinflammatory cytokines which 
are detrimental and neurotoxic (Diego Gomez-Nicola & V. Hugh Perry, 2015). More recent 
findings, however, have demonstrated that microglial activation is a plastic multifaceted 
response, which is not only context dependent, but also region and time dependent, being 
finely tuned to the nature of the stimulus, the local environment as well as the prior state of 
the cell (D. Gomez-Nicola & V. H. Perry, 2015). Therefore, the view that microglial activation 
is a monophasic, all or nothing, response is outdated and inaccurate (Bachiller et al., 2018) 
Multiphoton imaging studies, using the Cx3Cr1eGFP microglial reporter mouse, have 
demonstrated that microglial activation following injury is associated with alterations in 
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microglial motility as well as structure. Focal laser induced injuries were shown to lead to 
local microglial activation, causing a switch of behaviour from patrolling to shielding of the 
injured site (Nimmerjahn et al., 2005). Additional, complementary studies, demonstrated that 
the rapid process-extension response towards sites of laser injury were mediated by ATP 
binding to the purinergic receptor P2ry12 (Davalos et al., 2005; Haynes et al., 2006). The 
directionality of process movement to areas of damage is thought to be guided through 
purinoreceptor stimulation and may involve astrocytic assistance (Davalos et al., 2005; Haynes 
et al., 2006). Intravital imaging approaches have also demonstrated that alterations in 
microglial morphological parameters, such as soma size and sphericity, can be assessed and 
used to highlight a change in activation state (B. M. Davis, Salinas-Navarro, Cordeiro, Moons, 
& De Groef, 2017; Kozlowski & Weimer, 2012). Advancements in such imaging approaches, 
as well as microglial transgenic reporter lines allow for changes in microglial activation state 
to be identified in real-time, in vivo, under disease conditions.  
 
1.9.5 Evidence for microglial involvement in human VCI and 
other chronic degenerative diseases  
There is mounting evidence to implicate neuroinflammatory mechanisms in the onset and 
progression of cerebrovascular disease. Recent GWAS studies, identified 5 risk loci associated 
with neuroimaging markers of white matter dysfunction, with these genes also shown to be 
highly expressed by microglial and macrophages populations (Armstrong et al., 2020; Persyn 
et al., 2020).  Post mortem neuropathological evaluation of white matter lesions reveals myelin 
loss and axonal degeneration, associated with a prominent microvascular inflammatory 
response (Simpson, Fernando Ms Fau - Clark, et al., 2007; Simpson et al., 2009; J. M. Wardlaw 
et al., 2019). A key component of this response is the expansion and activation of microglial 
cells (Simpson, Ince Pg Fau - Higham, et al., 2007), with increased microglial number being 
detected frequently in human VCI cases (Akiguchi, Tomimoto H Fau - Suenaga, Suenaga T 
Fau - Wakita, Wakita H Fau - Budka, & Budka, 1997; Simpson, Fernando Ms Fau - Clark, et 
al., 2007; Simpson, Ince Pg Fau - Higham, et al., 2007). Furthermore, positron emission 
tomography (PET) imaging revealed indices of neuroinflammation as well as amyloid deposits 
within 50% of patients with mild cognitive impairment, potentially implicating microglial 
activation in early disease progression (Okello et al., 2009). Ageing, the greatest risk factor 
for VCI and dementia, alone has been shown to drive changes in microglial function (Wong, 
2013). Increased microglial activation was also observed post mortem within cognitively 
normal old age patients when compared to young and ‘SuperAger’ groups (Gefen et al., 2019).  
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Alongside evidence implicating microglia in the onset of white matter disease and the 
progression of VCI, GWAS studies have also identified 25 genetic loci associated with 
increased risk for late-onset AD, with the majority of them related to neuroinflammation and 
predominantly expressed on microglial cells, such as ApoE, Soi1, and Trem2 (Corder et al., 
1993; Guerreiro et al., 2013; Olichney et al., 1995). PET imaging, within symptomatic AD 
patients, also showed markers of microglial activation and tau pathology to be accurate 
predictors of further cognitive decline (Malpetti et al., 2020). Increased microglial numbers as 
well as increased levels of microglial proliferation were identified within both the grey and 
white matter of AD patients at post mortem. With such changes linked to elevated gene 
expression of the main components of the CSF1R signalling pathway such as CSF1R, CSF1, 
SpI1, CEBPA,  and RUNX1 (Adrian Olmos-Alonso et al., 2016a).  
Despite compelling clinical evidence implicating microglia in the onset and progression of 
VCI and dementia, direct evidence proving a causative role is yet to be reported. This has led 
to a reliance on animal models which allow for genetic and pharmacological approaches, not 
possible within clinical studies, to help provide definitive evidence of a direct causative 
microglial role in disease onset and progression.  
 
1.9.6 BCAS models: The contribution of microglia to white 
matter disease and cognitive impairment 
One of the most prominent features of the BCAS model is a robust increase in microglial 
number. In response to increasing durations of cerebral hypoperfusion, microglial numbers 
were observed to increase gradually in parallel with both white matter damage (Holland et al., 
2011; McQueen et al., 2014; Reimer et al., 2011; Shibata et al., 2004; Wakita et al., 1994) and 
cognitive impairment (Kitamura et al., 2017). Increased microglial number has also been 
demonstrated within grey matter regions, such as the hippocampus, following BCAS surgery 
(J. M. Roberts, Maniskas, & Bix, 2018).  
 
1.9.7 Pharmacological targeting microglial within BCAS and 
chronic degenerative disease models 
Pharmacological anti-inflammatory treatments, shown to have a beneficial impact within 
the BCAS model, are associated with reduced microglial proliferation. The broad-acting anti-
inflammatory drugs minocycline and dimethyl fumarate (DMF), were found to restore white 
matter function following BCAS, which was related to a reduction in the number of white 
matter microglia (Fowler et al., 2017; Manso et al., 2017). Similarly, the phosphodiesterase 3 
inhibitor cilostazol was found to reduced working memory impairments and improve white 
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matter function following BCAS, which was once again associated with reduced microglial 
numbers (Kitamura et al., 2017).  
The predominant system for the control of microglial/macrophage differentiation, 
maintenance, and proliferation in both health and disease is the CSF1R pathway (Martin-
Estebane & Gomez-Nicola, 2020). CSF1R signalling therefore represents a viable target for 
the manipulation of microglial populations, with pharmacological inhibitors available that are 
capable of blocking microglial proliferation alone or ablating microglia entirely. The 
pharmacological ablation of microglia, through treatment with CSF1R inhibitor PLX2297 
prior to BCAS surgery, was found to attenuate white matter damage and limit cognitive 
impairment (Kakae et al., 2019b). However, such treatments almost completely ablate 
microglial populations from the brain which has the potential to significantly impact the 
function of all components of the neuro-glial-vascular unit, making it very difficult to unpick 
the direct causative role of microglial proliferation.  
GW2580 is a pharmacological compound which acts to specifically inhibit the tyrosine 
kinase activity of the CSF1R. GW2580 treatment leads to a blockade of microglial 
proliferation, without the elimination of the endogenous microglial population (Conway et al., 
2005). Treatment with GW2580 was found to prevent the degeneration of synapses and 
impede disease progression within a APP/PS1 AD model (A. Olmos-Alonso et al., 2016), and 
has also been shown to be beneficial within other neurodegenerative diseases, including prion 
disease (Gomez-Nicola et al., 2013) and amyotrophic lateral sclerosis (Martínez-Muriana et 
al., 2016).  
There is therefore compelling evidence linking increased microglial numbers to white 
matter damage and cognitive impairments following BCAS, however a specific targeted 
approach has yet to be applied to demonstrate a clear causative role for microglial proliferation 
in these processes. 
 
1.10 Potential pathophysiological mechanisms underlying white 
matter damage and cognitive impairment 
 
1.10.1 Cerebrovascular dysfunction and microvascular 
inflammation 
As mentioned at the outset, the cerebrovascular blood supply is crucial to the maintenance 
of brain health and is required to be extremely dynamic to meet the rapidly changing metabolic 
needs of the brain. To successfully maintain homeostatic conditions within the brain, the 
cerebrovasculature carries out a number of dynamic functions such as autoregulation, 
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neurovascular coupling, as well as cerebrovascular pulsation. Alongside these crucial roles in 
the maintenance of homeostatic conditions, the cerebrovasculature also plays a fundamental 
role in inflammatory process through endothelial activation and the associated microvascular 
inflammatory response.  
 
1.10.2 Microvascular inflammation 
Endothelial cells form the inner lining of the BBB and have roles in many physiological 
processes, such as the transport of nutrients across the BBB, the export of critical toxins from 
the brain, angiogenesis, and the regulation of vascular tone (Sturtzel, 2017). Alongside its 
crucial role in homeostasis the endothelium also plays a fundamental role in inflammation. 
The endothelium dynamically regulates the inflammatory response within the brain through 
regulation of vascular permeability to macromolecules and leukocytes (Videm & Albrigtsen, 
2008). The endothelium can become activated in response to an array of different compounds 
ranging from pro-inflammatory cytokines and complement activation products, to reactive 
oxygen species and endotoxins (Videm & Albrigtsen, 2008). Endothelial activation is 
characterised by 5 core changes which are: the increased expression of leukocyte adhesion 
molecules, the loss of vascular integrity, a change of phenotype from antithrombotic to 
prothrombotic, cytokine production, and the upregulation of HLA molecules (Hunt & Jurd, 
1998). Adhesion molecules, such as integrin intercellular adhesion molecule-1 (ICAM-1), act 
to mediate leukocyte extravasation from the blood stream into the brain, in a process known 
as leukocyte extravasation, leading to pro-inflammatory environments within the brain (Figure 
1.6) (Schnoor, Alcaide, Voisin, & van Buul, 2015). Initially, leukocytes must adhere to the 
endothelial membrane to facilitate their migration from the blood stream into the brain’s 
parenchyma. Leukocytes flow through the blood stream, making brief contact with the 
endothelial wall where adhesion molecule expression is upregulated. This brief contact 
triggers the leukocyte to slow its movement, causing it to roll along the endothelium. Some 
leukocytes will then disengage from the endothelial wall and be carried away by the circulating 
blood flow. Others will form strong bonds to the endothelial wall causing them to come to a 
firm stop and adhere in place. Following adherence, leukocytes will either transmigrate into 
the brain, over the course of minutes, allowing them to enter the brain and facilitate 
inflammatory responses (Adams & Shaw, 1994), or they will detach and re-enter the 
circulation. Leukocyte rolling and adhesion alone, without transmigration, has been shown to 
lead to downstream signalling facilitating the recruitment and activation of microglial cells (H. 
Wang et al., 2015). The ability, therefore, for endothelial cells to facilitate neuroinflammatory 
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responses, highlights endothelial activation as a potentially relevant mechanism in the 




Figure 1.6 Schematic of leukocyte trafficking and transmigration. Illustration depicting 
the different steps of leukocyte interactions with endothelial cells during adhesion and 
transmigration. Leukocyte-endothelial reactions are mediated through leukocyte adhesion 
molecules, such as ICAM-1, expression on the endothelial cell wall. Figure adapted from 
(Schnoor et al., 2015) 
 
1.10.3 Evidence for cerebrovascular dysfunction and 
microvascular inflammation in human VCI and other chronic 
degenerative diseases 
Considerable evidence, gathered from both neuroimaging and pathological studies, 
indicates that cerebrovascular dysfunction has a crucial role to play in the pathophysiology of 
VCI and dementia (Di Marco et al., 2015; Poggesi et al., 2016; Joanna M. Wardlaw, Colin 
Smith, et al., 2013). Endothelial dysfunction has been highlighted as a pivotal mechanism 
underpinning cerebrovascular dysfunction, and leads to structural and functional changes 
within the cerebrovascular network (Poggesi A Fau - Pasi et al., 2016; J. M. Wardlaw et al., 
2013).Vascular risk factors associated with chronic cerebral hypoperfusion, SVD and VCI 
have also been associated with endothelial dysfunction such as ageing (Vendemiale, Romano 
Ad Fau - Dagostino, Dagostino M Fau - de Matthaeis, de Matthaeis A Fau - Serviddio, & 
Serviddio, 2013), hypertension (Iadecola & Davisson, 2008; Virdis et al., 2013) and diabetes 
(Hamilton & Watts, 2013; A. C. Roberts & Porter, 2013). It is proposed that these risk factors 
may alter cerebrovascular haemodynamics, leading to alterations in endothelial cell function. 
ICAM-1, a marker of endothelial activation has been implicated within a number of 
neurodegenerative disorders (Frohman, Frohman Tc Fau - Gupta, Gupta S Fau - de 
Fougerolles, de Fougerolles A Fau - van den Noort, & van den Noort, 1991; Grammas, 2011; 
Rentzos et al., 2005), with evidence from human MRI studies highlighting an association 
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between plasma ICAM-1 levels and the progression of white matter lesions (Markus et al., 
2005). Endothelial dysfunction has also been associated with impairments in cerebrovascular 
reactivity, which are thought to impede cerebral haemodynamic responses that are crucial to 
normal homeostatic functions. Such impairments to the cerebrovasculature could in turn lead 
to neurovascular coupling deficiencies, which are associated with transient and chronic 
cerebral hypoperfusion and the further exacerbation of VCI related pathology (M. Bordeleau, 
A. ElAli, & S. Rivest, 2016; Di Marco et al., 2015; Poggesi et al., 2016; Joanna M. Wardlaw, 
Colin Smith, et al., 2013; J. M. Wardlaw et al., 2013). Impaired cerebrovascular reactivity has 
been identified within regions of normally appearing white matter of elderly individuals, and 
is thought to proceed and therefore predict the appearance of white matter lesions (Sam et al., 
2016). 
Alongside evidence for a significant role in VCI, impaired cerebrovascular reactivity and 
impaired haemodynamic responses are being increasingly recognised in the early stages of AD 
(Sweeney, Kisler, Montagne, Toga, & Zlokovic, 2018). Impaired cerebrovascular reactivity, 
determined through diminished vasodilation responses to CO2 inhalation, was identified 
within early AD patients but not cognitively normal controls, as measured via transcranial 
Doppler (den Abeelen As Fau - Lagro, Lagro J Fau - van Beek, van Beek Ah Fau - Claassen, 
& Claassen, 2014) or functional MRI (fMRI) imaging (Yezhuvath et al., 2012). BOLD-fMRI 
imaging has also been used to demonstrate impaired neurovascular coupling, following visual 
stimulation and memory encoding, within a number of different brain regions of patients with 
mild cognitive impairment as well as AD (Rombouts et al., 2000).  
Given the substantial evidence for a range of impaired cerebrovascular mechanisms within 
VCI and dementia, further study into such mechanisms within the context of VCI is necessary 
to uncover common pathogenic mechanisms underpinning shared pathology. 
 
1.10.4 BCAS model: Evidence for cerebrovascular dysfunction 
and microvascular inflammation 
Microarray analysis of white matter samples have demonstrated alterations within 
endothelial related genes as early as 3-days following BCAS, alongside increases in pro-
inflammatory associated genes (Reimer et al., 2011). Endothelial activation, in a rat model of 
chronic cerebral hypoperfusion, was highlighted as one of the earliest changes leading to the 
progression of white matter pathology (Huang et al., 2010). In addition, treatment with the 
neuroprotective metabolic antioxidant lipoic acid, was found to reduce ICAM-1 expression, 
which was associated with significantly less severe white matter lesions and a reduction in 
activated microglia and reactive astrocytes (Huang et al., 2010). The role for endothelial 
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activation was further supported by the progressive upregulation of ICAM-1 observed up to 
3-months following BCAS surgery (Kitamura et al., 2017). Multiphoton imaging approaches 
have provided support to such findings, through the identification of leukocyte rolling and 
adhesion as early as 24-hours following BCAS surgery (Yata et al., 2014). Alongside evidence 
of endothelial activation following BCAS, there are also reports to suggest impairments in 
cerebrovascular control mechanisms, with neurovascular coupling responses found to be 
significantly impaired 1-month following BCAS surgery (Duncombe, Kitamura, et al., 2017).  
Despite these findings, investigations into the effects of BCAS on cerebrovascular 




Vascular cognitive impairment represents a monumental challenge to world health as the 
population ages. Currently, the mechanistic changes driving pathology and cognitive 
impairment remain largely unknown, and a more detailed and comprehensive understanding 
is crucial to the development of disease altering treatments. BCAS represents a key 
experimental model of VCI, recapitulating many aspects of cerebrovascular disease pathology, 
allowing pathological mechanisms to be interrogated and targeted. Microglial proliferation 
and activation as well as cerebrovascular dysfunction and microvascular inflammation have 
been highlighted, both clinically and pre-clinically, as potential mechanisms driving disease 
progression and cognitive impairment. This thesis aims to make use of targeted 
pharmacological treatments, transgenic mouse reporter lines, and intravital imaging 
approaches to interrogate the role of these processes more accurately in disease progression. 
Microglial proliferation and activation are commonly observed in both human and animal 
models of VCI, being linked to white matter damage and cognitive impairment. The primary 
aim of this thesis will be to determine the role of microglial proliferation in ensuing white 
matter damage and cognitive impairments, through a targeted pharmacological approach. 
Secondary to this, Cx3Cr1eGFP/+ mice alongside intravital multiphoton imaging will be used to 
further interrogate microglial structural and functional alterations in response to BCAS. 
Additionally, these mechanisms will be further investigated in a co-morbid situation through 
combination of BCAS with the App23 mouse model of amyloidosis. The final aim will be to 
apply intravital multiphoton imaging approaches to the study of cerebrovascular dysfunction 
and microvascular inflammation following BCAS surgery. 
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1.12 Hypothesis 
The overarching hypothesis of the present thesis is that microglial proliferation causes 
white matter damage underpinning vascular cognitive impairment. 
  
1.13 Aims 
The following general aims were investigated within chapters 3, 4, and 5 to address the 
above hypothesis and in parallel to provide further detail on microglial and cerebrovascular 
functions within a mouse model of VCI: 
1. To assess, using an animal model of BCAS, CBF alterations and the extent of 
microglial proliferation within both white and grey matter regions. Following this the 
effect of blocking microglial proliferation, with the use of the CSF1R inhibitor 
GW2580, was assessed to determine if this would prevent white matter damage and 
cognitive impairments following BCAS surgery in mice. 
2. To assess, using transgenic microglial reporter lines and intravital imaging, microglial 
structural and functional changes in vivo following BCAS. Following this the effect of 
co-morbid conditions on microglial structure and function were assessed, through the 
application of BCAS surgery to the APP overexpressing App23 mouse model. 
3. To assess, through intravital imaging, changes in CBF within cortical vessels in real 
time alongside in vivo measurements of cerebrovascular function and endothelial 







Materials and Methods 
 
2.1  Animals 
Mice were group housed on a 12-hour light and dark cycle with ab libitum access to food 
and water for all experiments. Detailed group numbers for each experiment can be found 
within study chapters under the relevant methods section. All experimental procedures were 
completed in compliance with the UK Home Office Animals (Scientific Procedures) Act 1986 
under Home Office granted personal and project licences and in agreement with veterinary 
and local ethical approval (Biomedical Research Resources, University of Edinburgh) and 
ARRIVE guidelines (Kilkenny, Browne, Cuthill, Emerson, & Altman, 2010). Throughout 
experiments and analysis assessors were blind to surgery, genotype, and treatment status of all 
mice. Mice were randomly assigned to experimental groups, details of which can be found 
within the methods section of the relevant chapters.  
 
2.1.1 C57BL/6J mice 
Wild-type C57BL/6J mice were purchased from Charles River Laboratories (JAXTM- 
C57BL/6J) and used for experiments detailed within chapters 3 and 5. 
 
2.1.2 Cx3Cr1eGFP/eGFP mice 
Cx3Cr1eGFP/eGFP mice were acquired as a generous gift from Professor Jeffrey Pollard, 
University of Edinburgh, and developed as previously described (Jung, Aliberti, et al., 2000). 
Briefly, the murine Cx3Cr1 gene locus was isolated from a 129/Sv phage library, through the 
hybridization with a human Cx3Cr1 cDNA probe, to generate a Cx3Cr1 targeting vector. A GFP 
neomycin resistant cassette, replacing the first 390bp of the Cx3Cr1 gene, was constructed 
using a fragment spanning the eGFP gene. Embryonic stem cells were then transfected with 
the targeting vector, with successful targeting assessed through Southern blot analysis. 
Embryonic stem cell clones, lacking the neomycin gene, were then injected into blastocysts to 
generate chimeric mice (Jung, Aliberti, et al., 2000).  
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2.1.3 App23 mice 
App23 heterozygous mice were purchased from The Jackson Laboratory (B6. Cg-
Tg(Thy1-APP)3Somm/J) and cross bred with Cx3Cr1eGFP/eGFP mice to generate mice for 
experiments detailed within chapter 4. App23 transgenic mice possess a 6.7 kbp murine Thy1 
cassette driving the expression of the human APP isoform 751, which contains the Swedish 
double mutation App751*K670N/M671L) (Sturchler-Pierrat et al., 1997). 
 
2.1.4 Cx3Cr1eGFP/+ and Cx3Cr1eGFP/+ App23+/- mice 
Cx3Cr1eGFP/eGFP mice were crossed with App23+/- mice to generate Cx3Cr1eGFP/+App23+/- and 
Cx3Cr1eGFP/+App23-/- mice that were used for the experiments detailed in chapter 4. To confirm 
genotypes for studies DNA was extracted and all mice were genotyped according to the 
methods detailed below.  
 
2.1.5 DNA extraction for genotyping 
DNA was extracted from ear or tail samples using 300µl of 50mM sodium hydroxide. Each 
sample, following the addition of sodium hydroxide, was centrifuged at 9000 rpm for 1-minute 
and then incubated at 950C for 30-minutes. Samples were cooled at room temperature for 10-
minutes before being vortexed. 50µl of 1M Tris HCL pH 8.0 was then added and each sample 
was vortexed. Samples were then allowed to incubate at room temperature for 30-minutes 
before being used for genotyping or frozen at -200C for future use.  
 
2.1.6 Cx3Cr1eGFP/+ genotyping 
PCR was performed using Taq Master Mix (hot start taq, Qiagen); 10µl were added to 2µl 
of DNA extracted from each sample along with 1µl of each of the 3 primers (Table 2.1) and 
5µl of nuclease free H2O. The PCR program used is detailed within Table 2.1. Upon 
completion the samples were maintained at 720C for 2-minutes before being held at 100C.  
Samples were then run on a 3% agarose gel (Agarose, Promega; in Tri/Borate/EDTA 
buffer, Sigma-Aldrich) with 15µl IntrogenTM SYBRTM Safe stain (ThermoFisher Scientific) at 
120V for 1-hour. Cx3Cr1 heterozygous bands are visible at 410bp and ≈500bp with wild-type 
mice showing a single band at 410bp.  
 
2.1.7 App23 genotyping 
PCR was performed using Taq Master Mix (hot start taq, Qiagen); 10µl were added to 2µl 
of DNA extracted from each sample along with 2µl of each of the 4 primers (Table 2.1). The 
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PCR program used is detailed within Table 2.1. Upon completion the samples were maintained 
at 720C for 2-minutes before being held at 40C. 
Samples were then run on a 3% agarose gel (Agarose, Promega; in Tri/Borate/EDTA 
buffer, Sigma-Aldrich) with 15µl IntrogenTM SYBRTM Safe stain (ThermoFisher Scientific) at 
120V for 1-hour. APP band is visible at 167bp and the GAPDH control band at 342bp. 
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2.2    Bilateral common carotid artery stenosis surgery 
Bilateral common carotid artery stenosis surgery was performed according to the method 
previously described (Figure 2.1) (Shibata et al., 2004). In brief, mice are anaesthetised by 
inhalation of 5% isoflurane in oxygen which is then reduced 1.5% and maintained during 
surgery. A small cervical neck incision is made to allow the common carotid arteries to be 
exposed by careful dissection and displacement of the superficial muscles, surrounding 
connective tissues, and vagus nerve. A 0.16 (chapter 3) or 0.18mm (chapters 4 and 5) internal 
diameter micro-coil (Sawane Spring Co. Japan) is then placed around the left common carotid 
artery (Figure 2.1). To prevent a drastic reduction in CBF, the animal is allowed a 30-minute 
recovery period before being re-anesthetised for the application of the second micro-coil 
(0.18mm) around the right common carotid artery. The incision is then sutured, and the animal 
is placed within a heated incubator, maintained at 380C, to recover from anaesthesia. As a 
control for all experiments, sham mice undergo an identical procedure with the only exception 
being the application of micro-coils. All surgical procedures were conducted under aseptic 
techniques, and animals were monitored closely for the 72-hours following surgery for any 
signs of poor health. Following the 72-hour observation period, mice were checked twice 
weekly, and weight was monitored to ensure that mice remained sufficiently healthy 
throughout all experiments. Excessive weight loss and poor recovery following surgery 
resulted in mice being humanely culled and removed from studies. Details of animal 
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Figure 2.1 Bilateral common carotid artery stenosis (BCAS) surgery. (A) Schematic 
diagram showing a micro-coil positioned bellow the carotid bifurcation of the common carotid 
artery. Image adapted from (Shibata et al., 2004). (B) Specifications of the micro-coils used to 
restrict CBF during BCAS surgery. Image adapted from (Masafumi Ihara & Tomimoto, 2011). 
 
2.3    Laser speckle imaging of resting cerebral blood flow 
Superficial cortical perfusion was measured throughout all studies through the use of laser 
speckle imaging. Mice were initially anaesthetised at 5% isoflurane in 100% oxygen, before 
being transferred to a stereotaxic frame where isoflurane was maintained at 3%. Ear and tooth 
bars were used to stabilise the head below the laser and anaesthesia was delivered, with 
ventilation, via a nose cone at a rate of 150 breaths per minute. Body temperature was 
monitored throughout imaging with the use of a rectal probe and maintained at 370C±0.50C 
using an electric heat blanket. A sterile scalpel is then used to create an incision through the 
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midline of the scalp, which is retracted using surgical clips to expose the skull. Once the 
incision has be completed, isoflurane was dropped to 2.5% and maintained for the reminder 
of imaging. The skull is cleaned, and residual fur is removed with the application of ultrasound 
gel, which also acts to prevent the skull surface drying during recording. For studies in which 
cranial windows have been implanted to facilitate multiphoton microscopy (chapters 4 and 5), 
laser speckle imaging is conducted directly through the window and therefore additional 
incisions are not required. Once stable, baseline blood flow within the barrel cortex is recorded 
using a laser speckle contrast imager (Moor FLPI2 Speckle Contrast Imager, Moor 
Instruments, UK), which generates speckle contrast images. Upon completion of at least 1-
minute of stable blood flow the incision is sutured, and the mouse is placed within an incubator 
maintained at 380C and allowed to recover. The topical anaesthetic lidocaine is then applied 
to the scalp to limit post-operative pain. Laser speckle imaging was repeated longitudinally at 
different timepoints following surgery depending on the study. Details of laser speckle 
imaging timepoints can be found within the method section of the relevant chapters. For 
statistical analysis values are presented as a percentage change from baseline values.   
C57/B6J mice were selected for all studies as they have an incomplete circle of Willis, due 
to a lack of posterior cerebral arteries (G. Yang et al., 1997). Thus meaning that compensatory 
blood flow mechanisms are not sufficient to rescue blood flow reductions following BCAS 
surgery, thus allowing CBF reductions to be maintained overtime (Qian, Rudy, Cai, & Du, 
2018). Despite this, a subset of mice showed resistance to BCAS surgery with little evidence 
of reductions in CBF. Through the injection of a fluorescently conjugated dextran, non-
responding mice were found to have intact circle of Willis’ (Figure 2.2B) with posterior 
cerebral arteries clearly visible leading to a conferred resistance to BCAS surgery. As a result, 
strict exclusion criteria were applied to each study to ensure that BCAS surgery was indeed 
leading to sufficient CBF reductions. The CBF reduction criteria differed between studies due 
to variations in the size of micro-coil used. Details of exclusion criteria used, as well as the 
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Figure 2.2 Intact circle of Willis within a subset of C57BL/6J mice confers BCAS 
resistance. (A) Schematic image of a completely intact circle of Willis. Image courtesy of 
OpenStax College, Radiopaedia.org, rID: 42608. (B) Florescent image generated within a 
BCAS resistant mouse, through injection of 70kDA FITC dextran immediately prior to tissue 
extraction. The posterior communicating artery (PcomA) is clearly visible and therefore 
provides compensatory blood flow to help counteract BCAS mediated CBF reductions. 
 
2.3.1 Laser speckle imaging analysis 
Laser speckle contrast images are analysed using the MoorFLPI-2 Review software 
(version 4.0). Regions of interest (ROI) are placed over the left and right hemispheres, between 
bregma and lambda. Care is taken to ensure that ROIs are away from large midline vessels, 
and that they do not overlap areas of skin, which can block the blood flow (Figure 2.3A). A 
mean flux value is generated from ROIs in the left and right hemisphere, which represents the 
average flux over 1-minute of stable blood flow recording (Figure 2.3B). Average flux values 
from the left and right hemispheres are then averaged to generate an overall value of flux to 
represent that imaging timepoint. Due to biological variation, the cortical CBF measurement 
for each animal was normalised to its own baseline value, which was obtained prior to surgery. 






Figure 2.3 Laser speckle image analysis. (A) Representative images demonstrating the 
ROI positioning for CBF measurements via laser speckle imaging. (B) Representative trace 
for cortical blood flow flux values of a typical sham recording. Light blue region demonstrates 
the ROI used to generate an average flux value for the recording, across both the left (mean 
F1) and right (mean F2) hemispheres. 
 
2.3.2 Laser speckle imaging of neurovascular coupling 
responses 
Mice are anesthetised by a combination of α-chloralose (50mg/kg) and urethane 
(750mg/kg) delivered via intraperitoneal injection. The standard anaesthetic isoflurane is not 
used due to its vasodilatory properties. The mouse is placed in the stereotaxic frame where ear 
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and tooth bars are used to stabilise the head below the laser. Body temperature was monitored 
throughout imaging with the use of a rectal probe and maintained at 370C±0.50C using an 
electric heat blanket. Laser speckle imaging was conducted directly through the cranial 
window. Before whisker stimulation, the left (unstimulated) whiskers are cut, and the right 
(stimulated) whiskers are trimmed to an approximate length of 1cm. A stable baseline blood 
flow recording within the barrel cortex is achieved and then recorded using a laser speckle 
contrast imager (Moor FLPI2 Speckle Contrast Imager, Moor Instruments, UK). The right 
whiskers are then deflected, with the use of an electric toothbrush, back and forth to generate 
a neurovascular coupling response within the contralateral barrel cortex. This process is 
repeated until at least 4 satisfactory neurovascular coupling responses are recorded. Following 
imaging the mouse is placed within an incubator maintained at 380C and allowed to recover 
before being returned to their home cage. 
 
2.3.3 Laser speckle neurovascular coupling image analysis 
Laser speckle contrast images were analysed with the use of the MoorFLPI-2 Review 
software (version 4.0). ROIs were positioned within the barrel cortex of the left hemisphere 
and mean response amplitude, across 30-seconds of stimulation, was recorded. Representative 
values were generated from an average of 4 stimulations per mouse. Data is presented as 
percentage increase from baseline. Stimulation recordings were excluded if baseline blood 
flow fluctuated during the assessment window or if operator error led to non-physiological 
responses. Details of recording exclusions based on these criteria can be found within the 
methods section of the relevant chapter. 
 
2.4    Cranial window surgery in preparation for multiphoton 
microscopy 
Prior to multiphoton microscopy it is necessary for a cranial window to be installed to 
facilitate laser penetration into the brain which would otherwise be attenuated by the skull. 
The cranial window procedure employed within the present studies was adapted from a 
method previously described within the literature (Drew et al., 2010). The surgery is conducted 
under sterile conditions using autoclaved instruments. Initially each mouse is weighed to 
ensure that the correct dose of the anti-inflammatories carprofen (5mg/kg) and dexamethasone 
(0.2mg/kg) is given to help reduce brain swelling and limit post-operative discomfort. The 
mouse is then anesthetised via inhalation of 5% isoflurane in oxygen. Once unconscious 
(unresponsive to foot pinch) the mouse is placed on a stereotaxic frame and maintained at 1.5-
3% isoflurane delivered via a face mask. The mouse’s temperature is checked via a rectal 
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thermometer and maintained at 370C ±10C throughout the surgery with the use of an electric 
blanket. Carporfen and dexamemethasone are then delivered by subcutaneous injection. The 
mouse’s head is shaved, and ointment is applied to the eyes to prevent them drying out during 
the procedure. The scalp is then sterilised with ethanol and the skin directly between the ears 
extending to between the eyes is removed to expose the skull. A scalpel is used to gently scrape 
away any residual membrane to ensure the skull is dry. Vetbond glue is then applied to seal 
the edges of the scalp to the exposed bone. Once dry, superglue is applied covering all the 
vetabond as well as some areas of skull to ensure a firm seal. A dental drill (16,000 rpm) is 
used to drill a rectangle, approximately 6x4mm in width positioned across both hemispheres’ 
inferior to bregma, until a very thin layer of bone remains. A drop of saline is then applied and 
allowed to soak into the skull before the craniotomy is removed via right-angled forceps. 
Gelfoam is applied to prevent any small bleeds that may occur. The gelfoam is removed and 
the skull around the craniotomy is dried before a 7mm glass coverslip is placed on top of the 
dura. Once exposed the dura is continuously bathed in saline to ensure that it is never allowed 
to dry. Cyanoarcylate-based glue is used to secure the glass coverslip in place. Once dry, 
superglue is applied to an aluminium head-plate which is gently secured to the skull ensuring 
that the whole window is clearly visible. Paladur dental cement is applied around the head-
plate to ensure that it is firmly attached, and all visible gaps are filled. Once the head-plate has 
fully dried the mouse is placed within an incubator and allowed to recover from anaesthesia. 
 
2.5    Multiphoton microscopy 
Multiphoton microscopy experiments, detailed within chapter 4, were carried out using a 
Leica SP8 DIVE microscope, which has an upright configuration with a single position 
nosepiece containing the motorised IRAPO L x25/0.95 lens, over a custom made Scientifica 
platform for mouse imaging. The system contains a tandem scanner: containing a linear 
tuneable scanner with speeds up to 3.6kHz and an 8kHz resonant scanner. All images were 
captured using the integrated Leica LAS X control software. For multiphoton microscopy 
studies, detailed within chapter 5, a LaVision Biotech TriMScope microscope was used, with 
an upright stand fitted with a Nikon CFI-Apo 25x NA1.1 lens. All images were acquired and 
recorded on the LaVision Imspector software. For both multiphoton microscope set-ups a 
custom-made platform was used, to secure the anaesthetised mouse under the lens. Animal 
anaesthesia is achieved using a VetTech anaesthetic rig set up for isoflurane. The mouse is 
monitored with Kent Scientific PhysioSuite with MouseStat Pulse Oximeter and Heart Rate 
monitor together with a heat pad. This can be used to measure the animal’s temperature, SpO2, 
respiratory rate and heart rate.  
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Prior to imaging mice are anesthetised at 5% isoflurane in 0.5 litres of O2 per minute. To 
enable the cerebral vasculature to be visualised, a range of fluorescently conjugated tracers are 
injected intravenously via the tail vein (Table 2.2). To perform the tail vein injection the 
isoflurane level is reduced to 2% and the mouse is placed on a heat pad, set at 370C, with a 
warm paper towel wrapped around the tail to encourage vasodilation of the tail vein. The 
fluorescently conjugated tracers are then injected. The mouse is secured via their head-plate 
to the custom-made imaging platform that has previously been warmed within the imaging 
chamber. Eye ointment is gently applied to the eyes to avoid dehydration during imaging. A 
cotton bud soaked in distilled H2O is then used to clean the cranial window. A rectal 
thermometer, attached to a heat pad, is inserted to ensure that the temperature is maintained 
between 36.5-37.50C throughout imaging. The holder is placed within the imaging chamber 
and a foot pad is attached to allow vitals to be monitored throughout. During imaging, 
isoflurane levels are kept between 1.25 and 2% and adjustments are made to ensure that heart 
and respiratory rates are maintained within acceptable ranges (Heart rate 400-600 beats per 
minute and respiratory rate 55-100 per minute). The holder is then secured, within the imaging 
chamber, using masking tape and the microscope lowered. Distilled H2O is placed on top of 
the cranial window to aid laser penetration. Following imaging an injection of saline is 
delivered subcutaneously to aid rehydration. All imaging procedures are completed within 2-
hours. 
 
Table 2.2 Tracers used for multiphoton microscopy 
 
 
2.5.1 In vivo assessment of microglial structure 
To enable the soma structure of individual microglia to be analysed, 3 separate z-stacks 
(203.46µm x 203.46µm x 50µm) were acquired from each animal at various depths throughout 
the cerebral cortex. The maximum depth of imaging did not exceed 300µm. Microglial cells 
were readily visible using the Cx3Cr1eGFP microglial reporter line, with the Rhodamine B tracer 
injected within the tail vein to allow the cerebral vasculature to be visualised. Z-stack areas 
had to encompass at least 5 complete microglial cells and were positioned away from large 
vessels to prevent the attenuation of the microglial signal. Following the acquisition of the 3 
 
 59 
microglial z-stacks the images were imported into the IMARIS software (Oxford Instruments) 
for further processing and structural evaluation.   
The IMARIS surface function is used to isolate the microglial cell soma to allow structural 
measurements to be gathered (Figure 2.4). Smoothing was carried out at a surface area detail 
level of 2µm, followed by a local contrast background subtraction limited by the diameter of 
the largest sphere which fits into the object, which was set to 30µm. The z-stack then 
underwent thresholding through background subtraction, which was manually adjusted to 
ensure that microglial processes are stripped and just the cell soma remains. The resulting 
surfaces are then classified according to 2 parameters: Firstly, by the number of voxels, which 
is manually adjusted to ensure that only microglial cell somas are selected. Secondary, by 
distance to image border XYZ which is set to 0.5µm to ensure that only microglial somas that 
are fully visible and complete within the imaging view are analysed. This processing allows 
3D reconstructions of each microglial soma to be generated within the IMARIS software, 
which then has the ability to generate structural measurements of each cell soma relating to 
volume, area, and sphericity (Figure 2.4C). Following processing, the surface ‘masks’ 
generated are compared to the original z-stack to ensure that each microglial cell is accurately 
represented (Figure 2.4D). The assessor was blind to surgical status and genotype throughout 
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Figure 2.4  Microglial structural analysis. (A) 2D image of a 3D reconstruction of a 50µm 
z-stack gathered within the cerebral cortex via multiphoton microscopy. (B) Processing of the 
original z-stack, within the IMARIS software, to isolate microglial somas. (C) Surface casts of 
each microglial soma within the field of view that is visible in its entirety. (D) Image 
demonstrating the generated surfaces overlaid onto the original Z-stack, highlighting the 
microglial somas in purple that are analysed for area, volume, and sphericity.  
 
2.5.2 In vivo assessment of microglial process dynamics 
To capture dynamic microglial process movements in real time, in vivo, repeated z-stacks 
were gathered consecutively over a 15-minute period via multiphoton microscopy. 
Consecutive z-stacks were gathered within 3 regions for each mouse, giving a quantification 
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of process motility over 45-minutes. Each z-stack took ≈48-seconds to acquire with a step size 
of 2 µ𝑚, depth of 50 µ𝑚 and a 203.46x203.46 µ𝑚 field of view.  
To calculate process motility z-stacks were processed and analysed using the ImageJ 
software (v1.46, NIH, Bethesda, MD, USA). Each z-stack was compressed to form a single 
maximum intensity image. 19 maximum intensity images were generated for each 15-minute 
imaging window and combined into a single stack. The StackReg plugin was then used to 
centre each image and then the imageCalculator plugin was used to calculate the pixel 
difference between 1 maximum intensity image to the next (M=I difference t=1 and 2/I t=1) 
(M=motility, I=intensity, t=stack number). Pixels present in t=1 but absent, 48-seconds later, 
in t=2 were defined as process retractions, whereas pixels that emerge in t=2 having been 
absent in t=1 are defined as process extensions. Process retractions and extensions are divided 
by the pixels present within t=1 to generate a process motility value as a percentage change, 
which represents process motility between stacks. Pixel differences across the entire 15-minute 
period were then averaged, with values from each of the 3 regions again averaged to generate 
an overall process motility value per mouse. Methodology was adapted from previously 
published workflows (M. A.-O. Kluge et al., 2017).  
Microglial process coverage (surveillance measurement) was also calculated using the 
ImageJ software (v1.46, NIH, Bethesda, MD, USA). Each z-stack gathered over the 15-minute 
imaging was collapsed to form individual maximum intensity images using the ImageJ z-
projection function. All maximum intensity images were then combined into a single stack 
before being binarized, using the ‘Moments dark’ autothreshold, to generate a mask of each 
stack slice. All binarised images within the stack are then summated to generate a single image 
displaying microglial coverage, of the entire field of view, over 15-minutes. The percentage 
area of microglial pixels is then calculated, representing the number of microglial pixels 
covering the entire field of view. A coverage value is then generated which represents the 
surveillance ratio, defined as the ratio of microglia-occupied pixels as a proportion of the total 
pixels within the field of view. This process was completed for all 3 regions and averaged to 
give an overall value of microglial coverage. Methodology was adapted from protocols 
previously published (Stowell et al., 2019).  
 
2.5.3 In vivo cerebral RBC velocity measurement via line scan 
analysis 
To calculate red blood cell (RBC) velocity within different components of the vascular 
network, line scanning was performed (Figure 2.5). Line scanning involves repeatedly imaging 
a single line, positioned within the central axis of a vessel, at a high scan speed of 1.5 kHz. 
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Line scans were positioned at a point along the vessel that was clearly visible with a strong 
signal, care was also taken to position scans away from vessel branch points to avoid turbulent 
flow (Figure 2.5A). Fluorescently conjugated dextran tracers upon introduction into the 
vasculature are too large to enter RBCs or escape the vascular lumen. As a result, RBCs appear 
on line scans as black loss of signal linear shadows, with the slope of each line being 
proportional to its velocity. Each line scan contains hundreds of RBCs and therefore by 
calculating the slope of each one, and averaging the values, a mean RBC velocity for the vessel 
can be generated, in a process known as line scanning particle image velocimetry (LSPIV). 
Line scan images are analysed using software and methodology that has been previously 
described (T. N. Kim et al., 2012) (Figure 2.5B) and the resulting values are converted to RBC 
velocity in mm per second using the formula outlined in Figure 2.5C. 
RBC velocity was measured within both leptomeningeal veins and arteries. These vessels 
are identified based on their direction of blood flow, size, and structure. Leptomeningeal veins 
show convergent flow and tend to have larger diameters with a less rigid cell wall, whereas 
leptomeningeal arteries show divergent flow and tend to have smaller diameters with rigid cell 
walls. Strict exclusion criteria were applied to all RBC velocity images, such that any linescan 
recording whose quality was not sufficient to give accurate readings of RBC velocity were 
excluded. The quality of linescan images were evaluated based on the shape and location of 
points throughout the fitted pixel displacement graphs (Figure 2.5B). Poor quality linescans 
generate a large number of outliers and show a disjointed fitted pixel displacement graph and 






Figure 2.5 RBC velocity analysis via line scanning particle image velocimetry 
(LSPIV). (A) Representative images of line scanning location within a vessel and the resulting 
line scan image (white line denotes linescan location). Scale bar 50µm left image 25µm right. 
(B) Representative images taken from the LSPIV assessment, displaying the raw line scan 
image as well as the pixel displacement across the image width, with the dotted line 
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representing the mean pixel displacement. (C) Mean pixel displacement values are converted 
to RBC velocity values in mm/second by the formula detailed. 
 
2.5.4 In vivo assessment of vascular pulsation 
Cerebral vascular pulsatility was evaluated with the use of multiphoton microscopy using 
a method based on those described previously within the literature (Jeffrey J. Iliff et al., 2013b; 
Kress et al., 2014). Vascular pulsation represents an important physiological function of the 
vasculature which has been proposed to be the driving force behind waste clearance from the 
brain (Jeffrey J. Iliff et al., 2013b; Schley, Carare-Nnadi R Fau - Please, Please Cp Fau - Perry, 
Perry Vh Fau - Weller, & Weller, 2006). Small dynamic changes in vessel diameter were 
measured within leptomeningeal veins, leptomeningeal arteries, ascending veins, and 
penetrating arteries with the use of line scanning methods.  
As described previously (section 2.5) the cortical vascular network can be readily 
visualised via multiphoton microscopy through the injection of fluorescently conjugated 
dextrans into the blood stream. Once visible, the pulsatility of individual vessels can be 
determined by positioning linescans orthogonal to the vessel’s axis. Linescans were performed 
at a frequency of 1086.96 Hz and repeated for 4000 loops equalling a duration of 3600ms. 
Care was taken to position line scans at points along the vessel that are clearly visible, with a 
strong signal and away from branch points. The resulting images are processed and analysed 
using the ImageJ software (v1.46, NIH, Bethesda, MD, USA). Linescan images are converted 
to an 8-bit format, smoothed using a Gaussian filter and manually thresholded to generate a 
sharp, noise free, vessel wall boundary. Any residual individual pixels found to be outside the 
boundary of the vessel, were considered noise and manually removed using the ‘fill’ feature. 
The assessor was blind to surgical group throughout imaging acquisition and analysis. 
Once a threshold has been applied to the image, the outside of the vessel will appear black 
indicating an absence of signal (low pixel intensity: value=0). Whereas the edge of the vessel 
will appear white (high pixel intensity: value >0) as the fluorescently conjugated dextran is 
unable to penetrate the vessel lumen generating a very intense signal within the vasculature. 
Any linescan image that post-processing was found to be excessively noisy, in which the 
vessel wall could not be readily identified, was excluded from the analysis.  
A collection of ROIs are then applied to each image (individual ROI dimensions: width: 
650 pixels, height: 10 pixels). Each ROI has a width of 650 pixels which exceeds the vessel 
wall on either side and allows the vessel width to be calculated. Regions of interest are placed 
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consecutively every 10 pixels resulting in a total of 400 regions with each region representing 
a recording of the vessel width every 9ms for a total of 3600ms.   
The ImageJ ‘multi-plot’ function generates a distribution of pixel intensities across the 
entire breadth of the ROI. Therefore, in order to determine the width of the vessel measured 
by any given line, the point at which the values transition from low pixel density (ie 0) to high 
pixel density (ie >0) on each side of the scan is calculated. This point will reflect the position 
of the endothelial wall on either side and therefore by measuring the difference between these 
two points we can calculate the vessel width in pixels. The laser scan path for each line scan 
is then used to generate a pixel to micron ratio, allowing the conversion of vessel width to 
microns.  
To calculate dynamic vessel width changes over time, vessel width (µm) within each region 
was plotted against time (ms). Vessel wall pulsatility (µm*ms) was calculated from the 
resulting graphs as the absolute value of area under the diameter-time plot, integrated to the 
running average calculated across the entire 3600ms sampling time, as performed previously 
(Jeffrey J. Iliff et al., 2013b). All peaks that were defined by fewer than 2 adjacent points were 
considered noise and excluded from the analysis, no criteria for the minimum peak height was 
applied. To calculate the total number of dynamic vessel pulses across the sampling time the 
total number of peaks were also calculated from the same diameter-time plots.  
  
 
   66 
 
 
Figure 2.6 Method to assess vascular pulsation in vivo via multiphoton microscopy. 
(A) The cerebral vasculature is visualised through the intravenous injection of fluorescently 
conjugated dextran’s (summarised in Table 2.2). Cortical surface veins and arteries (B) as 
well as ascending veins and penetrating arteries (C) were identified and assessed for pulsation 
through line scans carried out orthogonal to the vessel axis (orange line). (D) The resulting 
line scan of each vessel is analysed to generate vessel width calculations every 9ms. (E) 
Vessel diameters are then plotted as a function of time. Vascular pulsatility is defined as the 
absolute value of the integral of the vascular diameter measured against a running average 
over 3600ms. Frequency of pulsation is measured as number of vessel wall changes, 
identified as peaks, on the diameter-time graphs over 3600ms. Images adapted from (Jeffrey 
J. Iliff et al., 2013b). 
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2.5.5 In vivo assessment of leukocyte trafficking behaviours 
Upon the injection of a fluorescently conjugated tracer into the vasculature, leukocytes can 
be visualised as black (loss of signal) spheres. Time-lapse recordings of approximately 60-
seconds are then taken and leukocyte trafficking is assessed within leptomeningeal veins and 
arteries. In order to be defined as rolling, a leukocyte must be travelling at least one order of 
magnitude slower than the velocity of RBCs, have a clearly defined edge, be visible in two 
consecutive frames and be travelling in the same direction as the blood flow (Sperandio, 
Pickard J Fau - Unnikrishnan, Unnikrishnan S Fau - Acton, Acton St Fau - Ley, & Ley, 2006). 
To be defined as adhered, a leukocyte must remain stationary against the endothelial wall for 
at least 30-seconds and have a clearly defined edge (Yata et al., 2014) 
Both leukocyte rolling and adhesion were assessed within 5 veins and 5 arteries per mouse. 
The values for leukocyte rolling and adhesion are then combined, and the 5 vessel values 
averaged to generate an overall leukocyte trafficking value expressed per 100μm per minute. 
 
2.6    Behavioural testing 
Prior to behavioural testing, animals were handled daily for 2-weeks to help habituate the 
mice to each experimenter. Such practices help to limit anxious behaviour, which has the 
potential to significantly impact performance.  
 
2.6.1 Barnes maze 
Spatial learning and cognitive flexibility, within chapters 3 and 4, were assessed using the 
Barnes maze (C. A. Barnes, 1979). The Barnes maze is a land-based version of the Morris 
water maze and consists of a simple circular white platform (115 cm high x 91.5 cm wide) 
with 20 “escape holes” evenly spaced around the edge (San Diego Instruments) (Figure 2.7A). 
Under either hole 3, 8, 13, or 18 a black escape chamber is placed. The escape chamber remains 
in the same position for each mouse throughout their training period, however, its position its 
shifted clockwise, 5 holes, between mice to avoid olfactory cues influencing behaviour. To 
further limit the influence of olfactory cues ethanol is used between trails to clean the table 
(70%) and escape chamber (30%). Prior to the commencement of the task a holding cylinder 
(10.5 cm in diameter) was used to place the animals within the maze. The maze is brightly lit, 
and an aversive noise is played to motivate animals to escape. The mice use large spatial cues 
that are positioned on the walls around the maze to aid navigation and data is recorded using 
the Any-Maze tracking software (v4.99, Stoelting Europe, Ireland).  
The aim of the Barnes maze is to assess the animals’ ability to learn and remember the 
location of the escape chamber. Spatial learning was assessed during an initial learning phase 
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and spatial memory in a 72-hour probe test. Cognitive flexibility is then tested in a reversal 
learning phase, with memory of the reversal chamber location once again assessed via a 72-




Figure 2.7 Schematic illustrations of the Barnes maze. (A) Timeline representing the 
Barnes maze task with each sub-section. Each circle represents a single trial, with T1 and R1 
representing a training and reversal day respectively. (B) Illustration of the Barnes maze set 
up during the training phase. Shapes positioned around the maze represent visuals cues that 
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remain in a consistent position for all phases. The hole marked in red highlights the escape 
chamber location. (C) Illustration of the Barnes maze set up during the training probe. The red 
shaded quadrant indicates the location of the target zone, in which duration spent is recorded 
as a measure of memory. (D) Illustration of the Barnes maze set up during the reversal phase. 
The escape chamber, marked in blue, has be moved 1800 to the opposite side of the maze in 
relation to its position during the training phase. (E) Illustration of the Barnes maze set up 
during the reversal probe. Blue shaded area represents the target zone representing the new 
reversal escape chamber location. 
 
2.6.2 Acclimatisation phase 
To limit stress and anxiety responses associated with a novel environment, animals were 
acclimatised to the Barnes maze and the behavioural room for 3 consecutive days prior to the 
start of the task. During acclimatisation, to allow the mice to become accustomed to their new 
surroundings, no bright lights or aversive noise were used. For the first 2-days of acclimation, 
animals were placed in the holding cylinder for 10-seconds, and then returned to their home 
cage. On day 3, animals were placed within the holding cylinder for 10-seconds and then 
allowed to freely explore the maze for 3-minutes. Following the 3-minutes, animals were 
gently guided into the escape chamber where they were held for 1-minute before being 
returned to their home cage.  
2.6.3 Training phase 
Spatial learning trails commenced the day following the completion of the acclimatisation 
phase (Figure 2.7B). Animals completed 2 trails per day, with a 1-hour trial interval, over 6 
consecutive training days. Trails consisted of each animal being held within the holding 
cylinder for 10-seconds before the cylinder was removed and an aversive noise started playing 
(85db). Each mouse then had 3-minutes to locate and enter the escape chamber. Upon entering 
the escape chamber, the aversive noise is immediately stopped, and the hole covered for 1-
minute to prevent the animal from leaving. Upon the completion of the 1-minute hold, the 
mouse is returned to their home cage. If animals were unable to locate the escape chamber 
during the 3-minute time period, they would be guided to the escape chamber and kept within 
for 1-minute before being returned to their home cage. As soon as the mouse entered the escape 
chamber the aversive noise ceased. The time taken for each mouse to enter the escape chamber 
is referred to as escape latency and used as a measure of spatial learning. All maze equipment 
was cleaned with 70% ethanol between each animal, and the escape chamber was carefully 
cleaned with 30% ethanol and rinsed with water to avoid aversive alcohol vapours building 
up.  
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2.6.4 Training 72-hour probe 
Long-term spatial memory was assessed using a probe test carried out 72-hours after the 
final trial of the spatial learning phase (Figure 2.7C). Conditions remained constant for this 
phase apart from the removal of the escape chamber, and a shorter trial duration of 60-seconds. 
Trail length was reduced to help limit the effect of mice re-commencing search strategies once 
they have realised the escape chamber is missing. For analysis, the maze was segmented into 
4 quadrants and the time each animal spent within each quadrant was calculated. Memory was 
assessed as the proportion of time spent within the quadrant previously home to that animals’ 
respective escape chamber, which is referred to as the target quadrant. The percentage of trail 
time spent within the target quadrant is then compared to results from other experimental 
groups to discern differences in spatial memory. The time spent within the target quadrant is 
also compared to the 3 other quadrants to determine if a clear preference is apparent.  
 
2.6.5 Reminder phase 
Following the 72-hour probe, animals were subjected to 2 additional trials, in which the 
escape chamber is returned to help re-establish the chamber location memory following the 
probe trial. Conditions and trial duration were kept constant with the training phase.  
 
2.6.6 Reversal phase 
As a test of executive functioning and cognitive flexibility, the chamber location was 
shifted 180° to the opposite side of the maze for the reversal training phase (Figure 2.7D). 
Conditions and trial duration were the same as that described for the spatial learning phase. 
Reversal training trails were performed twice a day, with a 1-hour trail interval, for 3 
consecutive days. Escape latency was once again recorded and analysed as a measure of 
relearning (cognitive flexibility).  
 
2.6.7 Reversal 72-hour probe 
The reversal 72-hour probe is performed as described previously within section 2.6.4 and 
assess the time spent within the target quadrant previously home to the reversal phase escape 




2.6.8 Barnes maze exclusion criteria 
In order to accurately test spatial learning and memory as well as cognitive flexibility, 
animals need to be motivated to actively explore the maze and they also need to sufficiently 
understand that the aim of the task is to enter the escape chamber. To ensure this the following 
strict exclusion criteria were applied; animals must enter a minimum of 3 quadrants in 2 of the 
first 5 training phase trials and animals must voluntarily enter the escape chamber at least 3 
out of the final 6 trials to demonstrate that they have learned the task objective. Details of 
exclusions can be found within the method sections of the relevant chapters.  
 
2.7    Substance administration 
2.7.1 GW2580 administration 
GW2580 (LC Laboratories, PKC Pharmaceutical Inc., USA, and Test Diet Europe) was 
administered at 0.1% concentration within diet ad libitum starting 24-hours following BCAS 
surgery. 
 
2.7.2 5-Bromo-2’-deoxyuridine (BrdU) administration 
5-Bromo-2’-deoxyuridine (BrdU, B5002, Sigma-Aldrich) was administered via oral 
gavage, once daily, for the final 3-days of the short term and chronic studies detailed within 
chapter 3. BrdU was prepared at a concentration of 50mg/kg in 0.5% Hypromellose (H3785, 
Sigma-Aldrich) and 0.1% Tween®80 (P1754, Sigma-Aldrich). 
 
2.8    Tissue collection and processing 
2.8.1 Rapid brain extraction 
Animals from the study described within chapter 3 were sacrificed via cervical dislocation. 
Brains were then rapidly removed and transferred to ice-cold artificial CSF. A 1.6mm slice of 
brain section was then collected at -1.65mm posterior of bregma, in a Cellsafe+ Biopsy Capsule 
(Cell Path). The tissue samples were then fixed in 4% paraformaldehyde for 24-hours before 
being manually processed for paraffin embedding (Section 2.8.3). Tissue extracted for the 
experiments detailed within chapter 3, was gathered in this way to facilitate additional 
electrophysiological studies that do not fall within the scope of the present thesis.   
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2.8.2 Transcardial perfusion and brain extraction 
Animals from studies described within chapters 4 and 5 were sacrificed under deep 
anaesthesia (5% induction, maintained at 3%) by transcardial perfusion with 40ml of 0.9% 
heparinised (0.002%) phosphate buffered saline (PBS). The heart is exposed through a midline 
incision followed by the dissection of the mediastinum. A butterfly needle in then placed 
within the left ventricle and clamped to secure its position. The right atrium is then cut with 
scissors and the perfusion is carried out at 2ml/minute until blood and tissues are successfully 
cleared. The brain is then carefully removed and placed within 4% paraformaldehyde for 24-
hours in preparation for paraffin embedding (section 2.8.3) or freezing with isopentane 
(section 2.8.5), 
2.8.3 Paraffin processing 
For the studies described within chapter 3, fixed brain tissue slices were transferred to PBS 
and maintained within the cell sure tissue cassettes throughout paraffin processing. Brains 
extracted for studies detailed within chapter 5, were transferred from paraformaldehyde to PBS 
and sectioned into two 3mm coronal blocks, either side of bregma, using a mouse matrix. Both 
tissue blocks were then placed within a single tissue cassette for paraffin processing. The 
protocol undertaken for manual paraffin processing of tissue is described within Table 2.3. 





2.8.4 Microtome sectioning 
Paraffin embedded tissues generated for studies detailed within chapters 3 and 5 were cut 
to 6µm coronal tissue sections at -1.70mm posterior to bregma (Paxinos, 2001) using a rotary 
microtome (Leica RM2135, Leica Microsystems, Germany) and mounted on superfrost plus 
slides (VWR International). Mounted sections were dried on a heated pad for ≈30-minutes and 
then allowed to rest at room temperature for at least 24-hours prior to staining. 
 
2.8.5 Processing for freezing and cyrosectioning 
For the study detailed within chapter 4, brains were transferred from 4% paraformaldehyde 
to 30% sucrose for 72-hours, then frozen in -420C isopentane (chilled using dry ice). 10µm 
coronal sections were then collected at -1.70mm posterior of bregma (Paxinos, 2001) using a 
cryostat (Leica CM1950). Tissue sections were then mounted onto superfrost plus slides 
(VWR International) and allowed to dry at room temperature for at least 12-hours. Mounted 
sections were then stained directly after the drying duration or stored at -200C for future use. 
 
2.9    Flow cytometry 
For the flow cytometry cohorts detailed within chapters 3 and 4, mice were transcardially 
perfused and brains extracted according to the method detailed within section 2.8.2. With the 
exception of perfusion flow rate, which was increased from 2 to 4ml/minute to ensure that 
tissues could be processed as swiftly as possible. For flow cytometry experiments detailed 
within chapter 3, following extraction the brain was quickly cut into 2 mm sagittal slices using 
a matrix, then transferred to ice cold 1X HBSS with 25 mM HEPES. The corpus callosum was 
then dissected out using a dissecting microscope and transferred to fresh tubes containing ice 
cold 1X HBSS with 25 mM HEPES and kept on ice prior to processing. For flow cytometry 
experiments detailed within chapter 4, following extraction the brain was quickly cut into 2 
hemispheres using a matrix, then transferred to ice cold 1X HBSS with 25 mM HEPES. 
For processing of tissue into a single cell suspension, all tools and reagents were kept ice 
cold throughout, and centrifugation steps were performed at 4˚C. Tissue samples were quickly 
minced in 1X HBSS (without Ca2+ or Mg2+; Gibco) with 25 mM HEPES (Fisher Scientific) 
(HBSS with HEPES) using a scalpel prior to transfer to a or 2 ml dounce homogeniser with 
loose pestles. Tissue samples were homogenised with 30 passes of the dounce then filtered 
through a pre-wet 70 μm cell strainer (BD2 Falcon) which was washed with 2 ml HBSS with 
HEPES. Samples were centrifuged at 600 x g for 5-minutes prior to resuspension in a 30% 
PercollPLUS solution with 5 ml HBSS with HEPES overlaid on top. The cell suspension was 
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then centrifuged at 600 x g for 20-minutes with no break. Cells were resuspended in FACS 
buffer (1X PBS (Gibco) with 25mM HEPES and 0.1% BSA (Sigma Aldrich)) and incubated 
with Mouse BD Fc Block™ (BD Biosciences) for 30-minutes on ice. Cells were then 
immunostained with primary antibodies directed against CD11b (clone: M1/70), CD45 (clone: 
30-F11), Ly6C (clone: HK1.4), Ly6G (clone: 1A8) at 1:200 (Ly6C) or 1:500 dilution for 30-
minutes on ice. Cells were washed then analysed and sorted using a FACS Aria II (BD 
Biosciences). Cell sorting was performed by staff in the QMRI Flow Cytometry and Cell 
Sorting Facility (University of Edinburgh). Sorted cells were centrifuged at 6000 RPM for 5-
minutes at 4˚C then either resuspended in 350 µl RLT Buffer (Qiagen) and stored at -80˚C or 
processed immediately for RNA extraction. 
 
2.10 RNA extraction and cDNA synthesis 
For RNA extraction and cDNA synthesis within studies described in chapter 3, sorted cells 
from isolated corpus callosum samples were processed immediately post-sort and RNA was 
extracted using the High Pure RNA Isolation Kit (Roche) according to the manufacturer’s 
instructions. RNA quantities were determined by Agilent 4200 Tapestation (Agilent 
Technologies). cDNA was synthesised from 1.5 ng RNA using the Superscript IV Reverse 
Transcriptase (Life Technologies), according to the manufacturer’s instructions and used 
undiluted for qPCR reactions. cDNA samples were stored at -20ºC until use.  
For RNA extraction and cDNA synthesis within studies described in chapter 5, sorted cells 
in RLT Buffer were defrosted and vortexed for 1-minute to homogenise cells and RNA was 
extracted using the AllPrep DNA/RNA/miRNA Universal Kit (Qiagen) according to the 
manufacturer’s instructions. Sorted cells were processed immediately post-sort and RNA was 
extracted using the High Pure RNA Isolation Kit (Roche) according to the manufacturer’s 
instructions. RNA quantities were determined by Agilent 4200 Tapestation (Agilent 
Technologies). cDNA was synthesised from 15 ng RNA using the Superscript IV Reverse 
Transcriptase (Life Technologies), according to the manufacturer’s instructions and used 
undiluted for qPCR reactions. cDNA samples were stored at -20ºC until use. 
 
2.11 Quantitative (q)-PCR 
cDNA libraries were analysed by qPCR using the DyNAmo ColorFlash SYBR Green kit 
(Thermo Scientific) according to the manufacturer’s instructions. Briefly, the cDNA template 
was mixed with DyNAmo ColourFlash SYBR Green master mix (Fisher Scientific), nuclease-
free H2O and the following custom designed gene-specific primers (200 nM final 
concentration; Sigma Aldrich): CSF1R (forward: 5’-gaaggaaggccgaggctatg-3’, reverse: 5’-
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gagaagccactgtccctgc-3’), Aif1 (forward: 5’-tggaggggatcaacaagcaa-3’, reverse: 5’-
tccatttccattcagatcaaatcc-3’), 18s (forward: 5’-cccagtaagtgcgggtcat-‘3, reverse: 5’-
ccgagggcctcactaaacc-3’) and Cx3Cr1 (forward: 5’-gccaactccatgaacaaccg-3’, reverse: 5’-
ttgacttccgagttgcggag-3’). Primers were validated to confirm efficiency prior to use. qPCR 
cycles were performed on a Bio-Rad CFX96 thermocycler (Bio-Rad Laboratories) as follows: 
hot-start denaturation cycle 95°C for 10-minutes, 40 cycles of amplification at 95°C for 15-
seconds, 62.5°C for 20-seconds, and 72°C for 30-seconds, followed by one cycle of 95°C for 
1-minute, 55°C for 30-seconds, with a ramp up to 30-seconds at 95 °C with continuous 
detection of fluorescence. Cycle threshold (Ct) values of target genes were normalized Aif1 
for CSF1R quantification and to 18S for Cx3Cr1 quantification. The data are expressed as fold 
change relative to control group (wild-type or shams) using the 2^ (−ΔΔCt) method. 
 
2.12 Immunohistochemical staining  
2.12.1 Immunohistochemical DAB staining 
Paraffin sections were deparaffinised for 30-minutes within a tabletop oven set to 600C, 
followed by 2 x 15-minute xylene washes. Sections were then washed with ethanol at 100% 
for 2 x 5-minutes, 90% for 5-minutes, and 70% for 5-minutes. Endogenous peroxidases were 
then quenched using 3% hydrogen peroxide in methanol for 30-minutes. Slides were washed 
in running water for 15-minutes before antigen retrieval, if required (Iba-1, but not for MAG 
staining). For citric acid retrieval, sections were incubated in 10 mM citric acid (pH6) and then 
heated to 950C for 10-minutes within a Decloaking chamber (Biocare Medical). Following 
removal, sections were washed in PBS and blocked at room temperature for 1-hour with 10% 
normal serum and 0.5% bovine serum albumin, before incubation at 40C overnight (minimum 
16-hours) with primary antibody diluted in block. Sections were then removed from the cold 
room and allowed to rest at room temperature for 10-minutes followed by 2 x 5-minute PBS 
washes. Biotinylated secondary antibodies were then applied for 1-hour at room temperature. 
To further amplify the signal, the Vector ABC Elite Kit (Vector Labs, UK) is then applied and 
allowed to incubate for 1-hour at room temperature. To allow visualisation of peroxidase 
activity, 3,3’ diaminobenzidine tetrahydrochloride (DAB, Vector Labs, UK) is applied for 3-
minutes before being washed off with distilled H20. Sections were then washed in running 
water before dehydration through a series of ethanol washes (70% for 2-minutes, 90% for 2-
minutes. 100% for 2 x 5-minutes). The sections are then place within xylene for 15-minutes 
before mounting with DPX (Sigma, UK). Primary and secondary antibody details and 
concentrations can be found within Table 2.4. 
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Table 2.4 Antibodies used for immunohistochemical staining 
 
 
2.12.2 Immunofluorescent labelling 
Following the deparaffinisation steps detailed within section 2.12.1, slides are rinsed for 
15-minutes in running water. For Iba-1/BrdU staining citric acid retrieval was carried out as 
described above in section 2.12.1, details of Lamp2 immunofluorescent staining can be found 
within section 2.12.3. Following citric acid retrieval sections were washed in PBS and blocked 
at room temperature for 1-hour (10% normal serum, 0.5% bovine serum albumin in PBS), 
before incubation at 40C overnight (minimum 16-hours) with primary antibody diluted in 
block. Primary antibodies were diluted in blocking solution made up in 0.3% Triton-X PBS. 
The following day sections were then washed in PBS before incubation with biotinylate 
secondary antibodies for 1-hour at room temperature and protected from light. The sections 
were then washed with PBS, followed by Tris-buffer before being allowed to air dry for 15-
20-minutes before mounting with Vectashield Hardset containing DAPI (Vector, UK). 
Primary and secondary antibody details and concentrations can be found within Table 2.4. 
 
2.12.3 Tyramide Immunofluorescent labelling  
For Iba-1/Lamp2 immunofluorescent staining an alternative staining protocol using 
tyramide was employed. Following the deparaffinisation steps detailed within section 2.12.1, 
slides were rinsed in running water for 10-minutes. Tris-EDTA (pH9) antigen retrieval was 
then carried out within a water bath set to 97.50C for 30-minutes. Following a 20-minute 
cooling period at room temperature, the slides were washed with PBS before being blocked 
(10% animal serum in PBS) for 1-hour at room temperature. Slides were then incubated 
overnight with primary antibody, diluted in block, at 40C. The following day slides we rested 
at room temperature for 10-minutes before 3 x 3-minute washes with Tris-buffered saline with 
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0.05% tween. Endogenous peroxidases were then quenched using 3% hydrogen peroxide in 
methanol for 30-minutes, followed by 3 x 3-minute washes in TBS with 0.05% tween. The 
sections were then incubated with a secondary antibody mix in 0.1% BSA TBST for 1-hour 
and 30-minutes, followed by 3 x 3-minute washes in TBS with 0.1% tween. The next steps 
made use of the Alexa Fluorophore-488 Superboost Kit Streptavidin kit (Thermofisher) and 
was conducted according to the manufacturer’s instructions. Firstly, slides were incubated in 
tertiary antibody for 45-minutes followed by 3 x 3-minute washes with TBS containining 0.1% 
tween. Tyramide amplification was then achieved by mixing the 1x reaction buffer with 1x 
H2O2 solution and adding 100µl to each tissue section. The tyramide reaction was then stopped 
after 8-minutes of incubation by adding the stop solution, diluted 1:11 with PBS, for 1-minute. 
The slides were then washed in PBS before a second round of Tris-EDTA (pH9) antigen 
retrieval at 97.50C for 30-minutes. Following retrieval, the slides were left to cool at room 
temperature for 20-minutes before 3 x 3-minute washes in PBS, followed by incubation with 
blocking solution (10% animal serum in PBS) for 1-hour at room temperature. Slides were 
then incubated with primary antibody solution, diluted in PBS containing 10% normal animal 
serum, overnight at 40C. The next day, following a rest period of 10-minutes at room 
temperature, the slides were washed 3 x 3-minutes in PBS before incubation with a secondary 
antibody solution, diluted in PBS, for 1-hour at room temperature. The slides then underwent 
3 x 3-minute washes in PBS before being mounted with fluorescence mounting medium 
(Agilent DAKO). Primary and secondary antibody details and concentrations can be found 
within Table 2.4. 
 
2.12.4 Preparation for Cx3Cr1eGFP cell counts 
Frozen sections were air dried for 10-minutes then washed in PBS for 2 x 5-minutes. 
Sections were then dehydrated through a series of ethanol washes; 70% for 2-minutes, 90% 
for 2-minutes, 100% for 5-minutes, and 100% for 10-minutes. Finally, sections are washed 
with xylene for 10-minutes. Sections were then rehydrated through washes with 100% ethanol 
for 10-minutes, 100% ethanol for 5-minutes, followed by 2 x 5-minute washes with PBS. 
Slides were then allowed to air dry for 10-minutes before mounting with Vectashield Hardset 
containing DAPI (Vector, UK). 
 
2.12.5 Immunohistochemical staining controls 
Prior to the full runs of immunohistochemical staining experiments, optimisations were run 
on small sample cohorts to ensure that antibody conditions and concentrations were optimised. 
To ensure for accurate staining, a section generated from a previous study with a known level 
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of staining was always included within optimisation runs alongside tissue taken from the 
present study cohorts. To ensure antibody specificity of staining, all immunohistochemical 
optimisations and full runs included a negative control, where the primary antibody was not 
applied but all other steps were consistent. Stained sections were only analysed if this negative 
control was clear. To prevent batch variation, which can occur between different experiments, 
all sections from one immunohistochemical analysis were stained within a single experiment. 
 
2.13 Imaging acquisition and analysis of immunohistochemical 
staining 
2.13.1 Imaging acquisition 
DAB-labelled sections were imaged using an Axio Scan.Z1 slide scanner (x20, Ziess, 
Germany). Immunofluorescent labelling for Iba1/BrdU was imaged using a Zeiss 710 confocal 
microscope (x20 Zeiss, Germany), or a Leica TCS SP5 confocal microscope (x20 Leica 
Microsystems, Germany). Iba-1/Lamp2 staining was imaged using a Zeiss LSMZ10 confocal 
microscope (x20 Zeiss, Germany).  
2.13.2 Image analysis 
Image analysis for immunohistochemically stained sections was performed using ImageJ 
software (v1.46, NIH, Bethesda, MD, USA). Due to the large file sizes generated through slide 
scanner imaging, each slide scanned image was compressed by either 50 or 75% before 
analysis, to enable ImageJ to open the image. Iba-1 DAB, Iba-1/BrdU, Iba-1/Lamp2 and 
Cx3Cr1eGFP cell counts were all manually generated with the use of the CellCounter plugin. 
ROI placements can be seen in Figure 2.8, great care was taken to match regions as closely as 
possible between mice, with ROI areas also being kept as consistent as possible. Each ROI 
was manually positioned by the assessor, who was blind to surgical, genotype, and treatment 
status of the mice throughout. Corpus callosal and cortical ROIs were drawn manually using 
the straight-line tool, whereas consistently sized rectangles were used to assess all other 
regions. For percentage area of staining methods, a rolling 50-pixel background subtraction 
was applied. A manual threshold was then selected by the assessor for each individual brain 
region, and then applied to all images gathered from that region to generate a percentage value 
to reflect total area of positive staining. MAG-stained sections were graded subjectively on a 
scale from 0 to 3 depending on the extent of myelin debris. Sections were assessed manually 
through an Olympus BX51 microscope, Olympus, UK with grades from each side of the brain 






Figure 2.8 Regions of interest used for image analysis of immunohistochemical 
stains. Regions representing the cortex (Cxt), corpus callosum (CC), hippocampal CA1 (CA1), 
fimbria (FI), internal capsule (IC), and optic tract (OT) were all manually generated for both the 
left and right hemisphere using ImageJ software. Image represents figure 45, Bregma -
1.70mm from the mouse atlas (Paxinos, 2001) 
 
2.13.3 Exclusion criteria 
Due to minor variation in the anatomical level of sections stained, some ROIs had to be 
slightly adjusted or images excluded entirely. Images were also excluded if excessive tissue 
damage or external debris was present leading to blocking of the antibody signal.  
 
2.14 Statistical analysis 
Statistical analysis was carried out using either SPSS (Version22, IBM corp) or Graphpad 
prism (v5, GraphPad Software Inc, La Jolla, USA) statistical software. Details of the specific 
statistical tests that were performed can be found within the methods section of the relevant 
chapter. Unless specifically stated otherwise, all data is presented as median±interquartile 
range and significance is gated at p<0.05.  
  
 
   80 
Chapter 3 
 
Investigating the role of microglial proliferation in 
the development of white matter damage and 




Chronic cerebral hypoperfusion has been shown to lead to diffuse white matter damage 
which is strongly correlated to cognitive decline. Despite these associative links, the 
pathological mechanisms by which chronic cerebral hypoperfusion leads to white matter 
damage and ultimately cognitive impairment remain largely unknown, evidence does however 
suggest that microglia and neuroinflammation may place a causal role. Chronic cerebral 
hypoperfusion, modelled in mice through bilateral common carotid artery stenosis (BCAS), 
leads to the progressive expansion of microglial cells within white matter regions (Coltman et 
al., 2011; Holland et al., 2015; Manso et al., 2017; Reimer et al., 2011). White matter 
microglial expansion was found to positively correlate with increased myelin pathology, 
diminished white matter signalling and impaired spatial learning and memory (Fowler et al., 
2017; Kitamura et al., 2017; Manso et al., 2017). Treatment with broad acting anti-
inflammatory drugs such as dimethyl fumarate, cilostazol and minocycline were found to 
rescue white matter signalling and cognitive impairments following BCAS (Fowler et al., 
2017; Kitamura et al., 2017; Manso et al., 2017). Interestingly, despite varied mechanisms of 
action, reduced white matter microglia numbers was a common outcome of each anti-
inflammatory treatment, correlating with improved functional and cognitive outcomes. Taken 
together these results led to the hypothesis that microglial expansion is a key pathological 
process driving white matter dysfunction and cognitive impairments following chronic 
cerebral hypoperfusion. To date, pharmacological interventions have only been able to 
demonstrate a correlation between reduced microglial number and improved functional 
outcomes. Therefore, to interrogate the role of microglial expansion following BCAS more 
specifically, the drug GW2580 was selected. GW2580 is an orally available inhibitor of cFMS 
receptor kinase, which is a fundamental mediator of colony-stimulating-factor-1 (CSF-1) 
signalling. CSF-1 signalling, through cFMS receptor kinase promotes the survival, 
proliferation, and differentiation of microglia (Conway et al., 2005). GW2580 treatment 
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allows for the specific and targeted blockade of microglial proliferation to accurately integrate 
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3.1.1 Hypothesis 
This study tests the hypothesis that microglial proliferation leads to white matter damage 
and cognitive impairment following bilateral common carotid artery stenosis 
 
3.1.2 Aims 
Using a model of BCAS within wild-type, C57BL/6J mice, the studies aimed to: 
1. Assess the effect of BCAS on temporal cortical blood flow changes following 
surgery  
2. Investigate the response of white matter immune cell populations following 1-
week of BCAS 
3. Assess white and grey matter microglial expansion and proliferation, 1 and 6-
weeks following BCAS 
4. Investigate the impact of BCAS on the integrity of white matter regions, 6-weeks 
following surgery 
5. Assess the effect of BCAS on spatial learning and memory, 6-weeks following 
surgery  
6. Investigate the effect, on the above measures, of blocking microglial proliferation 





3.2 Materials and Methods 
 
3.2.1 Experimental Mice 
Wild-type (C57BL/6J) (n=99) were purchased from Charles River Laboratories (JAXTM- 
C57BL/6J) and used for all studies having been assigned to each experimental group at 
random. Mice, 3-4 months old, were studied at a short-term 1-week timepoint as well as a 
chronic 6-week timepoint following surgery. A total of 51 mice began the 1-week study and 
48 the 6-week study. Details of group numbers and exclusions can be found in the relevant 
methods sections below, alternatively an overall summary can be found within Table 3.1. 
 
Table 3.1 Number of mice within each experimental group with details of exclusions
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3.2.2 Bilateral common carotid artery stenosis 
Bilateral common carotid artery stenosis (BCAS) surgery was performed as previously 
described (section 2.2). Micro-coils, of internal diameter 0.16mm and 0.18mm were applied 
to the left and right common carotid arteries, respectively. As a control, sham mice underwent 
the same procedure minus the application of micro-coils. Due to signs of poor health 3 mice 
from the 1-week histology cohort, 4 mice from the 1-week FACS cohort and 7 mice from the 
6-week cohort were humanely culled and excluded from the study. More detailed information 
on exclusions following surgery are reported in Section 3.2.3 and detailed in Table 3.1.  
 
3.2.3 Laser speckle imaging assessment of resting cortical 
blood flow 
Laser speckle imaging was used to assess CBF within sham and BCAS mice following 
surgery as previously described (Section 2.3). For the short-term 1-week studies, blood flow 
responses were assessed prior to surgery (baseline) as well as 24-hours and 1-week following 
surgery. For the chronic 6-week study, CBF was analysed at baseline, 24-hours and 6-weeks 
following surgery. To enable stenosis mediated effects to be accurately assessed, a strict 
exclusion criterion was adopted by which 24-hour post-surgery blood flow reductions needed 
to exceed 35% for the mouse to be included in the study. This exclusion criteria was applied 
to both the short-term and chronic studies leading to the exclusion of 6 mice from the 1-week 
histology cohort, 2 mice from the 1-week FACS cohort and 9 from the 6-week study (detailed 
within Table 3.1) 
 
3.2.4 GW2580 administration 
GW2580 (LC Laboratories, PKC Pharmaceuticals Inc., USA) was delivered within the diet 
for the chronic 6-week study as previously described (Section 2.7.1). Food intake and animal 
weight were closely monitored throughout the study, with no group differences identified.  
 
3.2.5 5-Bromo-2’-deoxyuridine (BrdU) administration 
5-Bromo-2’-deoxyuridine (BrdU, B5002, Sigma-Aldrich) was administered via oval 
gavage once a day for the final 3-days of both the short-term and chronic study as previously 




3.2.6 Barnes maze behavioural testing 
The Barnes maze is a test of visuo-spatial learning and memory and was carried out within 
the chronic 6-week study cohort, as previously described (Section 2.6). The training period 
commenced 4-weeks and ended 6-weeks following sham/BCAS surgery. An exclusion 
criterion based on maze exploration, as previously described (Section 2.6.8), was applied 
highlighting 1 mouse who was subsequently excluded from all studies (Table 3.1).   
 
3.2.7 Tissue collection and processing 
To collect tissue for histology, animals were sacrificed via cervical dislocation as 
previously described (Section 2.8.1). The tissue was then processed for paraffin embedding as 
previous described (Section 2.8.3). Tissue was then microtome sectioned in preparation for 
immunohistochemical staining (Section 2.8.4). For flow cytometry experiments, mice were 
transcardially perfused with ice cold PBS containing 0.1% heparin under deep isoflurane 
anaesthesia (Section 2.8.2). The white matter was then isolated as described within Section 
2.9) 
 
3.2.8 Flow cytometry and cell sorting 
Isolated white matter tissue was processed into a single cell suspension as detailed within 
Section 2.9. Cells were then immunostained with primary antibodies directed against CD11b, 
CD45, Ly6C, and Ly6G at 1:200 (Ly6C) or 1:500 dilution for 30-minutes on ice. Cells were 
washed then analysed and sorted using a FACS Aria II (BD Biosciences). Cell sorting was 
performed by staff in the QMRI Flow Cytometry and Cell Sorting Facility (University of 
Edinburgh). Sorted cells were centrifuged at 6000 RPM for 5-minutes at 4˚C and then 
processed immediately for RNA extraction. 
 
3.2.9 RNA extraction and cDNA synthesis 
Sorted cells from isolated corpus callosum samples were processed for RNA extraction 
immediately post-sort using the High Pure RNA Isolation Kit (Roche) according to the 
manufacturer’s instructions (as detailed within Section 2.10). RNA quantities were determined 
by Agilent 4200 Tapestation (Agilent Technologies). cDNA was synthesised from 1.5 ng RNA 
using the Superscript IV Reverse Transcriptase (Life Technologies), according to the 
manufacturer’s instructions and used undiluted for qPCR reactions. cDNA samples were 
stored at -20ºC until use.  
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3.2.10 Quantitative (q)-PCR 
cDNA libraries were analysed by qPCR using the DyNAmo ColorFlash SYBR Green kit 
(Thermo Scientific) according to the manufacturer’s instructions (as described within Section 
2.11). Briefly, the cDNA template was mixed with DyNAmo ColourFlash SYBR Green 
master mix (Fisher Scientific), nuclease-free H2O and the following custom designed gene-
specific primers (200 nM final concentration; Sigma Aldrich): CSF1R (forward: 5’-
gaaggaaggccgaggctatg-3’, reverse: 5’-gagaagccactgtccctgc-3’) and Aif1 (forward: 5’-
tggaggggatcaacaagcaa-3’, reverse: 5’-tccatttccattcagatcaaatcc-3’). qPCR cycles were 
performed on a Bio-Rad CFX96 thermocycler (Bio-Rad Laboratories) as described previously 
(Section 2.11). Cycle threshold (Ct) values of target genes were normalized to Aif1, with data 
expressed as fold change relative to control group (shams) using the 2^ (−ΔΔCt) method. 
 
3.2.11 Immunohistochemistry 
Immunohistochemical staining was performed on 6m paraffin embedded sections as 
previously described (Sections 2.12.1, 2.12.2, and 2.12.3). Tissue was stained with antibodies 
against Iba-1, BrdU, Lamp2 and MAG. Additional information on antibodies used can be 
found within Table 2.4. 
 
3.2.12 Image acquisition and analysis 
DAB-stained sections for Iba-1 and MAG quantification were imaged using an Axio 
ScanZ1 slide scanner (x20, Zeiss, Germany) as previously described (Section 2.13.1). 
Fluorescently stained sections for Iba1, BrdU and Lamp2 analysis were imaged using confocal 
microscopy, as previously described (Section 2.13.1). Cell count and percentage area per cell 
analysis was completed using the ImageJ software (v1.46, NIH, Bethesda, MD, USA) as 
previously described (Section 2.13.2). MAG staining was analysed semi-quantitatively using 
a 4-point scale, as previously described (Section 2.13.2).  
 
3.2.13 Statistical analysis 
Statistical analysis was performed using SPSS (v22, IBM Corp.) software. Repeated 
measures two-way ANOVA’s were used to assess group differences in CBF as well as the 
Barnes maze measures of escape latency, movement distance and movement speed (training 
and reversal phases), with Bonferroni post hoc follow up analysis. Barnes maze training and 
reversal probe target zone preference were analysed using the Friedman test to determine 
differences in time spent within each quadrant. The Wilcoxon signed ranks post hoc test was 
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then applied to determine target zone preference. Independent samples Mann-Whitney U tests 
were used to analyse 1-week microglial DAB and microglial proliferation counts as well as 
FACS immune cell comparisons and CSF1R expression. Independent samples Kruskal-Wallis 
tests were used to analyse 6-week microglial DAB counts, microglial proliferation, Lamp2 
and MAG analysis as well as Barnes maze training and reversal probe target zone comparisons, 
with Dunn’s post hoc follow up analysis. Correlations were analysed using the Spearman’s 
ranked correlation coefficient. For parametric statistical tests, data is presented as mean ± 
standard error of the mean (SEM) and for nonparametric testing, data is presented as median 
± interquartile range (IQR) (specified in relevant figure legend). Statistical significance was 
determined at p<0.05.   
 
3.2.14 Experimental contributions 
The majority of experiments and analysis detailed within this chapter were conducted by 
myself. The studies, however, were also supported by Dr Emma Sigfridsson, Dr Jessica 
Duncombe, Dr Edel Hennessey, Dr Katie Askew, Dr Juraj Koudelka, Dr Stefan Szymkowiak 
and Professor Karen Horsburgh. I performed laser speckle imaging, behavioural testing, tissue 
processing and sectioning, immunohistochemical staining and slide scanner/confocal imaging 
of Iba-1 (DAB) and Lamp2 stains as well as all the data analysis presented within this chapter, 
with the exception of the 1-week FACs counts and 6-week MAG grading. Dr Emma 
Sigfridsson performed laser speckle imaging, behavioural testing, tissue processing/sectioning 
and stained/analysed MAG within the 6-week tissue. Dr Jessica Duncombe performed BCAS 
surgery, administered oral gavages, processed tissue, stained 6-week tissue for Iba-1/BrdU and 
imaged 1- and 6-week Iba-1/BrdU tissues. Dr Edel Hennessey administered oral gavages, 
collected/processed tissue and stained for Iba1/BrdU, all within the 1-week study. Dr Katie 
Askew performed the 1-week FACs isolation and quantification of immune cell populations 
and CSF1R expression. Dr Juraj Koudelka assisted with tissue collection at the 6-week time-
point. Dr Stefan Szymkowiak optimised and assisted with tyramide Lamp2 staining. Professor 
Karen Horsburgh performed BCAS surgery for the 1-week FACS cohort. 
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3.3 Results 
 
3.3.1 BCAS induces a significant and sustained reduction in 
cerebral blood flow  
The first aim of this study was to assess the temporal profile of CBF changes up to 1-week 
post-BCAS. CBF was measured using laser speckle imaging at baseline (24-hours before 
surgery), 24-hours and 1-week following sham/BCAS surgery (Figure 3.1). Resting CBF was 
reported as percentage change from baseline flux (arbitrary unit). BCAS surgery on average 
elicited ≈60% reduction in CBF, which was maintained at 1-week following surgery, whereas 
sham mice displayed relatively stable blood flow measurements over the same period (Figure 
3.1A). Statistical analysis revealed a significant overall effect of time (F(1,20) = 73.637, 
p<0.001) and surgery (F(1,25) = 142.847, p<0.001) as well as a significant time-surgery 
interaction (F(2,50) = 54.613, p<0.001). Post hoc analysis using the Bonferroni correction 
revealed that BCAS elicited a significant reduction in CBF at 24-hours (Sham; 103.4±4.6, 
BCAS; 41.92±4.5, p<0.001) and 1-week (Sham; 88.3±3.7, BCAS; 39.2±3.5, p<0.001) 
following surgery (Figure 3.1).  
Overall, these data demonstrate that BCAS surgery elicits a significant reduction in CBF, 






Figure 3.1 BCAS induces a sustained reduction in CBF. (A) BCAS surgery reduced 
CBF by ≈60%, in contrast sham mice showed stable blood flow over the same period. Data 
presented as Mean±SEM. ***p<0.001. (B) Representative images displaying laser speckle 
imaging of the cerebral vasculature within sham and BCAS mice at baseline, 24-hours and 1-
week following surgery. Blue represents low and red represents high flow.   
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3.3.2 Microglial expansion dominates the early inflammatory 
response following BCAS 
Previous research has demonstrated that BCAS leads to increased microglial numbers 
within specific white matter regions (Duncombe, Kitamura, et al., 2017; Fowler et al., 2017; 
Manso et al., 2017). Investigations into the effect of BCAS on the other immune cell 
populations within the white matter, however, has been limited. To accurately determine the 
contribution of other myeloid cell types to the inflammatory response following BCAS, flow 
cytometric quantification was carried out (Figure 3.2). Brain cell suspensions were prepared 
from the corpus callosum and stained with a panel of myeloid cell markers to enable cell 
populations of microglia, macrophages, neutrophils, and monocytes to be quantified 1-week 
following sham/BCAS surgery (Figure 3.2A). In agreement with previous 
immunohistochemical analysis, microglial numbers (CD11b+CD45low) were found to be 
significantly increased within the corpus callosum of BCAS mice (15,095±6,246) in 
comparison to shams (7518±3,451) (U=18, p<0.05) (Figure 3.2A). In respect to other myeloid 
cell populations, no significant difference in cell numbers were observed within macrophages 
(CD11b+veCD45high), neutrophils (Ly6G+ve) or monocytes (Ly6C+ve) following BCAS (Figure 
3.2A).  
Taken together these data indicate that microglia are the principal mediators of the 
neuroinflammatory environment following BCAS, with little or no contribution of other 






Figure 3.2 Microglial expansion dominates the early inflammatory response 
following BCAS. (A) Increased microglial cells within BCAS mice in comparison to shams, 
with no observed differences in macrophage, neutrophil or monocyte populations as measured 
by flow cytometry. Data presented as Median±IQR. p<0.05*. (B) Representative plots 
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displaying cell populations isolated, via flow cytometry, from the white matter of both sham 
and BCAS mice. Red indicates the highest density of cells with blue representing the lowest 
density.  
 
3.3.3 BCAS induces microglial expansion following 1-week of 
reduced cerebral blood flow 
Having demonstrated that microglial dominate the early neuroinflammatory response 
following BCAS surgery, the next aim was to determine if increased microglial numbers could 
be identified within regions important for learning and memory. Here, immunohistochemical 
DAB labelling using the pan myeloid cell marker Iba1 was used to determine if microglial 
expansion could be observed as early as 1-week following BCAS surgery, in both white and 
grey matter regions (Figure 3.3). Microglial expansion was calculated via cell counts per 
0.1mm2, alongside percentage area measurements. Percentage area measurements, when 
normalised to total cell number, provide additional information relating to microglial 
activation state, as increased microglial surface area has been associated with microglial 
activation (B. M. Davis et al., 2017; Kozlowski & Weimer, 2012).  
Iba1+ve cell counts within the hippocampus CA1 region, 1-week following surgery, 
identified a significant increase within BCAS mice (14.9±21.25) in comparison to shams 
(6.6±1.55) (U=152, p<0.01) (Figure 3.3A). Percentage area was then compared with values 
normalised to the total number of Iba1+ve cells. Percentage area of staining per Iba1+ve cell was 
found to be significantly increased within BCAS mice (0.23%±0.18) in comparison to shams 
(0.12%±0.05) (U=152.5, p<0.01) (Figure 3.3B). This analysis was then repeated within the 
corpus callosum to see if the white matter showed a similar response to that seen within the 
grey matter. Quantification of the total number of Iba1+ve cells showed a trend for increased 
cell numbers following surgery within BCAS mice (8.74±9.19) in comparison to shams 
(6.55±2.65) (p=0.054) (Figure 3.3C). The percentage area of staining per Iba1+ve cell showed 
a significant increase within BCAS mice (0.17%±0.07) compared to shams (0.14%±0.06) 
(U=132.5, p<0.05) (Figure 3.3D). 
Overall, these data show evidence of not only microglial expansion, as early as 1-week 
following BCAS, but also increased cell size potentially indicating a structural conformational 






Figure 3.3 BCAS induces microglial expansion 1-week following surgery. (A) Iba1+ve 
cell counts per 0.1mm2 increased within the hippocampal CA1 region of BCAS mice compared 
to shams. (B) Iba1 area per cell showed a significant increase within the hippocampus of 
BCAS mice in comparison to shams. (C) A trend for increased Iba1+ve cell counts within the 
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corpus callosum of BCAS mice compared to shams. (D) Significant increase in IBA1 area per 
cell within the corpus callosum of BCAS mice compared to shams. Data presented as 
Median±IQR. (E) Representative images of DAB Iba1 staining within the hippocampus CA1 
and corpus callosum of sham and BCAS mice 1-week following surgery. Scale bar 50µm. 
Black dashed lines outline regions analysed.  
 
3.3.4 Microglial expansion following BCAS is associated with a 
significant increase in local proliferation  
To determine if the microglial expansion observed 1-week following BCAS could be 
attributed to increased local proliferation, the number of microglial cells co-expressing BrdU 
was evaluated 1-week following surgery (Figure 3.4). The total number of Iba1+veBrdU+ve cells 
increased within the hippocampus CA1 region of BCAS mice (5.95±15.46) when compared 
to shams (0±0) (U=144.5, p<0.01) (Figure 3.4A). To confirm that this observation was indeed 
an increase in proliferation rate and not simply due to increased total iba1+ve cells within BCAS 
mice, the percentage of Iba1+ve cells proliferating was also calculated (Figure 3.4B). A 
significant increase in the percentage of Iba1+ve cells proliferating was observed within BCAS 
mice (30.39%±53.31) in comparison to shams (0±0) (U=144.5, p<0.01) (Figure 3.4B). The 
total number of proliferating microglia was also found to be significantly increased 1-week 
following surgery, within the corpus callosum of BCAS mice (1.18±4.6) when compared to 
shams (0±0) (U=161, p<0.001) (Figure 3.4C). The same significant increase was observed 
when percentage of microglial cells proliferating was calculated, with BCAS mice 
(15.78±46.26) displaying a higher proportion when compared to shams (0±0) (U=160, 






Figure 3.4 BCAS mediated microglial expansion is driven by local proliferation. (A) 
Increased number of proliferating Iba1+ve cells within the hippocampal CA1 region of BCAS 
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mice in comparison to shams. (B) The percentage of proliferating Iba1+ cells were increased 
within BCAS mice when compared to shams. (C) Increased number of proliferating Iba1+ve 
cells within the corpus callosum of BCAS mice in comparison to shams. (D) Increased 
percentage of proliferating Iba1+ve cells within the corpus callosum of BCAS mice in 
comparison to shams. Data presented as Median±IQR. p<0.01**, p<0.001***. (E) 
Representative images of Iba1/BrdU/DAPI staining within the hippocampus CA1 and corpus 
callosum regions from sham and BCAS mice. Iba1-green, BrdU-red, and DAPI-blue. White 
arrowheads highlight proliferating microglial cells. Scale bar 50µm. 
 
To determine if the proliferative response following BCAS is predominantly associated 
with microglial cells, the number of BrdU+veDAPI+ve cells were also calculated (Figure 3.5). 
There was a significant increase in the proliferation of non-microglial cells within the 
hippocampus CA1 region of BCAS mice (1.25±5.26) in comparison to shams (0.14±0.28) 
(U=135, p<0.05) (Figure 3.5A). To determine the significance of this response in comparison 
to microglial proliferation, the percentage of proliferating cells that are Iba1+ve was calculated. 
The results show that the majority of proliferating cells are Iba1+ve within BCAS mice 
(78.55±85.60) and show a significantly greater proportion than that of shams (0±0) (U=144.5, 
p<0.01) (Figure 3.5B). In contrast, within the corpus callosum, there was no significant 
difference between the proliferation of non-microglial cells between BCAS (2.00±2.73) and 
sham mice (1.19±3.16) (p=0.943) (Figure 3.5C). Once again when the data is displayed as the 
percentage of proliferating cells that are Iba1+ve, there is a clear significant increase within 
BCAS mice (43.80±50.71) in comparison to shams (0±0) (U=160, p<0.001) (Figure 3.5D).  
Taken together these data indicate that the microglial expansion observed within white and 
grey matter regions 1-week following BCAS is driven by increased local proliferation. 
Furthermore, the proliferative response is predominantly microglial, with very little 






Figure 3.5 Proliferation following BCAS is predominantly microglial. (A) Proliferation 
of Iba1-ve cells was increased within the hippocampus CA1 region of BCAS mice in comparison 
to shams. (B) Significant increase in the proportion of proliferating cells that are Iba1+ve within 
the hippocampus of BCAS mice compared to shams. (C) No observed differences in Iba1-ve 
cell proliferation within the corpus callosum of sham and BCAS following surgery. (D) 
Increased percentage of proliferating cells that are Iba1+ve within the corpus callosum of BCAS 
mice when compared to shams. Data presented as Median±IQR. p<0.05*, p<0.01**, 
p<0.001***. (E) Representative image displaying BrdU+veDAPI+veIba1-ve cells (denoted by 
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white arrow heads) and BrdU+veDAPI+veIba1+ve cells (denoted by white arrows) within the 
hippocampal CA1 region. Iba1-green, BrdU-red, DAPI-blue. Scale bar 50µm. 
 
3.3.5 CSF1R inhibition has no impact on the magnitude of 
cerebral blood flow reductions following BCAS 
The short-term study, described within sections 3.3.1-3.3.4, demonstrated that microglial 
expansion, driven by local proliferation, dominates the early neuroinflammatory response 
following BCAS. In attempt to uncover the pathway by which microglial proliferation is 
stimulated, microglial cells were isolated from the corpus callosum of sham and BCAS mice 
1-week following surgery. A ≈3-fold increase in CSF1R expression was identified within 
BCAS mice (2.18±1.43) when compared to shams (1.01±0.18) (U=21, p<0.05), as measured 
by qPCR (Figure 3.6). CSF1R signalling has been highlighted as a key pathway promoting the 
survival, proliferation and differentiation of microglia (Conway et al., 2005). It was, therefore, 
hypothesised that this pathway is the most likely candidate driving microglial proliferation 
following BCAS. The oral inhibitor GW2580 has previously been shown, in models of chronic 
neurodegeneration, to effectively inhibit microglial proliferation without affecting cell 
survival, through the competitive inhibition of CSF1R (Adrian Olmos-Alonso et al., 2016b). 
To allow the effect of blocking microglial proliferation on pathological and cognitive 
outcomes to be assessed, GW2580 was administered within diet over a 6-week period 




Figure 3.6 Increased microglial CSF1R expression following BCAS. (A) Increased 
CSF1R expression was identified within isolated corpus callosal microglial cells following 
BCAS. Data presented as Median±IQR. p<0.05*. 
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The first aim of the long-term study was to investigate the effect of GW2580 on cortical 
blood flow following BCAS, to determine if blocking CSF1R signalling had any impact on 
CBF reductions following BCAS surgery. Laser speckle imaging was utilised to assess CBF 
at baseline, 24-hours, and 6-weeks following sham/BCAS surgery (Figure 3.7). BCAS surgery 
elicited a ≈50% reduction in CBF which persisted at 6-weeks, whereas sham mice showed 
stable blood flow measurements over the same period (Figure 3.7A). Overall, there was a 
significant effect of group (F(2,28) = 107.243, p<0.001), time (F(1.57, 43.97) = 167.414, p<0.001) 
as well as a significant interaction between group and time (F(3.14, 43.97) = 30.90, p<0.001).  
Bonferroni post hoc analysis revealed a significant reduction in CBF 24-hours following 
surgery (sham; 97.06±5.82, BCAS; 52.24±9.65, p<0.001) which was persistent at 6-weeks 
(sham; 94.83±7.39, BCAS; 49.74±15.32, p<0.001) (Figure 3.7A). In contrast, no significant 
difference in blood flow reduction following GW2580 treatment was observed at 24-hours 
(sham; 97.06±5.82, BCAS+GW2580; 51.56±8.85, p<0.001) or 6-weeks (sham; 94.83±7.39, 
BCAS; 54.46±10.17, p<0.001) following surgery (Figure 3.7A).  
These data illustrate that CBF is persistently reduced up to 6-weeks following BCAS. 
Furthermore, the extent and duration of CBF reductions following BCAS are unaffected by 
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 Figure 3.7 BCAS induces persistent reductions in CBF regardless of CSF1R 
inhibition. (A) BCAS induces a significant and persistent reduction in CBF within both the 
vehicle and GW2580 groups in comparison to shams. Data presented as Mean±SEM. 
p<0.001*** (* indicates post hoc analysis comparing sham to BCAS), p<0.001### (# indicates 
post hoc analysis comparing BCAS to BCAS+GW2580).  (B) Representative images of laser 
speckle imaging of cortical blood flow at baseline, 24-hours, and 6-weeks following surgery 
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within sham, BCAS and BCAS+GW2580 mice. Red indicates high and blue low blood flow 
(arbitrary flux units). 
 
3.3.6 CSF1R inhibition following BCAS prevents microglial 
expansion 
The next aim of the study was to assess changes in microglial numbers following long-term 
BCAS, and to determine if GW2580 can inhibit any observed increases. Immunohistochemical 
DAB staining of Iba1 was utilised to assess microglial expansion within the white matter 
regions; corpus callosum, internal capsule and fimbria as well as the grey matter region of the 
hippocampus (Figure 3.8 and Figure 3.9). Overall, there was a significant group effect on the 
number of Iba1 positive cells/0.1mm2 within the corpus callosum (χ2(2) = 15.255, p<0.001), 
with post hoc analysis revealing significantly increased microglial numbers within BCAS 
(9.53±7.31) compared to BCAS+GW2580 mice (5.80±1.66) (p<0.001) (Figure 3.8A). 
Similarly, there were overall group differences within the internal capsule (χ2(2) = 10.386, 
p<0.01) and fimbria (χ2(2) = 7.094, p<0.05), with post hoc analysis revealing significant 
increases in microglial numbers within BCAS mice (IC; 8.25±6.29, F; 7.89±14.01) in 
comparison to BCAS+GW2580 mice (IC; 5.03±2.70, F; 6.10±1.89) (p<0.01, p<0.05 
respectively) (Figure 3.8B/C).  
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Figure 3.8 CSF1R inhibition prevents BCAS mediated white matter microglial 
expansion. Increased Iba1+ve cells within BCAS but not BCAS+GW2580 mice 6-weeks 
following surgery within the corpus callosum (A), internal capsule (B) and fimbria (C). Data 
presented as Median±IQR. p<0.05*, p<0.01**, p<0.001***. (D) Representative images of DAB 
Iba1 staining within the corpus callosum, internal capsule and fimbria of sham, BCAS, and 
BCAS+GW25080 mice 6-weeks following surgery. Scale bar 50µm. 
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In respect to grey matter, the hippocampus CA1 region showed an overall group difference 
(χ2(2) = 15.679, p<0.001), with post hoc analysis revealing significantly increased microglial 
numbers within BCAS mice (7.08±1.40) in comparison to both sham (5.44±1.09) (p<0.05) 
and BCAS+GW2580 groups (5.24±1.26) (p<0.01) (Figure 3.9A).  
Collectively, these results demonstrate widespread microglial expansion following 6-





Figure 3.9 CSF1R inhibition prevents BCAS mediated hippocampal microglial 
expansion. (A) Increased Iba1+ve cells within the hippocampus CA1 region of BCAS but not 
sham or BCAS+GW2580 mice 6-weeks following surgery. Data presented as Median±IQR. 
p<0.05*, p<0.01**. (B) Representative images of Iba1 DAB staining within the hippocampus 
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3.3.7 Modest levels of microglial proliferation at 6-weeks 
following BCAS blocked through CSF1R inhibition 
Having demonstrated the effectiveness of GW2580 treatment in blocking microglial 
expansion following 6-weeks of BCAS, the next aim was to assess proliferation at this more 
chronic timepoint. Immunofluorescent staining using Iba1 and BrdU was once again employed 
to assess microglial proliferation within the hippocampus and corpus callosum 6-weeks 
following surgery (Figure 3.10). Within the hippocampus CA1 region a significant overall 
group effect was identified (χ2(2) = 6.815, p<0.05), with post hoc analysis demonstrating a 
significant increase in proliferating microglial cells within BCAS mice (0±0.15) in comparison 
to BCAS+GW2580 mice (0±0) (p<0.05) (Figure 3.10A). When the percentage of Iba1+ve cells 
proliferating was calculated an overall group effect was determined (χ2(2) = 6.191, p<0.05), 
with post hoc analysis revealing a strong trend for an increased proportion of proliferating 
microglia in BCAS mice (0±1.05) compared to BCAS+GW2580 mice (0±0) (p=0.051) (Figure 
3.10B). Despite some evidence of proliferating microglia within the corpus callosum of a sub-
set of BCAS mice, there were no significant group effects for the number of proliferating 
microglial cells (p=0.079) (Figure 3.10C) or the proportion of microglial cells proliferating 






Figure 3.10 CSF1R inhibition prevents BCAS mediated hippocampal microglial 
proliferation. (A) Increased hippocampal CA1 microglial proliferation within BCAS but not 
sham or BCAS+GW2580 mice 6-weeks following surgery. (B) A trend for an increased 
percentage of microglial cells proliferating within the hippocampus of BCAS but not sham or 
BCAS+GW2580 mice. No significant difference in proliferating microglial cells (C) or 
percentage of microglial cells proliferating (D) within the corpus callosum across all groups. 
Data presented as Median±IQR. p<0.05*. Representative images of Iba1/Brdu/DAPI staining 
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within the hippocampus CA1 and corpus callosum of sham, BCAS, and BCAS+GW2580 mice 
6-weeks following surgery. Iba1-green, BrdU-red, DAPI-blue. Scale bar 50µm. 
 
Proliferation of non-microglial cells was limited at 6-weeks following surgery with no 
significant group differences observed within the hippocampus CA1 (p=0.841) (Figure 3.11A) 
or corpus callosum (p=0.491) (Figure 3.11C). When the percentage of cells proliferating that 
are microglial was calculated an overall significant group difference was observed within the 
hippocampus CA1 region (χ2(2) = 6.995, p<0.05), however, post hoc analysis revealed no 
significant differences between groups (Figure 3.11B). No significant differences between the 
percentage of proliferating cells that are microglial was observed within the corpus callosum 
(0.079) (Figure 3.11D). The data does, however, once again clearly highlight that the majority 
of proliferation detected is microglial derived.  
Overall, these data indicate that microglial proliferation, within the 3-days prior to the 6-
week timepoint following BCAS, is limited. When microglial proliferation was present 





Figure 3.11 Limited proliferation of non-microglial cell types 6-weeks following 
BCAS surgery. Limited proliferation of Iba1-ve cells across all 3 groups within the hippocampus 
CA1 region (A) and corpus callosum (C). No significant difference in the percentage of 
proliferating cells that are microglial within the hippocampus (B) or corpus callosum (D) across 
all 3 groups. Data presented as Median±IQR. (E) Representative image displaying 
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BrdU+veDAPI+veIba1-ve cells (denoted by white arrow heads) within the hippocampal CA1 
region. Iba1-green, BrdU-red, DAPI-blue. Scale bar 50µm. 
 
3.3.8 CSF1R inhibition protects against white matter damage 
following BCAS 
Myelin associated glycoprotein (MAG) accumulation within white matter tracts is 
indicative of white matter damage and is associated with myelin damage and white matter 
dysfunction (Aboul-Enein et al., 2003; Barker, Wellington, Esiri, & Love, 2013). To 
investigate the integrity of white matter following BCAS, and the impact of CSF1R inhibition, 
MAG immunohistochemical staining was carried out and graded semi-quantitatively on a 4-
point scale. MAG levels were assessed within the corpus callosum, internal capsule, and 
fimbria, with scores summated to generate an overall value representing white matter damage 
(Figure 3.12). Statistical analysis revealed a significant overall group effect (χ2(2) = 11.653, 
p<0.01), with post hoc testing demonstrating a significant increase in MAG severity score 
within BCAS mice (2±5) in comparison to sham (0±0) (p<0.01) and BCAS+GW2580 groups 






Figure 3.12 CSF1R inhibition prevents widespread white matter damage following 
BCAS. (A) Widespread white matter damage within the corpus callosum, internal capsule, 
and fimbria of BCAS mice but not within sham or BCAS+GW2580 groups. Data presented as 
Median±IQR. p<0.05*, p<0.01**. (B) Representative images of MAG DAB staining within the 
corpus callosum, internal capsule, and fimbria of sham, BCAS, and BCAS+GW2580 mice. 
Scale bar 50µm. 
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To determine if white matter microglial expansion is associated with increased white matter 
damage, MAG severity scores were correlated to microglial cell counts within the same areas 
(Figure 3.13). The extent of white matter damage was found to be positively correlated with 
the number of microglial cells within the same area (rs(20) = 0.644, p<0.01) (Figure 3.13). 
Collectively, these data illustrate that white matter damage following BCAS is correlated 





Figure 3.13 The severity of white matter damage is positively correlated to increased 
microglial numbers. The averaged white matter damage (MAG score) was positively 
correlated to the average Iba1+ve cell number across a number of white matter regions (corpus 
callosum, internal capsule, and fimbria). As all sham mice showed 0 MAG grading scores, 
their data was omitted from the analysis. Data presented as Mean.  
 
3.3.9 BCAS induced impairments in spatial learning are 
completely restored through CSF1R inhibition 
The results presented within this chapter thus far demonstrate that chronic BCAS leads to 
both corpus callosum and hippocampal microglial expansion, alongside white matter damage. 
The corpus callosum and hippocampus represent important components of the frontal-
subcortical circuitry that has been implicated in spatial learning the memory (Duncombe, 
Kitamura, et al., 2017). The next aim of the study, therefore, was to investigate the impact of 
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chronic BCAS on spatial learning and memory, as well as to determine if GW2580 treatment 
could rescue any observed deficits.  
Spatial learning and memory as well as cognitive flexibility were assessed using the Barnes 
maze, which was carried out over 2 consecutive weeks, commencing 4-weeks following 
surgery. Spatial learning was assessed via escape latency measurements which reflect the time 
taken for each mouse to locate and enter the escape chamber. When escape latency was 
assessed, over the 6-day training period, a significant overall effect of time was observed 
(F(3.340,93.507) = 65.078, p<0.001), indicating learning across trials (Figure 3.14A). An overall 
effect of group was also evident (F(2,28) = 13.116, p<0.001). Although sham and BCAS 
performance is comparable at training day 1, post hoc analysis revealed a significant increase 
in BCAS escape latency across subsequent trails (T2; p<0.05, T3; p<0.001, T4; p<0.01), 
demonstrating impaired spatial learning compared to shams. Over the same training period, 
however BCAS+GW2580 mice showed escape latency times comparable to shams which 
were significantly different to that of the BCAS group (T3; p<0.01, T4; p<0.05, T6; p<0.05) 
(Figure 3.14A). Overall, these data illustrate that chronic BCAS leads to impaired spatial 
learning which can be rescued through the blockade of microglial expansion via CSF1R 
inhibition.  
As an additional measure of spatial learning, total distance travelled during each trial was 
calculated (Figure 3.14B). Reduced travel distance over subsequent trails would be indicative 
of spatial learning as the mouse would be taking a more direct route to the escape chamber as 
the location is learnt. A significant overall effect of time was identified (F(5,140) = 31.972, 
p<0.001), as well as an overall significant group difference (F(2,28) = 7.478, p<0.01) with no 
interaction (p=0.493). Post hoc analysis revealed a significant increase in distance travelled, 
and therefore impaired spatial learning, within BCAS mice in comparison to shams across 
several trails (T2; p<0.05, T3; p<0.01, T4; p<0.05) (Figure 3.14B). Distance travelled within 
the BCAS+GW2580 mice was comparable to shams and significantly reduced in comparison 
to BCAS alone, although post hoc analysis revealed this difference was only statically 
significant at one timepoint (T2; p<0.05) (Figure 3.14B).  
Due to the motile nature of the task, average speed measurements were gathered to ensure 
that mobility differences did not exist between groups. Overall a significant main effect of 
time was observed (F(3.176,88.938) = 11.322, p<0.001). However, no significant effect of group 
was observed (p=0.322) as well as no significant interactions (p=0.084) indicating that escape 
latency can be used as a measure of learning without speed as a confounding factor (Figure 
3.14C).  
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Following the spatial learning task, a probe trial was conducted, in which the escape 
chamber was removed, and the percentage of time spent within the quadrant previously home 
to the escape chamber was measured (Figure 3.14D). The probe trial was conducted 72-hours 
following the last training day and therefore represents a longer-term spatial reference memory 
assessment. Time spent within the target zone was compared across all 3 groups, with 
statistical analysis revealing a significant overall group difference (χ2(2) = 7.790, p<0.05). Post 
hoc analysis demonstrated that sham mice spent significantly more time within their target 
quadrant (58.33±11.67) when compared to both BCAS (39.17 ±22.08) (p<0.05) and 
BCAS+GW2580 groups (35.83±20.83) (p<0.05). No significant difference between BCAS 
and BCAS+GW2580 groups was identified (p=0.903). In order that confirm that target 
quadrant times did indeed reflect a preference for that quadrant, time spent within all 4 
quadrants was compared (Figure 3.14D). Sham mice showed an overall significant difference 
between time spent within each quadrant (2(3) = 18.506, p<0.001), with post hoc analysis 
revealing a significant increase in time spent within the target zone compared to the other 3 
zones (clockwise; p<0.01, opposite; p<0.01, counter-clockwise p<0.01). An overall difference 
in quadrant preference was also identified within the BCAS group (2(3) = 8.300, p<0.05) 
however, post hoc analysis revealed a significant preference for the target quadrant over the 
opposite (p<0.05) and counter-clockwise (p<0.05) but not the clockwise (p=0.07) zone, 
indicating no target zone preference. Overall, BCAS+GW2580 mice showed no significant 










Figure 3.14 CSF1R inhibition restores BCAS mediated spatial learning impairments. 
(A) Increased escape latency within BCAS mice, indicative of impaired spatial learning, in 
comparison to both sham and BCAS+GW2580 groups which show comparable learning 
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profiles. (B) Increased distance travelled within BCAS mice indicates poorer spatial learning 
in comparison to sham and BCAS+GW2580 groups. (C) Comparable movement speed across 
all groups indicating that learning measures are not impacted by motility differences. Data 
presented as Mean±SEM. p<0.05*, p<0.01**, p<0.001*** (* indicates post hoc analysis 
comparing sham to BCAS), p<0.05#, p<0.01## (# indicates post hoc analysis comparing BCAS 
to BCAS+GW2580. (D) Sham mice demonstrate a target zone preference indicating intact 
spatial memory in contrast to BCAS and BCAS+GW2580 groups which show no preference 
for the target zone. Data presented as Median±IQR. p<0.05*, p<0.01**. (E) Representative 
movement traces during day 1 and 6 of the training period taken from sham, BCAS and 
BCAS+GW2580 groups. Stars indicate target hole. (F) Trace and occupancy plots gathered 
during probe trails of sham, BCAS, and BCAS+GW2580 mice. Stars indicate target hole; 
brighter colours indicate increased time spent in that area (occupancy plot only).  
 
To determine if white matter microglial expansion is associated with impairments in spatial 
learning, average escape latency was correlated to microglial cell counts within the corpus 
callosum (Figure 3.15A). A significant positive correlation was identified (rs(29) = 0.522, 
p<0.01), indicating that increased microglial numbers within the corpus callosum are linked 
to a poorer spatial learning performance (Figure 3.15A). Furthermore, to investigate the link 
between spatial learning impairments and white matter damage, MAG severity scores within 
the corpus callosum were correlated to average escape latency. Increased white matter damage 
was found to be positively correlated with a poorer spatial learning performance (rs(20) = 0.451, 
p<0.05) (Figure 3.15B). 
In conclusion, these data demonstrate that chronic BCAS leads to impairments in spatial 
learning and memory which are correlated to increased white matter microglial numbers and 
increased white matter damage. CSF1R inhibition, through GW2580 treatment, rescues 







Figure 3.15 Increased average escape latency positively correlates with microglial 
numbers and MAG grading within the corpus callosum. Averaged escape latency 
(indicative of spatial learning) is positively correlated with the numbers of microglial cells (A) 
and MAG grading (B) within the corpus callosum. As all sham mice showed 0 MAG grading 
scores, their data was omitted from the analysis. Data presented as Mean. 
 
3.3.10 Cognitive flexibility is unaltered following BCAS  
To test cognitive flexibility an additional reversal training segment was completed within 
the Barnes maze following the reference memory probe (Figure 3.16). The reversal training 
phase, completed over 3 consecutive days, required mice to learn that their escape chamber 
had been relocated 1800, to the other side of the maze. A significant overall effect of time was 
observed (F(2,56) = 31.975, p<0.001) indicating learning over the reversal training phase (Figure 
3.16A). Although the BCAS groups performance appeared poorer than both sham and 
BCAS+GW2580 groups, an overall group effect narrowly missed statistical significance 
(p=0.053) (Figure 3.16A). Distance travelled was also used as a measure of learning, as with 
escape latency a significant overall effect of time was observed (F(2,56) = 11.322, p<0.001),  
with once again an overall group effect narrowly missing statistical significance (p=0.053) 
(Figure 3.16B). Once again speed was measured throughout the trails to determine if motility 
could influence the results. Overall, no significant effect of time (p=0.06) or group was 
observed (p=0.12), indicating that motility was comparable across groups (Figure 3.16C). 
A probe trail was completed 72-hours following the last reversal training day to assess 
adaptive spatial memory (Figure 3.16D). Time spent within the target zone was compared 
across groups with no overall significant difference identified (p>0.05). When quadrant zone 
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preference within each group was analysed however, a significant difference between time 
spent within each quadrant was observed within sham mice (2(3) = 10.820, p<0.05), with post 
hoc testing demonstrating a reversal target zone preference over the other quadrants 
(clockwise; p<0.01, opposite; p<0.05, counter-clockwise; p<0.05). Regarding BCAS and 
BCAS+GW2580 groups no significant differences between time spent within each quadrant 
were identified (p=0.241 and p=0.113 respectively) (Figure 3.16D). 
Overall, these data indicate that BCAS leads to impairments in adaptive spatial memory, 






Figure 3.16 A trend for improved cognitive flexibility via CSF1R inhibition following 
BCAS. Overall, there was a significant effect of time indicating learning, with a trend for group 
differences when measured by escape latency (A) and total distance (B). (C) Speed was found 
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to be comparable across all three groups. Data presented as Mean±SEM. (D) Sham mice 
demonstrate a target zone preference, whereas BCAS and BCAS+GW2580 groups show no 
preference for the target zone. Data presented as Median±IQR. p<0.05*, p<0.01**. (E) 
Representative movement traces during day 1 and 3 of the reversal training period taken from 
sham, BCAS, and BCAS+GW2580 groups. Stars indicate target hole. (F) Trace and 
occupancy plots gathered during reversal probe trails of sham, BCAS, and BCAS+GW2580 
mice. Stars indicate target hole; brighter colours indicate increased time spent in that area 
(occupancy plot only).  
 
3.3.11 CSF1R inhibition protects against increased microglial 
lysosomal expression following BCAS 
The data so far has clearly demonstrated microglial expansion following BCAS, which can 
be successfully prevented through CSF1R inhibition. However, it is still unclear as to whether 
BCAS is impacting the phenotypic state of microglia, and therefore the link between 
microglial expansion and neuroinflammation is unclear. During the short-term study, 
microglial area per cell was found to be increased following BCAS (Figure 3.3), indicating a 
conformational change indicative of microglial activation. To assess the activation state of 
microglia following BCAS more directly, immunofluorescent staining using the lysosome-
associated membrane protein 2 (Lamp2) was carried out within the corpus callosum, optic 
tract, and hippocampus CA1 region. Increased Lamp2 expression within microglia has been 
linked to increased phagocytic activity and is used more broadly as a marker of microglial 
activation (Kocur et al., 2015). 
There was an overall group effect on the number of Lamp2+veIba1+ve cells within the corpus 
callosum (χ2(2) = 18.307, p<0.001), with post hoc analysis revealing a significant increase 
within BCAS mice (2.50±3.43) in comparison to sham (0±0.5) (p<0.01) and BCAS+GW2580 
groups (0±0.15) (p<0.001) (Figure 3.17A). In order rule out that this effect is simply driven 
by increased microglial number with the same Lamp2+ve cell occurrence, Lamp2+veIba1+ve cell 
count was normalised to the number of Iba1+ve cells (Figure 3.17B). In agreement with 
previous data an overall group effect was identified (χ2(2) = 18.273, p<0.001), with post hoc 
analysis once again demonstrating a significant increase in BCAS mice (0.16±0.17) in 
comparison to sham (0±0.05) (p<0.01) and BCAS+GW2580 groups (0±0.02) (p<0.001) 
(Figure 3.17B). Within the optic tract there was a significant overall group effect (χ2(2) = 
15.559, p<0.001) and post hoc analysis identified a significant increase in Lamp2+veIba1+ve 
cells within BCAS mice (16.90±12.80) in comparison to shams (0±1.30) (p<0.001) (Figure 
3.17C). In contrast to the corpus callosum however, BCAS+GW2580 mice were found to have 
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significantly higher Lamp2+veIba1+ve cells (13.35±15.90) in comparison to shams (p<0.05), 
with no significant difference when compared to BCAS mice (p=0.571) (Figure 3.17C). When 
the number of Lamp2+ve microglial cells were normalised to total microglial numbers a similar 
trend was observed, with a significant overall effect (χ2(2) = 13.885, p<0.01). Post Hoc analysis 
revealed once again a significant increase within BCAS (0.42±0.12) and BCAS+GW2580 
mice (0.38±0.40) in comparison to shams (0±0.13) (p<0.01 and p<0.05 respectively), with no 
observed difference between BCAS groups (p=1.000) (Figure 3.17D). Despite a strong 
Lamp2+ve microglial response within the white matter, the effect within the hippocampal grey 
matter region was muted. A strong Lamp2 response was observed in a subset of BCAS mice 
however this represented the minority of cases and therefore there was no overall difference 
between groups for cell counts (p=0.334) (Figure 3.17E) or counts normalised to total Iba1 
numbers (p=0.430) (Figure 3.17F).  
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Figure 3.17 CSF1R inhibition protects against corpus callosum microglial activation 
following BCAS. (A) Increased Lamp2+veIba1+ve cells within the corpus callosum of BCAS 
mice but not sham or BCAS+GW2580 groups 6-weeks following surgery. (B) When 
normalised to number of Iba1+ve cells, BCAS mice show significantly increased numbers of 
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Lamp2+ve cells within the corpus callosum when compared to sham and BCAS+GW2580 
groups. (C) Increased Lamp2+veIba1+ve cells within the optic tract of BCAS and 
BCAS+GW2580 mice compared to shams, 6-weeks following surgery. (D) When normalised 
to total Iba1+ve cells, BCAS and BCAS+GW2580 mice show increased Lamp2+ve cells 
compared to shams. Increased numbers of Lamp2+veIba1+ve cells within the hippocampal CA1 
region of a subset of BCAS mice but overall, no group differences were detected for total 
Lamp2+ve cells (E) or when normalised to total Iba1+ve cells (F). Data presented as 
Median±IQR. p<0.05*, p<0.01**, p<0.001***. (G) Representative images of Lamp2/Iba1 
staining within the corpus callosum, optic tract, and hippocampus CA1 region taken from 
sham, BCAS, and BCAS+GW2580 mice. Iba1-green, Lamp2-megenta. White arrow heads 
represent Lamp2/Iba1 colocalised cells. Scale bar 50µm. 
 
Having previously demonstrated that microglial expansion within the corpus callosum is 
positively correlated to increased white matter damage and spatial learning impairments, the 
next aim was to determine if increased Lamp2 expression was also involved. To determine if 
microglial Lamp2 expression is associated with increased white matter damage, MAG severity 
scores were correlated to microglial Lamp2+ve cell counts within the corpus callosum (Figure 
3.18A). The extent of white matter damage was found to be positively correlated to the number 
of Lamp2+ve microglial cells within the corpus callosum (rs(29) = 0.655, p<0.001) (Figure 
3.18A). Furthermore, to investigate the link between Lamp2 expression and impairments in 
spatial learning, average escape latency was correlated to Lamp2+ve microglial cell counts 
within the corpus callosum (Figure 3.18B). A significant positive correlation was identified 
(rs(29) = 0.616, p<0.01), indicating that increased Lamp2+ve microglial numbers are linked to a 
poorer spatial learning performance (Figure 3.18B). 
Overall, these data indicate that chronic BCAS leads to increased microglial lysosomal 
expression within white matter regions, which is associated with increased white matter 
damage and impaired spatial learning. CSF1R inhibition, through GW2580 treatment, reduces 
white matter microglial Lamp2 expression, however this effect is region dependent.   
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Figure 3.18 Lamp2 positive microglial cells are associated with increased white 
matter damage within the corpus callosum and impaired spatial learning. (A) 
Lamp2+Iba1+ cells positively correlate with increased MAG severity score within the corpus 
callosum. (B) Lamp2+Iba1+ cells positively correlate with increased escape latency times, 





The present study set out to investigate the role of microglial proliferation in the onset of 
white matter damage and cognitive impairment following BCAS. The results demonstrate that 
BCAS leads to both white and grey matter microglial proliferation, which is associated with 
increased white matter damage and impaired spatial learning. Blocking microglial 
proliferation through GW2580 treatment was found to prevent microglial expansion, preserve 
white matter integrity, and rescue spatial learning impairments following BCAS surgery.   
 
3.4.1 Resting cerebral blood flow is significantly reduced 
following BCAS and unaltered by GW2580 treatment 
The overall aim of this study was to investigate how sustained reductions in CBF leads to 
white matter damage and ultimately cognitive deficits. To achieve CBF reductions, the 
bilateral common carotid artery stenosis (BCAS) model was used. BCAS was found to lead to 
both short term and chronic reductions in CBF measured within the superficial cortex via laser 
speckle imaging. A ≈50-60% reduction in CBF was apparent 24-hours following BCAS 
surgery, which was maintained up to 6-weeks later with no obvious restoration. Such blood 
flow reductions were comparable to those previously reported within the literature (Fowler et 
al., 2017; Miki et al., 2009).  
In the current study a mixed coil BCAS model was used, which applied 0.16mm and 
0.18mm micro-coils to the common carotid arteries to reduced blood flow to the brain. The 
mixed coil model is a modification of the well-established 2x0.18mm BCAS model (Shibata 
et al., 2004) and was selected due to its ability to induce definite and reproducible white matter 
lesions which are associated with the early onset of neuropsychological deficits (Miki et al., 
2009). This differs from the 2x0.18mm BCAS model which elicits a milder, ≈20-40%, 
reduction in CBF leading to a slower progressive onset of wide spread diffuse axonal damage, 
loss of white matter integrity and impairments in visuo-spatial learning and memory 
(Duncombe, Kitamura, et al., 2017).  
In the present study blood flow was assessed via laser speckle analysis which allows 
repeated measurements, longitudinally, following surgery. Laser speckle analysis is however, 
restricted to the upper layers of the cortex and does not provide information on subcortical 
blood flow changes that might occur in response to BCAS surgery. Previous BCAS studies 
have demonstrated however, via MRI, that blood flow is affected throughout the brain, with 
significant reductions being evident in both cortical and sub-cortical regions (Boehm-Sturm et 
al., 2017; Hattori et al., 2016; Kitamura et al., 2017). Such data indicates that BCAS surgery 
effects blood flow throughout the brain, highlighting the importance of studying both cortical 
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and subcortical changes following surgery. It is important to note however, that both laser 
speckle and MRI analysis of CBF changes following BCAS are conducted under anaesthesia. 
Anaesthetics such as isoflurane have been shown to lead to vascular dilation and therefore 
blood flow may differ between anaesthetised and awake mice (Fan et al., 2016).  
The BCAS procedure employed for the present study involved the application of a 0.16mm 
micro-coil to the right and a 0.18mm coil to the left common carotid arteries. Due to the 
difference in coil diameter, hemispheric disparities in blood flow were apparent early 
following surgery, however these did not persist long term (data not shown). As all measures 
were conducted at 1- or 6-weeks following surgery, when hemispheric blood flow had 
equalised, the hemispheric differences due to surgery were considered minimal. As an 
additional precaution, immunohistochemical analysis was completed on both hemispheres 
with values averaged.  
C57/B6J mice were selected for studies as they have an incomplete circle of Willis, due to 
a lack of posterior cerebral arteries (G. Yang et al., 1997). Thus meaning that compensatory 
blood flow mechanisms are not sufficient to rescue blood flow reductions following BCAS 
surgery in C57/B6J mice (Qian et al., 2018). Despite this, a subset of mice showed resistance 
to BCAS surgery with little evidence of reduced CBF via laser speckle imaging. Through the 
injection of a fluorescently conjugated dextran, non-responding mice were found to have intact 
circle of Willis’, with posterior cerebral arteries clearly visible leading to a conferred resistance 
to BCAS surgery (Figure 2.2). This therefore would indicate a level of genetic divergence 
within the C57/B6J mouse line. The present study aimed to investigate microglial responses 
to sustained CBF reductions. Therefore, to ensure that resilient mice did not compromise the 
study, strict exclusion criteria were established, such that mice needed to demonstrate at least 
a 35% reduction in CBF, 24-hours following BCAS surgery, to be included.  
GW2580 treatment was shown to have no effect on blood flow reductions following BCAS 
surgery. Ensuring that any observed benefits to GW2580 treatment were independent of 
improved CBF following BCAS surgery.  
 
3.4.2 Microglia dominate the early inflammatory response 
following BCAS 
Microarray analysis conducted within the white matter 3-days following BCAS surgery 
identified alterations in pathways associated with neuroinflammation, cytokine-cytokine 
receptor interactions and cell proliferation (Reimer et al., 2011). Despite these findings’ 
investigations assessing the profile of immune cells within the white matter following BCAS, 
have been limited (Duncombe, Kitamura, et al., 2017). To accurately assess such changes 
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white matter tissue taken from the corpus callosum was analysed via flow cytometry. Flow 
cytometric analysis revealed that BCAS surgery resulted in a 2-fold increase in microglial cells 
with macrophage, neutrophil and monocyte numbers unchanged. These findings are in 
agreement with previous investigations using the BCAS model which show, via 
immunohistochemistry, a robust increase in white matter microglial numbers following 
surgery (Coltman et al., 2011; Fowler et al., 2017; Holland et al., 2015; Kitamura et al., 2017; 
Manso et al., 2017; Reimer et al., 2011).  A lack of macrophage response was also in agreement 
with previously published work, which demonstrated via Iba-1/TMEM119 co-labelling 
limited macrophage numbers within the corpus callosum in response to BCAS (Manso et al., 
2017). Additionally, surgical techniques using bone marrow chimeric mice found no evidence 
of peripheral macrophages within the white matter following BCAS (Miyanohara et al., 2018).   
Limited monocyte and neutrophil infiltration following BCAS, however, has not been 
shown previously and would suggest that the BBB is intact following 1-week of BCAS 
surgery. This is in agreement with previous findings which demonstrated that BBB disruption 
is not observed until 6-months following BCAS surgery, as detected by parenchymal 
fibrinogen and markedly reduced tight junction claudin-5 expression (Holland et al., 2015). 
Other groups however, have demonstrated cortical, hippocampal, and striatal BBB leakage 
through the quantification of Evans blue, as early as 14-days post-BCAS (J. M. Roberts et al., 
2018). It could, therefore, be hypothesised that BBB leakage is brain region dependent with 
white matter regions showing increased resistance. However, additional investigations, 
focussing on BBB integrity within specific white matter regions would be required to confirm 
such a theory. 
As a confirmation of microglial expansion following BCAS surgery, microglial numbers 
were calculated, via immunohistochemistry, 1-week following BCAS within both white and 
grey matter regions. Iba-1 cell counts demonstrated increased microglial numbers within the 
hippocampus following BCAS surgery, however, quantification within the corpus callosum 
only reported a strong trend for increased microglial numbers. Increased hippocampal 
microglial numbers is in agreement with previously published work assessing early 
neuroinflammatory changes following BCAS (J. M. Roberts et al., 2018). A lack of clear 
microglial expansion within the corpus callosum, however, does somewhat contradict flow 
cytometry results, which demonstrated a 2-fold microglial increase when compared to shams. 
This can however be attributed to the fact that immunohistochemical analysis is only assessing 
numbers within a subregion of the corpus callosum, from a 6µm section, whereas flow 
cytometry is analysing almost the entire corpus callosum and therefore can be deemed a more 
reliable assessment.  
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Despite only a trend for increased corpus callosum numbers, percentage area of Iba1 
staining per cell was found to increase following BCAS, indicating enlarged microglial size. 
Previous studies have demonstrated that microglia undergo conformational changes when a 
switch from homeostatic to activated forms occurs (Karperien, Ahammer, & Jelinek, 2013). 
Increased microglial size has been reported after a number of inflammatory inducing insults 
such as LPS treatment, mechanical injury, and optic nerve crush injury (B. M. Davis et al., 
2017; Kozlowski & Weimer, 2012; Stence, Waite M Fau - Dailey, & Dailey, 2001). Increased 
area of staining per cell does provide some data to illustrate altered microglial phenotype 
following surgery, however more advanced imaging techniques, such as multiphoton 
microscopy and 3-dimensional (3D) structural modelling, would be required to accurately 
confirm such a finding.  
One important consideration for immunohistochemical analysis, is that Iba1 is a pan 
myeloid cell marker and therefore will be expressed on macrophages as well as microglia. 
Flow cytometry data, however, shows that the early neuroinflammatory response following 
BCAS is dominated by microglia. TMEM119 staining following BCAS also showed a 1 to 1 
overlap with Iba-1, demonstrating microglial specific expansion following BCAS (Manso et 
al., 2017). Therefore, the contribution of macrophages to Iba1 cell counts is likely to be 
minimal. 
 
3.4.3 Microglial expansion following BCAS is driven by local 
proliferation 
To determine if microglial expansion is driven by the local proliferation of endogenous 
microglial following BCAS, BrdU was administered over the last 3-days prior to the 1-week 
timepoint. BrdU incorporates into the DNA of actively dividing cells, allowing proliferating 
cells to be identified via immunohistochemistry. Iba1-BrdU co-staining demonstrated 
significantly increased levels of microglial proliferation within both white and grey matter 
regions, 1-week following BCAS surgery. These findings are in agreement with previous 
literature, which reported increased white matter microglial numbers associated with local 
proliferation, following 10-weeks of BCAS (Manso et al., 2017). However, the present study 
provides the first evidence to demonstrate early microglial proliferation in response to BCAS. 
This finding however is supported by previous literature that demonstrated significant 
alterations in 15 genes associated with the regulation of cell proliferation, through microarray 
analysis completed on white matter tissue samples taken 3-days following BCAS (Reimer et 
al., 2011).  
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Such findings also align with recent clinical evidence which identified 5 risk loci, through 
GWAS, associated with neuroimaging markers of white matter dysfunction that were all 
highly expressed by microglial/macrophages populations (Armstrong et al., 2020; Persyn et 
al., 2020). Furthermore, increased microglial number is a frequently observed feature, at post 
mortem, within human VCI cases (Simpson, Fernando Ms Fau - Clark, et al., 2007; Simpson, 
Ince Pg Fau - Higham, et al., 2007). 
Under normal homeostatic conditions microglial proliferation is matched to apoptosis to 
maintain a stable population of microglial cells throughout the brain. The balance between 
microglial proliferation and apoptosis has be shown to become disrupted in neurodegenerative 
conditions leading to excessive microglial proliferation (Diego Gomez-Nicola & V. Hugh 
Perry, 2015). Taken together these findings therefore provide strong evidence to demonstrate 
that microglial expansion occurs early, following BCAS surgery, within both white and grey 
matter regions and is driven by local proliferation.  
Alongside the quantification of proliferating microglial cells, the number of non-microglial 
proliferating cells was also calculated. Analysis of non-microglial cell proliferation showed 
significant increases within the hippocampus, but not the corpus callosum, following BCAS. 
Flow cytometry data demonstrated no change in the numbers of macrophages, neutrophils, or 
monocytes following BCAS, suggesting that these non-microglial proliferating cells are 
unlikely to be immune related. Although, flow cytometry was completed within the corpus 
callosum and therefore it is possible that the immune cell profile may differ within the 
hippocampus. It has been shown however, that astrogliosis occurs in response to BCAS 
(Kitamura et al., 2017), with changes observed subsequent to microglial alterations (Holland 
et al., 2015). Consistent with these findings, the release of microglial cytokines has been 
identified as a key mechanism triggering astrogliosis (Liddelow et al., 2017). Increased GFAP, 
a marker of astrogliosis, has also been demonstrated within hippocampus, cortex, and striatum 
at early timepoints following BCAS (J. M. Roberts et al., 2018). Therefore, astrocytic 
proliferation is a likely candidate for the non-microglial proliferation observed within the 
hippocampus.  
Endothelial cell proliferation is another possible candidate for the non-microglial 
proliferation occurring within the hippocampus following BCAS. As angiogenesis has been a 
proposed mechanism by which the cerebral vasculature may attempt to counteract the 
detrimental effects of BCAS. Previous studies, however, using Ki67 as a marker of 
proliferation, identified only 6.8% co-localisation with the endothelial marker PECAM-1 
within the hippocampus and striatum of mice following BCAS (J. M. Roberts et al., 2018). 
The authors then went on to demonstrate, within the grey matter, 71.8% co-localisation of 
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Ki67 with the microglial marker CD11b, 55.1% with the astrocytic marker GFAP and 30.8% 
with the oligodendrocyte marker OSP (J. M. Roberts et al., 2018). Further, supporting the 
present findings of microglial proliferation early following BCAS and highlighting astrocytes 
and oligodendrocytes as the most likely candidates for the non-microglial proliferation 
observed. In the present study, however, non-microglial proliferation is proportionally seen to 
be minimal when compared to microglial proliferation, which clearly dominates the early 
neuroinflammatory response following BCAS.  
 
3.4.4 GW2580 treatment prevents microglial expansion following 
BCAS 
As mentioned previously, robust increases in white matter microglial numbers have been 
consistently demonstrated following BCAS surgery (Coltman et al., 2011; Fowler et al., 2017; 
Holland et al., 2015; Kitamura et al., 2017; Manso et al., 2017; Reimer et al., 2011). The 
present study, however, was the first evidence to clearly show that local microglial 
proliferation dominates the early neuroinflammatory response following BCAS. This 
therefore led to the hypothesis that the blockade of microglial proliferation could have a 
beneficial impact on downstream white matter impairment and cognitive dysfunction. 
A key mechanism by which microglial proliferation is regulated is through the colony-
stimulating factor 1 receptor (CSF1R) (Raivich et al., 1998). The ligands CSF-1 (also known 
as M-CSF) and interleukin-34 (IL-34) bind to the CSF1R leading to downstream signalling 
promoting the survival, differentiation, and proliferation of mononuclear phagocytes, with the 
most notable of these being microglial cells (Hume & MacDonald, 2012). In the present study, 
white matter microglia were found to have a ≈3-fold increase in CSF1R expression following 
short-term BCAS, thus highlighting CSF1R signalling as the likely mechanism underlying 
microglial proliferation. GW2580 is an orally available inhibitor of CSF1R and therefore 
provided a specific method by which microglial proliferation could be blocked following 
BCAS (Conway et al., 2005). 
In the present study, chronic treatment with the competitive CSF1R antagonist GW2580 
was found to successfully inhibit microglial expansion within white and grey matter regions, 
following BCAS. Previous research using the same 75mg/kg GW2580 dosing regime, reported 
≈50% reduction in microglial proliferation in models of prion disease (Gomez-Nicola et al., 
2013) and Alzheimer’s disease (Adrian Olmos-Alonso et al., 2016b). Here we report almost a 
complete inhibition of microglial proliferation, with BCAS+GW2580 mice even showing a 
slight dip in microglial numbers below that of shams. The difference in GW2580 effectiveness 
within the present study is likely due to the severity of disease models being assessed. Prion 
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and AD models elicit a robust and chronic neuroinflammatory response, characterised by 
increased pro-inflammatory genes such as IL-1β, CSF1, and IL-34, observed as late as 18-
weeks following prion inoculation (Gomez-Nicola et al., 2013) and 9-months within AD mice 
(A. Olmos-Alonso et al., 2016). BCAS in contrast, leads to more subtle inflammatory 
responses, with microarray analysis demonstrating increased pro-inflammatory gene 
expression 3-days following surgery (Reimer et al., 2011), with only very subtle changes 
detected 6-weeks later (Manso et al., 2017). GW2580 acts as a competitive antagonist at the 
intracellular tyrosine kinase domain of the CSF1 receptor (Dai et al., 2002), and therefore 
under extremely high levels of proliferation, GW2580 may be out-competed for binding by 
the endogenous ligands CSF1 and IL-34. Therefore, the almost complete blockade in 
microglial proliferation observed following BCAS likely reflects a proliferation rate at which 
GW2580 can successfully outcompete endogenous CSF1 and IL-34 ligands. However, to 
accurately assess this, CSF1 and IL-34 ligand expression within BCAS mice with and without 
GW2580 treatment would need to be quantified. 
In the present study microglial numbers within BCAS mice, following GW2580 treatment, 
were found to be lower than that of shams. One explanation for this could be that GW2580 
treatment, alongside blocking BCAS mediated proliferation, is also preventing normal 
homeostatic microglial proliferation. Longitudinal fate mapping studies, however, 
demonstrate that microglial proliferation within the mouse neocortex is a rather deactivated 
process, with ≈50%  of all microglial cells persisting until the end of the mouse’s lifespan 
(Fuger et al., 2017). Thus, indicating that microglial homeostatic proliferation rates are low 
and therefore unlikely to account for such a difference in microglial numbers (Askew et al., 
2017). An alternative explanation is that BCAS results in microglial apoptosis which would 
account for the dip in microglial numbers within BCAS mice following GW2580 treatment. 
Such an effect would not be as easily observed within the BCAS group due to a prominent 
microglial proliferative response. Previous studies, however, found no increase in numbers of 
apoptotic cells within the white matter, 3-days or 1-month following BCAS (Reimer et al., 
2011). Although, this might not be the case in the present study which utilised a mixed coil 
BCAS model with assessments at a more chronic timepoint. It could, therefore, be the case 
that modest levels of apoptosis, coupled to a blockade of homeostatic proliferation, coincide 
to lead to an overall dip in microglial numbers following GW2580 treatment. To confirm this, 
additional experiments would be required using apoptotic markers or fate mapping 
technologies, alongside sham groups treated with GW2580. 
To assess microglial proliferation at a chronic timepoint following BCAS, BrdU was 
administered for the 3-days prior to the 6-week timepoint. Immunohistochemical analysis 
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revealed very little evidence of microglial proliferation 6-weeks following surgery. The same 
BrdU treatment regime was used for both short-term and chronic studies. This suggests that 
microglial proliferation rates are higher at 1-week compared to 6-weeks following BCAS. As 
evidenced in the present study, CBF reductions are apparent 24-hours following surgery and 
maintained consistently up to 6-weeks later. Previous studies have also demonstrated that 
reduced white matter oxygen tension can be detected 3-days following BCAS and was 
maintained at hypoxic levels when assessed 1- and 6-weeks following surgery (Duncombe, 
Kitamura, et al., 2017). Despite persistent cerebral hypoperfusion and white matter hypoxia, 
microglial proliferation rates in the present study were found to be higher when assessed at 1-
week compared to 6-weeks. Thus, indicating that signalling mechanisms, triggering the 
proliferation of microglial, occur early following BCAS and do not persist at later timepoints. 
In support of this, previous microarray analysis demonstrated increased endothelial related 
gene expression, alongside of a battery of proinflammatory genes, acutely following BCAS 
(3-days) (Reimer et al., 2011). Such responses, however, were difficult to detect when assessed 
chronically (6-weeks) following surgery (Manso et al., 2017). However, it is important to note 
that 3 BrdU doses would be unlikely to capture all the proliferation ongoing at either timepoint. 
Therefore, to assess microglial proliferation more comprehensively, chronic BrdU dosing 
would be required.  
 
3.4.5 GW2580 treatment prevents white matter integrity 
disruption following BCAS 
In agreement with previous studies (Coltman et al., 2011; Kitamura et al., 2017; McQueen 
et al., 2014; Reimer et al., 2011) white matter damage was found to be widespread with 
increased MAG accumulations identified within the corpus callosum, fimbria, and internal 
capsule following chronic BCAS. White matter damage was also found to positively correlate 
with increased microglial number within all white matter regions analysed.  
GW2580 treatment was found to ameliorate white matter damage through the blockade of 
microglial proliferation across white matter regions. BCAS studies have previously reported a 
close association between microglial number and impairments in white matter function 
(Fowler et al., 2017; Kitamura et al., 2017; Manso et al., 2017). Additional, broad spectrum 
anti-inflammatory pharmacological approaches, linked to reduced microglial number, have 
demonstrated reductions in white matter damage and improvements in white matter function 
following BCAS (Fowler et al., 2017; Manso et al., 2017; Miyanohara et al., 2018). The 
present study, however, provides the first direct evidence to demonstrate that microglial 
proliferation is crucial to white matter damage, following BCAS.  
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Microglia are proposed to be detrimental to both the white matter and oligodendrocytes 
through the chronic release of free radicals and cytokines following sustained 
neuroinflammation (Howell et al., 2010). Increased Lamp2 expression within the corpus 
callosum also demonstrates that microglial proliferation is accompanied by increased 
microglial activation, likely leading to the release of pro-inflammatory cytokines driving 
further damage. Increased lamp2 expression is indicative of lysosomal activity which would 
suggest increased microglial phagocytic activity. Whether microglia are indeed phagocytosing 
material within the white matter tracts is currently unknown. However, it would suggest that 
damage is occurring within these regions leading to increased debris, triggering clearance 
pathways. In agreement with the role of microglia in white matter damage, previous studies 
using the anti-convulsant levetiracetam, showed that white matter damage and cognitive 
impairment were reversed due to reduced microglial activity. Inhibition of microglial activity 
was also found to be associated with reduced oligodendrocyte cell death within the cerebral 
white matter (Inaba et al., 2019). Additional experiments using more detailed imaging 
approaches, such as electron microscopy, would be required to definitively prove that 
microglial are indeed phagocytosing debris within white matter tracts following BCAS. 
However, the present study does clearly demonstrate that microglial proliferation is a 
fundamental step in the onset of white matter damage following BCAS.  
In support of our present findings, previous studies using GW2580 treatment have 
demonstrated improved white matter integrity and function in mouse models of multiple 
sclerosis (Crespo et al., 2011) and spinal cord injury (Gerber et al., 2018). Furthermore, 
approaches to deplete microglia have shown promise in the reversal of white matter damage. 
For example, treatment with the CSF1R inhibitor PLX5622, in an experimental autoimmune 
encephalomyelitis mouse model of multiple sclerosis, demonstrated reduced demyelination, 
immune cell activation, and preserved mature myelinating oligodendrocytes within white 
matter lesion areas (Nissen, Thompson, West, & Tsirka, 2018). The pharmacological or 
genetic depletion of microglia has also been shown to have a beneficial impact on white matter 
pathology within a range of neurodegenerative disease models (Garcia-Agudo et al., 2019; 
Janova et al., 2018; Klein et al., 2015), including chronic stroke (Jackson, Dumanli, Johnson, 
Fagan, & Ergul, 2020). 
Interestingly however, human loss of function mutations within the CSF1R gene have been 
identified and lead to the onset of hereditary diffuse leukoencephalopathy with spheroids 
(Rademakers et al., 2011). CSF1R-related leukoencephalopathy patients typically present with 
frontotemporal dementia-like cognitive phenotypes with neuroimaging evidence of white 
matter abnormalities, thinning of the corpus callosum, diffusion-restricted lesions in the white 
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matter, and brain calcifications (Konno, Kasanuki, Ikeuchi, Dickson, & Wszolek, 2018). Thus, 
highlighting that long-term inhibition of CSF1R signalling is likely to be harmful to the white 
matter and therefore further research is required to elucidate the beneficial timing of such 
pharmacological interventions.  
 
3.4.6 GW2580 treatment rescues spatial learning impairments 
following BCAS 
The corpus callosum and hippocampus represent important components of the frontal-
subcortical circuitry that has been implicated in spatial learning the memory (Duncombe, 
Kitamura, et al., 2017). Previous studies have also demonstrated a close relationship between 
white matter damage and cognitive impairments following BCAS (Ben-Ari et al., 2019; 
Coltman et al., 2011; Holland et al., 2015; Nishio et al., 2010; Shibata et al., 2007), with some 
evidence of improvements following broad acting anti-inflammatory interventions 
(Miyanohara et al., 2018; C. Qin et al., 2017). To date however the direct relationship between 
microglial proliferation and cognitive impairment has not been reported.  
Here, the assessment of spatial learning and memory, via the Barnes maze, identified 
significant impairments 6-weeks following BCAS surgery. These findings are in agreement 
with previous studies which report spatial learning deficits following BCAS, using a 
conventional 8-arm radial maze or Y-maze tests (Maki et al., 2011; Shibata et al., 2007; 
Washida et al., 2010). Previous experiments using the Barnes maze however, were only able 
to detect spatial learning impairments 5-6 months following BCAS (Holland et al., 2015; 
Nishio et al., 2010). The accelerated onset of Barnes maze cognitive impairment in the present 
study is likely a reflection of the more severe blood flow reductions achieved here (50-60%) 
when compared to the previous BCAS studies (20-40%) (Holland et al., 2015; Nishio et al., 
2010).  
Chronic GW2580 treatment was found to preserve spatial learning, following BCAS, 
which was associated with reduced white matter microglial numbers and white matter damage. 
In agreement with these findings, the pharmacological ablation of microglia prior to BCAS 
surgery, through PLX3397 treatment, was found to supress white matter damage and restore 
cognitive abilities (Kakae et al., 2019a). Disruption of white matter tracts, especially within 
the prefrontal cortex, has been suggested as a mechanism underpinning spatial learning deficits 
following BCAS (Burton et al., 2004; Shibata et al., 2007). Furthermore, ischemic disruption 
of the prefrontal cortical-subcortical circuits has been implicated in the cognitive and mood-
behaviour abnormalities seen in human VCI (Bonelli & Cummings, 2007; Lanza et al., 2017). 
Due to the significant white matter integrity improvement following GW2580 treatment, it can 
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therefore be inferred that rescued white matter integrity culminates in preserved spatial 
learning, following BCAS. Indeed, it has been suggested that spatial learning is dependent on 
white matter circuitry which allows for efficient communication between brain regions 
(Coltman et al., 2011; Shibata et al., 2007). This is in agreement with previous research which 
demonstrated that disruption of axon-glial integrity and microglial expansion were associated 
with impairments in spatial learning (Kitamura et al., 2017).  
Despite significant improvements in spatial learning, GW2580 treatment was found to only 
display modest restorative effects on spatial memory. Spatial memory has been proposed to 
be related to cognitive domains that are reliant on an intact hippocampus, as well as effective 
hippocampal signalling through frontal-subcortical circuitry (Nishio et al., 2010; Sharma, 
Rakoczy, & Brown-Borg, 2010). In agreement with this, milder models of BCAS, absent of 
hippocampal inflammatory responses and pathology, display spatial learning but not spatial 
memory impairments (Shibata et al., 2007). In the present study we observe a significant 
proliferative microglial response within the CA1 region of the hippocampus following BCAS 
surgery. Even though chronic GW2580 treatment was found to successfully inhibit this 
microglial expansion, no spatial memory improvements were observed. This may reflect the 
fact that GW2580 is unable to prevent damage to other cell types within the hippocampus, 
most namely neurons and synapses which could be significantly impacted following BCAS 
leading to memory impairments. Thus, indicating that damage may occur through microglial-
independent processes. It could also be the case that GW2580 treatment, restores frontal-
subcortical circuitry to such an extent that spatial learning is maintained, however, damage 
may persist and thus sustain deficits in spatial memory. 
Following the training phase, the escape chamber was relocated 1800 to the other side of 
the maze and visuo-spatial learning and memory of this new location was assessed (Pompl, 
Mullan Mj Fau - Bjugstad, Bjugstad K Fau - Arendash, & Arendash, 1999). A slight trend for 
worsened reversal learning was apparent following BCAS with a slight improvement in 
response to GW2580 treatment. Sham mice, however, were the only group able to demonstrate 
intact memory for the target zone during probe trails. Reversal learning within the BCAS 
group did appear to show a slower rate of learning in comparison to both sham and 
BCAS+GW2580 groups. This contrasts with the clear learning impairment observed within 
BCAS mice during the training phase in comparison to sham and BCAS+GW2580 groups. 
This may reflect the fact that the reversal phase is much shorter than the training phase, and 
therefore sham and BCAS+GW2580 groups might not have had sufficient time to clearly 
outperform the BCAS group (O'Leary & Brown, 2009).    
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Throughout both standard and reversal training phases escape latency was used as the 
outcome measure of performance. Escape latency refers to the time taken for the mouse to 
locate and enter the escape chamber, which can be highly influenced by movement speed.  To 
ensure that mobility differences between groups were not influencing learning outcomes, 
movement speed was compared across groups. Movement speed, during both training and 
reversal phases, was found to be comparable across all groups, and therefore had no influence 
on learning outcomes in the present study.  
Across both training and reversal phases, GW2580 treatment showed some benefit to 
learning outcomes with no observed improvement in long-term memory impairments 
following BCAS. This is an important distinction, as blocking microglial proliferation appears 
to selectively rescue learning but not memory deficits following BCAS. Human VCI is 
characterised by impairments in cognitive functions important for executive functioning and 
speed of processing, which are reliant of healthy white matter (de Groot et al., 2000). In later 
stages of disease processes, severe memory impairments become apparent which are 
associated with increased severity of SVD pathology (Smallwood et al., 2012). Furthermore, 
a common finding within patients showing vascular brain lesions as a result of cerebrovascular 
disease are impairments in executive functions, such as cognitive flexibility, as well as 
processing speed (Looi & Sachdev, 1999). This therefore indicates that CSF1R inhibition 
alone is not sufficient to rescue both learning and memory impairments following BCAS, 
indicating additional mechanism effecting cognition beyond white matter damage, or simply 
that restoration of frontal-subcortical circuitry is not sufficient to restore spatial memory.   
Overall, this data provides the first evidence to demonstrate that microglial proliferation 
significantly contributes to white matter damage and spatial learning impairments following 
BCAS. 
 
3.4.7 GW2580 treatment prevents BCAS mediated increases in 
microglial lysosomal expression within the corpus callosum 
Lamp2 expression has been shown to be required for the fusion of lysosomes and 
phagosomes within microglial cells (Huynh et al., 2007). Therefore, increased lamp2 
expression can be considered a marker of increased microglial phagocytic activity as well as 
a general indicator of microglial activation (Kocur et al., 2015). In the present study, increased 
lamp2 expression was observed within white but not grey matter regions following BCAS. 
This may reflect increased myelin debris within white matter regions causing an increased 
need for phagocytic activity to facilitate clearance. In support of this a recent study identified, 
using CLARITY imaging, that spatial learning and memory deficits as well as white matter 
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damage following BCAS, were associated with microglial activation and an increase in the 
number of reactive microglia adhering to and phagocytosing myelin (Zhang et al., 2020). Thus, 
demonstrating that microglia are directly damaging myelinated axons. Myelin phagocytosis 
was found to be associated with an upregulation in the expression of complement C3 and its 
receptor C3aR (Zhang et al., 2020). Furthermore, human post mortem neuropathological 
investigations have highlighted increased CD68+ve microglia, indicative of increased 
phagocytic activity, as a prominent feature of deep subcortical lesions within an ageing 
population (Waller et al., 2019). Additionally, the increased production of myelin fragments 
released from aging myelin sheaths has been shown to lead to the formation of insoluble, 
lipofuscin-like lysosomal inclusion within microglia. Over-time such insoluble inclusions 
overwhelm the lysosomal capacity of microglial cells resulting in microglial senescence and 
immune dysfunction in ageing (Safaiyan et al., 2016). 
Increased white matter, but not grey matter, lysosomal activity may indicate that the level 
of damage within white matter areas exceeds that of the hippocampus leading to an increased 
need for phagocytic processes. Indeed, white matter regions have been shown to be 
particularly vulnerable to vascular disruption (Black, Gao F Fau - Bilbao, & Bilbao, 2009; 
Iadecola, 2013), which has been attributed to the relative scarcity of collateral blood flow in 
deep white matter regions (Iadecola, Park, & Capone, 2009). Furthermore, ageing has been 
demonstrated to reveal brain region specific differences in microglial phenotype, with white 
matter microglia displaying increased levels of the phagocytic related marker CD68 (Hart, 
Wyttenbach, Perry, & Teeling, 2012). 
In response GW2580 treatment, microglial lamp2 expression within the corpus callosum 
was found to be significantly reduced to sham levels. When lamp2 expression was normalised 
to the total number of microglial cells, BCAS+GW2580 mice still demonstrated very low 
numbers of lamp2 expressing microglia within the corpus callosum. Previous studies have 
suggested that GW2580 leads to an overall shift of inflammatory profile from pro- to anti-
inflammatory (Gomez-Nicola et al., 2013; A. Olmos-Alonso et al., 2016). In support of this, 
work using cultured human microglia has demonstrated that increased CSF1R signalling leads 
to the production of pro-inflammatory cytokines (Walker, Tang, & Lue, 2017). Reduced lamp2 
expression could therefore indicate that GW2580 treatment is not only blocking microglial 
proliferation but is also causing a switch to a more anti-inflammatory microglial phenotype 
following BCAS. In agreement with this explanation, GW2580 treatment in a mouse model of 
Parkinson’s disease was observed to block microglial proliferation, leading to reduced mRNA 
expression of pro-inflammatory markers, with no effect on anti-inflammatory markers (Neal 
et al., 2020).  
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Alternatively, another explanation could be that early microglial proliferation leads to the 
release of harmful pro-inflammatory cytokines resulting in myelin and axonal damage within 
the white matter. Over more chronic time periods cellular debris collects leading to increased 
lysosomal activity within microglial cells, to enable debris to be phagocytosed and cleared. 
GW2580 would therefore act to block microglial proliferation, significantly reducing 
neuroinflammation, and thus preventing white matter damage and the need for phagocytic 
processes. In support of this, research within a rat MCCAO model, demonstrated that 
microglial were activated via complement 3 receptor signalling, leading to microglial adhering 
to and phagocytosing myelin. Genetic deletion of the complement 3 receptor was then found 
to limit microglial activation and attenuate white matter injury and cognitive deficits following 
hypoperfusion (Zhang et al., 2020). Increased microglial activation and proliferation has also 
been identified within the white matter of ageing human brains, being identified not only 
within lesioned areas but also within the non-lesioned white matter (Simpson, Ince Pg Fau - 
Higham, et al., 2007). Further investigations therefore are required to shed light on these 
process by looking at lamp2 activity acutely following BCAS. 
GW2580 treatment was found to have no positive effect on lamp2 expression within the 
optic tract, which could indicate that this region is particularly susceptible leading to a more 
significant response. Iba1 cell counts within the optic tract during the lamp2 analysis revealed 
a big increase following BCAS with only a modest, non-significant, reduction following 
GW2580 treatment (data not included). Indicating that GW2580 treatment was ineffective 
within this area. This regional effect might reflect a magnitude of proliferative response within 
the optic tract that the current dose of GW2580 is unable to compete with and therefore cannot 
completely block. GW2580 acts as a competitive antagonist at the intracellular tyrosine kinase 
domain of the CSF1 receptor (Dai et al., 2002), and therefore under extremely high levels of 
proliferation GW2580 may be out-competed for binding by the endogenous ligands CSF1 and 
IL-34. Thus, microglia are still proliferating within this area and increased phagocytic activity 
is still present. Indeed, microglial numbers within the optic tract were shown to only be 
reduced by ≈35% following GW2580 treatment. This explanation is supported by previous 
investigations using the same 75mg/kg GW2580 dose in more severe disease models, that 
were able to achieve only a 50% reduction in microglial proliferation (Gerber et al., 2018; 
Gomez-Nicola et al., 2013; Martínez-Muriana et al., 2016; A. Olmos-Alonso et al., 2016).  
 
3.4.8 Study limitations and future directions 
In the present study, despite clear evidence of microglial proliferation contributing to white 
matter damage and cognitive impairment, data relating to the behaviour and activation state of 
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microglia in response to BCAS is lacking. In recent years significant advancements in 
intravital imaging approaches, alongside transgenic microglial reporter lines, have been made 
providing unprecedented access to the assessment of microglial behaviour in vivo. For 
example, multiphoton microscopy, alongside microglial reporter mice, can be used to 3D 
reconstruct individual microglial cells through which microglial activation state can be 
determined by the assessment of structural parameters (B. M. Davis et al., 2017; Kozlowski & 
Weimer, 2012). Microglial process motility has also be demonstrated to be dynamic and alter 
under disease conditions (Nimmerjahn et al., 2005). The aim, therefore, in chapter 4 was to 
utilise these state-of-the-art methods to allow for a more in-depth assessment of microglial 
structure and function following BCAS.  
 A key indication of microglial activation state, determined from the present study, was the 
observation of white matter microglial proliferation associated with increased lysosomal 
activity. However, an investigation into the lysosomal activity of microglial within white 
matter tracts, as well as a determination of what debris might be stimulating such as response, 
was not in the scope of the present study. Future studies, however, could make use of 3D 
electron microscopy to clearly demonstrate phagocytosing microglial following BCAS 
(Tremblay, Lowery, & Majewska, 2010). Alternatively, confocal microscopy and 
immunofluorescence has been shown to be a powerful method to assess phagocytosis, through 
the observation of 3D poches within terminal microglial branches that completely surround 
apoptotic cells (Sierra et al., 2010). 
In the current study evidence of microglial activation was presented through an increase in 
microglial size 1-week following BCAS, as well as increased lysosomal activity 6-weeks 
following surgery. These data, although inferring microglial activation, do not provide clear 
evidence that microglial are actively contributing to neuroinflammation following BCAS. 
Therefore, in future studies it will be important to show such changes more comprehensively, 
to help clearly demonstrate that microglial are actively contributing to neuroinflammatory 
mediated damage. For example, white matter microglial could be isolated through flow 
cytometry and qPCR carried out to highlight increased expression of pro-inflammatory 
cytokines such as TNF-α, IL-1 and IL-6 (J. A. Smith, Das A Fau - Ray, Ray Sk Fau - Banik, 
& Banik, 2012). The present study also lacked the evaluation of perivascular macrophages 
which are likely to be impacted following BCAS due to their proximity to the vasculature. 
Furthermore, CSF1R signalling is important for the proliferation of perivascular macrophages 
and therefore the effects of GW2580 treatment currently cannot be solely attributed to 
microglial cells (Miron & Priller, 2020). Future studies should, therefore, look to delineate 
perivascular macrophages more comprehensively from microglial cells to determine the true 
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contribution of each to pathology following BCAS surgery, as well as uncover their individual 
responses to GW2580 treatment.  
A key limitation of the present study is the lack of understanding as to what signalling 
mechanisms drive microglial proliferation following BCAS. Previous studies, through the 
implantation of fibre-optic oxygen sensors within the corpus callosum, demonstrated reduced 
PO2 levels following BCAS. PO2 levels were shown to dramatically reduced to hypoxic levels 
within 24-hours, and remain reduced when assessed 1- and 6-weeks later (Duncombe, 
Kitamura, et al., 2017). It has been shown that injured neurons produce increased amounts of 
CSF1 leading to microglial proliferation and activation (Guan et al., 2016). Therefore, hypoxia 
could be the mechanism by which neurons produce CSF1 triggering increased microglial 
proliferation following BCAS. Additional studies are however required to clearly prove such 
a mechanistic link. For example, correlating increased hypoxia within white matter regions to 
increased CSF1 production would help delineate such a mechanism. Additionally, microarray 
analysis conducted 3-days following BCAS demonstrated endothelial related gene changes 
occurring alongside inflammatory associated genes (Reimer et al., 2011). Thus, providing 
some evidence to suggest that the endothelium may be one of the earliest responders to hypoxia 
following BCAS surgery. In future studies it would be important to investigate endothelial 
related changes to determine if signalling from endothelial cells to microglial could be the first 
mechanism triggering harmful microglial proliferation following BCAS.  
Interestingly, GW2580 treatment here was found to preserve spatial learning but not 
memory following BCAS. A limitation of the present study is the lack of mechanistic insight 
as to why memory impairments could not be rescued. The hippocampus is a region heavily 
implicated in the formation of spatial memory (Nishio et al., 2010; Sharma et al., 2010). Here, 
despite no memory improvement, increased microglial proliferation within the CA1 region 
following BCAS was found to be successfully blocked through GW2580 treatment. In future 
experiments it would be important to assess hippocampal neuronal apoptosis, through caspase-
3 immunohistochemistry, to help determine if such changes are underpinning memory deficits, 
even in the absence of microglial proliferation. Additionally, GW2580 treatment may not fully 
repair the frontal-subcortical circuitry damage following BCAS, thus restoring spatial learning 
but not memory. Future electrophysiological experiments testing hippocampal communication 
with other brain regions, such as the prefrontal cortex, would help delineate the underlying 
mechanisms impairing spatial memory following BCAS. 
The observation of impaired spatial memory in absence of microglial proliferation indicates 
that non-microglial related damage could still be occurring. Increased reactive oxygen species 
production could be one mechanism by which spatial memory is impaired in the absence of 
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microglial expansion (H. A. Kim et al., 2012). Additional experiments targeting NADPH 
oxidase could help elucidate such mechanisms. For example, a combination therapy approach 
with GW2580 and the NADPH oxidase inhibitor apocynin could be used to see if both spatial 
learning and memory impairments could be rescued following BCAS (Y. Y. Qin et al., 2017). 
Alternatively, for a more targeted approach, NADPH oxidases knockout transgenic mice could 
be used to study the implications of Nox signalling on spatial memory impairments following 
BCAS (Buvelot, Jaquet, & Krause, 2019).  
In the current study microglial proliferation, in response to BCAS, was found to be key to 
the development of white matter damage and cognitive impairment. What remains unclear, 
however, is the mechanisms by which microglia can cause such damage. In an attempt to 
uncover such mechanisms, a bulk transcriptome study of isolated white matter has been 
undertaken since the completion of this study. A key outcome of the RNA sequencing analysis 
was the identification of microglial, as well as endothelial enriched gene sets, which were 
found to be significantly increased following BCAS and subsequently modified following 
GW2580 treatment. Endothelial dysfunction, through both clinical and pre-clinical studies, 
has been identified as a key early initiator of cerebrovascular disease (Iadecola et al., 2019; 
Rajani & Williams, 2017; F. Wang et al., 2018; J. M. Wardlaw et al., 2019). The role of 
endothelial dysfunction following BCAS, was investigated within chapter 5, through in vivo 
intravital imaging. 
In the present study we have demonstrated that the blockade of microglial proliferation is 
able to attenuate damage and cognitive impairment following BCAS. The view, however, that 
all microglia are bad in the context of BCAS and removing them is advantageous is very 
simplistic. The recent advancement of single-cell RNA sequencing methods has allowed 
microglia to be studied on an individual basis, across the mouse lifespan, as well as in the 
context of disease. Such studies have demonstrated a very complex picture, demonstrating that 
microglia are a very heterogenous population in which gene expression can vary even in the 
same brain region (Hammond et al., 2019; Stratoulias, Venero, Tremblay, & Joseph, 2019; 
Tan, Yuan, & Tian, 2020). Therefore, future studies will need to make use of such sequencing 
technologies to enable a complete picture of microglial changes, following BCAS with and 
without GW2580 treatment, to be determined.  
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3.5 Conclusion 
In conclusion, the data presented within this chapter provides the first conclusive evidence 
that white matter microglial proliferation is fundamental to white matter damage following 
BCAS. Furthermore, specific blockade of microglial proliferation, through competitive 
inhibition of CSF1R signalling, can restore white matter integrity and rescue impairments in 






Investigating structural and functional microglial 




The studies in the previous chapter, demonstrated that microglial proliferation following 
BCAS is associated with both white matter damage and cognitive impairments. These studies, 
however, were limited by the fact that all investigations were conducted post mortem. Thus, 
preventing any inference on microglial phenotype that can be determined through alterations 
in both shape and dynamic process movement. The next aim, therefore, was to further 
characterise microglial responses to BCAS through, in vivo, structural, and functional 
evaluations.  
Under normal homeostatic conditions, microglia display a characteristic morphology with 
a small spherical cell soma surrounded by highly ramified flopodia-like processes. In 
homeostatic ‘resting’ states, microglial processes are highly motile, extending and retracting 
continuously in order to sample their local environment and contact neighbouring cells 
(Nimmerjahn et al., 2005). In response to injury or infection however, homeostatic microglia 
undergo dynamic, multi-step, conformational changes culminating in the retraction of 
processes leading to a more amoeboid appearance, characteristic of microglial activation (M. 
A.-O. Kluge et al., 2017; Stence et al., 2001).  
The development of intravital imaging approaches, alongside genetic labelling tools, has 
led to a greater understanding of dynamic microglial behaviours in the context of both 
homeostasis and disease (Wieghofer, Knobeloch Kp Fau - Prinz, & Prinz, 2015). Through the 
replacement of the Cx3Cr1 gene with a green florescent protein (eGFP), transgenic reporter 
mice were developed allowing the visualisation of microglia as well as monocytes, subsets of 
natural killer cells and dendritic cells (Jung, Aliberti J Fau - Graemmel, et al., 2000). 
Heterozygous Cx3Cr1eGFP/+ mice have been extensively used in the field of neuroinflammation, 
due to their ability to accurately target microglia with a high degree of specificity (Nimmerjahn 
et al., 2005; Wieghofer et al., 2015). Previous studies employing genetic labelling and 
intravital imaging, demonstrated that the quantification of microglial morphological 
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parameters, such as soma size and sphericity, can accurately distinguish between resting and 
activated microglial populations (B. M. Davis et al., 2017; Kozlowski & Weimer, 2012). Such 
morphological changes were also observed alongside increased expression of markers of 
microglial activation such as CD68 and MHC11 (Kettenmann et al., 2011; Lartey et al., 2014). 
Microglial process movements have also been shown to be highly dynamic and accurately 
reflect microglial responses to damage and disease. As part of normal homeostatic functioning 
microglia extend and retract processes continuously to sample their local environment. These 
process behaviours can change under disease conditions, indicating altered microglial 
functions, even in the absence of gross structural changes (Kluge et al., 2018; M. G. A.-O. h. 
o. o. Kluge et al., 2017). To date, such detailed phenotypical microglial evaluations have not 
been carried out within the context of BCAS. 
It is being increasingly recognised that dementia syndromes rarely exist in isolation, with 
reports suggesting that neurovascular pathology is present in up to 80% of sporadic late-onset 
AD patients (Toledo et al., 2013). It is therefore, becoming ever more apparent that 
pathological causes of dementia need to be assessed in combination to fully uncover the 
common mechanisms leading to neuroinflammation, neuro-glial-vascular unit dysfunction and 
ultimately cognitive impairment.  
App23 mice have been engineered to overexpress human APP containing the Swedish 
(KM670/671NL) mutation driven by a Thy1 promoter. App23 mice progressively develop 
both meningeal and parenchymal amyloid deposits and display pathological, cognitive, and 
behavioural alterations common to Alzheimer’s disease (AD) (Shang J Fau - Yamashita et al., 
2016; Sturchler-Pierrat et al., 1997). Previous studies using co-morbid constructs of App23 
and BCAS show exacerbated neuronal loss, BBB leakage, and demonstrate exacerbated AD 
pathology including neurovascular unit disruption, loss of axon-glial integrity, and 
cerebrovascular remodelling (Shang J Fau - Yamashita et al., 2016; Zhai Y Fau - Yamashita, 
Yamashita T Fau - Nakano, Nakano Y Fau - Sun, Sun Z Fau - Morihara, et al., 2016). The 
effect of amyloidosis and BCAS on the microglial population, however, has not been 
extensively analysed.  
In the present study, Cx3Cr1eGFP/+ microglial reporter mice were used alongside multiphoton 
microscopy to allow structural and functional microglial changes to be evaluated following 
BCAS. Furthermore, microglial responses will be assessed in conjunction with neurovascular 
and cognitive functional evaluations. Additionally, the effect of amyloidosis will be assessed, 
alongside BCAS, to determine if microglial responses as well as neurovascular and cognitive 




This study set out to test the hypothesis that phenotypic alterations in microglia occur in 
response to BCAS leading to neuro-glial-vascular unit dysfunction and cognitive impairment, 
which is further exacerbated in the presence of increased amyloid. 
 
4.1.2 Aims 
Using a model of BCAS, within Cx3Cr1eGFP/+ microglial reporter mice, the studies aimed 
to: 
1. Assess the temporal profile of cortical CBF changes following BCAS 
2. Investigate microglial structural alterations in response to BCAS, 1-week 
following surgery   
3. To assess microglial process dynamics in response to BCAS, 1-week following 
surgery  
4. To investigate microglial expansion within white and grey matter regions in 
response to BCAS, 3-months following surgery  
5. To investigate neurovascular coupling mechanisms in response to BCAS, 3-
months following surgery  
6. To investigate spatial learning and memory in response to BCAS, 3-months 
following surgery 
7. To determine the effect of amyloidosis and BCAS on microglial responses, 
neurovascular coupling mechanisms, and spatial learning and memory 3-months 
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4.2 Materials and Methods 
 
4.2.1 Experimental mice 
Cx3Cr1eGFP/eGFP mice were acquired as a generous gift from Professor Jeffrey Pollard and 
cross-bred with App23 heterozygous mice to generate Cx3Cr1eGFP/+App23+/- and 
Cx3Cr1eGFP/+App23-/- mice. All mice were assigned to surgical groups at random. Mice, 7-9 
months old, were studied at a short-term 1-week timepoint as well as a chronic 3-month 
timepoint following surgery. A total of 19 mice began the 1-week study and 36 the 3-month 
study. Details of group numbers and exclusions can be found in the relevant methods sections 
below, alternatively an overall summary can be found within Table 4.1. 
 




4.2.2 Bilateral common carotid artery stenosis 
Bilateral common carotid artery stenosis (BCAS) surgery was performed according the 
method previously described (Section 2.2). For the present study, a milder form of BCAS was 
achieved through the application of 0.18mm diameter micro-coils to both the left and right 
common carotid arteries. As a control for all experiments sham mice underwent an identical 
procedure with the only exception being the application of micro-coils. For the 1-week 
multiphoton imaging study all mice recovered well following surgery. For the 3-month study 
1 Cx3Cr1eGFP/+App23 sham and 1 Cx3Cr1eGFP/+App23 BCAS mouse recovered poorly following 
surgery and therefore were humanely culled and excluded from the study (Table 4.1). 
 
4.2.3 Craniotomy and cranial window surgery in preparation for 
multiphoton microscopy 
Cranial window surgery was carried out 4-weeks prior to multiphoton microscopy 
according to the method outlined within Section 2.4. Strict exclusion criteria were applied to 
minimise any effect of cranial window implantation on the neuro-inflammatory response, 
details found within Section 2.4. No mice were excluded from the study based on these 
exclusion criteria.    
 
4.2.4 Laser speckle imaging assessment of resting cortical 
blood flow 
Laser speckle imaging was used to assess cortical CBF within both sham and BCAS mice 
as previously described (Section 2.3). For the multiphoton imaging, 1-week, study CBF was 
assessed at baseline and 24-hours following surgery. For the 3-month study blood flow was 
assessed at baseline, 24-hours, 1-month, and 3-months following surgery. Due to the milder 
nature of BCAS surgery, blood flow reductions needed to exceed 25% for the mouse to be 
included within the study. According to this criteria, 1 Cx3Cr1eGFP/+ BCAS mouse from the 1-
week study and 1 Cx3Cr1eGFP/+ BCAS mouse from the 3-month study were excluded (Table 
4.1).  
 
4.2.5 Laser speckle assessment of neurovascular coupling 
responses 
Neurovascular coupling responses were assessed 3-months following sham/BCAS surgery. 
A detailed method for neurovascular coupling measurements can be found within Section 
2.3.2. Stimulation recordings were excluded if baseline blood flow fluctuated during the 
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assessment window or if operator error led to non-physiological responses. According to these 
criteria 1 Cx3Cr1eGFP/+ sham and 1 Cx3Cr1eGFP/+App23 BCAS stimulations were excluded 
resulting in an average value of 3 measurements for these mice.  
 
4.2.6 Multiphoton microscopy 
Multiphoton microscopy was carried out using the set-up and parameters detailed within 
Section 2.5. Approximately 30-minutes prior to imaging, mice receive a tail vein injection of 
100µl Rhodamine B (15mg/ml) (Table 2.2), to allow the vasculature to be readily visualised. 
Microglial were readily visible due to the genetic eGFP tag attached to the Cx3Cr1 receptor.  
 
4.2.7 In vivo assessment of microglial structure 
Detailed methods for microglial structural evaluations can be found within Section 2.5.1. 
In brief, 3 z-stacks were acquired within the cerebral cortex of each mouse. Z-stacks were then 
processed using the IMARIS software to generate ‘surface casts’ of each microglial cell 
(Figure 2.4). Exclusion parameters were implemented so that a microglial cell was only 
analysed if its full form was visible within the field of view. Surface casts were generated of 
each cell soma within the field of view and used to generate values for area, volume, and 
sphericity.   
 
4.2.8 In vivo assessment of microglial process dynamics 
To capture dynamic microglial process movements in real time, in vivo, repeated z-stacks 
were gathered consecutively over a 15-minute period via multiphoton microscopy, according 
to the method detailed within Section 2.5.2. Microglial process motility was analysed by 
calculating the pixel differences between consecutive maximum intensity images. To calculate 
microglial process coverage (surveillance measurement), the percentage area of microglial 
pixels within maximum intensity images was calculated. The coverage value represents the 
surveillance ratio which is defined as the ratio of microglia-occupied pixels as a proportion of 
the total pixels within the field of view.  
 
4.2.9 Barnes maze behavioural testing 
The Barnes maze is a test of visuo-spatial learning and memory and was carried out as 
previously described within Section 2.6. The training period commenced 10-weeks and ended 
12-weeks following sham/BCAS surgery. An exclusion criterion based on maze exploration, 
previously described (Section 2.6.8), was applied highlighting 3 Cx3Cr1eGFP/+ sham, 2 
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Cx3Cr1eGFP/+ BCAS, 1 Cx3Cr1eGFP/+App23 sham and 2 Cx3Cr1eGFP/+App23 BCAS mice for 
exclusion (Table 4.1).  
 
4.2.10 Tissue collection and processing 
For the behavioural cohort, animals were sacrificed 3-months post sham/BCAS surgery via 
transcardial perfusion, and the brains extracted, and flash frozen in liquid nitrogen as 
previously described within Section 2.8.2. The tissue was then cut into 12µ𝑚 coronal sections 
using a cryostat, as previously described (Section 2.8.5). For flow cytometry experiments, 
mice were transcardially perfused with ice cold PBS containing 0.1% heparin under deep 
isoflurane anaesthesia (Section 2.8.2). The brain was then swiftly extracted and dissected into 
2 hemibrains.  
 
4.2.11 Flow cytometry and cell sorting 
Isolated hemibrains were processed into a single cell suspension as detailed within Section 
2.9. Cells were then immunostained with primary antibodies directed against CD11b, CD45, 
Ly6C, and Ly6G at 1:200 (Ly6C) or 1:500 dilution for 30-minutes on ice. Cells were washed 
then analysed and sorted using a FACS Aria II (BD Biosciences). Cell sorting was performed 
by staff in the QMRI Flow Cytometry and Cell Sorting Facility (University of Edinburgh). 
Sorted cells were centrifuged at 6000 RPM for 5-minutes at 4˚C and then stored at -800C. 
 
4.2.12 RNA extraction and cDNA synthesis 
Sorted cells in RLT Buffer were defrosted and vortexed for 1-minute to homogenise cells 
and RNA was extracted using the AllPrep DNA/RNA/miRNA Universal Kit (Qiagen) 
according to the manufacturer’s instructions (Section 2.10). Sorted cells were processed 
immediately post-sort and RNA was extracted using the High Pure RNA Isolation Kit (Roche) 
according to the manufacturer’s instructions. RNA quantities were determined by Agilent 
4200 Tapestation (Agilent Technologies). cDNA was synthesised from 15 ng RNA using the 
Superscript IV Reverse Transcriptase (Life Technologies), according to the manufacturer’s 
instructions and used undiluted for qPCR reactions. cDNA samples were stored at -20ºC until 
use.  
 
4.2.13 Quantitative (q)-PCR 
cDNA libraries were analysed by qPCR using the DyNAmo ColorFlash SYBR Green kit 
(Thermo Scientific) according to the manufacturer’s instructions (Section 2.11). Briefly, the 
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cDNA template was mixed with DyNAmo ColourFlash SYBR Green master mix (Fisher 
Scientific), nuclease-free H2O and the following custom designed gene-specific primers (200 
nM final concentration; Sigma Aldrich): 18s (forward: 5’-cccagtaagtgcgggtcat-‘3, 
reverse: 5’-ccgagggcctcactaaacc-3’) and Cx3Cr1 (forward: 5’-gccaactccatgaacaaccg-3’, 
reverse: 5’-ttgacttccgagttgcggag-3’). qPCR cycles were performed on a Bio-Rad CFX96 
thermocycler (Bio-Rad Laboratories) as described previously within Section 2.11. Cycle 
threshold (Ct) values of target genes were normalized to 18S, with data expressed as fold 
change relative to control group (wild-type) using the 2^ (−ΔΔCt) method. 
 
4.2.14 Image acquisition and analysis 
For detailed information on multiphoton image capture and analysis please refer to Sections 
2.5, 2.5.1 and 2.5.2. To allow for Cx3Cr1eGFP positive cell number to be quantified, coronal 
12 µ𝑚 sections were cover-slipped with vectashield containing DAPI (Section 2.12.4). Images 
for Cx3Cr1eGFP/DAPI sections were acquired on an Axio ScanZ1 slide scanner (x20, Zeiss, 
Germany) as previously described within Section 2.13.1. Cell count analysis was completed 
using the ImageJ software (v1.46, NIH, Bethesda, MD, USA), with use of the cell counter 
plugin, as previously described within Section 2.13.2.  
 
4.2.15 Statistical analysis 
Statistical analysis was performed using SPSS (v22, IBM Corp.) and Prism (v8, GraphPad 
Software Inc, La Jolla, USA) software packages. Multiphoton cell counts, process motility and 
coverage, immunohistochemical cell counts, neurovascular coupling and Barnes maze 
learning profile comparisons were analysed using independent samples Mann Whitney U tests. 
Repeated measures two-way ANOVA’s were used to assess group differences in CBF as well 
as the Barnes maze measures of escape latency, movement distance, and movement speed 
(training and reversal phases), with Bonferroni post hoc follow up analysis. Barnes maze 
training and reversal probe data were analysed using the Friedman test to determine 
differences in time spent within each quadrant. The Wilcoxon signed ranks post hoc test was 
then applied to determine target zone preference. Measures of microglial structure (soma area, 
volume, and sphericity) were analysed using nested t-tests. Cx3Cr1 receptor expression was 
analysed with the use of an independent samples t-test. All statistical analysis was completed 
within SPSS, except for microglial structural analysis, which were analysed using the Prism 
software. For parametric statistical tests, data is presented as mean ± standard error of the mean 
(SEM) and for nonparametric testing data is presented as median ± interquartile range (IQR) 
(specified in relevant figure legend). Statistical significance was determined at p<0.05.   
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4.2.16 Experimental contributions 
The majority of experiments and analysis detailed within this chapter were conducted by 
myself. The studies, however, were also supported by Dr Juraj Koudelka, Dr Katie Askew, Dr 
Gaia Brezzo, and Professor Karen Horsburgh. I performed multiphoton imaging, laser speckle 
imaging, neurovascular coupling measurements, behavioural testing, tissue collection and 
processing, immunohistochemical staining and imaging as well as all the data analysis 
presented. Dr Juraj Koudelka performed cranial window surgery, operated the software for 
image capture during multiphoton imaging and assisted with tissue collection and processing. 
Dr Katie Askew completed flow cytometry and qPCR as well as assisting with laser speckle 
imaging, neurovascular coupling assessments, behavioural testing, and tissue collection and 
processing. Dr Gaia Brezzo assisted with neurovascular coupling assessments. Professor 
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4.3 Results 
 
4.3.1 BCAS induces a significant and sustained reduction in 
cerebral blood flow within Cx3Cr1eGFP/+ mice 
Having demonstrated previously that genetic diversity, within C57BL/6J mice, can confer 
resistance to BCAS surgery (Figure 2.2). The first aim of this study was to confirm that BCAS 
surgery can elicit significant and sustained reductions in CBF within Cx3Cr1eGFP/+ mice. Laser 
speckle imaging was employed to assess CBF at baseline, 24-hours, 1-month, and 3-months 
following sham/BCAS surgery (Figure 4.1). BCAS surgery using 2x0.18mm micro-coils 
elicited a CBF reduction of ≈26% at 24-hours, which progressed to a reduction of ≈30% at 3-
months (Figure 4.1A). Statistical analysis demonstrated a significant overall effect of time 
(F(1.33,18.64) = 10.83, p<0.01), group (F(1,14) = 51.38, p<0.001) as well as a significant time-group 
interaction (F(1.33,18.64) = 8.84, p<0.01). Bonferroni post hoc analysis revealed a significant CBF 
reduction in BCAS mice when compared to shams, at 24-hours (sham: 111.1±2.39, BCAS: 
73.5±5.07, p<0.001), 1-month (sham: 93.9±2.87, BCAS: 80.1±3.44, p<0.01) and 3-months 
(sham: 95.2±3.11, BCAS: 69.8±4.87, p<0.01) following surgery (Figure 4.1A).  
Overall, these data demonstrate that BCAS surgery, within Cx3Cr1eGFP/+ mice, leads to a 






Figure 4.1 BCAS elicits a significant and sustained reduction in CBF within 
Cx3Cr1eGFP/+ mice. (A) Laser speckle imaging shows a significant reduction in CBF following 
BCAS surgery, with an ≈26% reduction at 24-hours which was sustained leading to a reduction 
of ≈30% at 3-months. (B) Representative images of CBF recordings of sham/BCAS mice at 
baseline, 24-hours, 1-month, and 3-months following surgery. Blue represents the lowest 
blood flow with red representing high blood flow levels.  
 
4.3.2 Microglial structure is unaltered following BCAS within 
Cx3Cr1eGFP/+ mice 
The next aim of this study was to determine if BCAS leads to microglial conformational 
changes indicative of microglial activation. Cx3Cr1eGFP/+ mice alongside multiphoton 
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microscopy were employed to assess changes in microglial structure, in vivo, 1-week 
following BCAS (Figure 4.2). Multiple z-stacks were gathered from the cerebral cortex and 
reconstructed to capture the structure of individual microglial cells in 3D (Figure 4.2). 
Analysis of soma area as well as soma volume revealed no significant difference between 
sham (area: 32340m2±76, volume: 12586m3±407) or BCAS groups (area: 3568m2±106, 
volume: 13589m3±452.79) 1-week following surgery (p=0.27 and p=0.40 respectively) 
(Figure 4.2A/B). Microglial soma sphericity was also found to be unaltered within BCAS mice 
(0.78±0.01) in comparison to shams (0.80±0.01, p=0.50) (Figure 4.2C). To determine if 
microglial expansion could be detected, irrespective of structural changes, the total number of 
Cx3Cr1+ve cells present within each z-stack was quantified (Figure 4.2D). Statistical analysis 
revealed no significant difference between the number of Cx3Cr1+ve microglial cells within 
BCAS mice (10.15±1.77) when compared to shams (11.43±4.11, p=0.15) (Figure 4.2D). 
Overall, these data show no evidence of microglial structural or density changes, within the 






Figure 4.2 Microglial structure unaltered in Cx3Cr1eGFP/+ mice following BCAS. 
Microglial structure was analysed using reconstructed z-stacks taken from the cerebral cortex 
via multiphoton microscopy. Soma area (A), volume (B) and sphericity (C) were found to be 
unaltered following BCAS surgery. Data presented as Mean±SEM. (D) No significant 
difference between the total number of microglial cells within each cortical field of view was 
identified following BCAS. Data presented as Median±IQR. (E) Representative images of 2D 
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summated stacks generated from the 3D z-stacks used for structural analysis. Scale bar 
50µm. 
 
4.3.3 Microglial process dynamics are unaltered following BCAS 
within Cx3Cr1eGFP/+ mice 
Although no microglial structural changes were observed 1-week following BCAS, we 
wondered whether, more subtle, dynamic changes were occurring. Previous studies have 
demonstrated that microglial process movement can be altered in disease conditions, indicative 
of altered microglial functions, despite the absence of gross structural changes (Kluge et al., 
2018; M. G. A.-O. h. o. o. Kluge et al., 2017). Microglial process motility was captured in vivo 
via repeated z-stacks taken from the cortex of Cx3Cr1eGFP/+ mice with the use of multiphoton 
microscopy. Both extension and retraction of processes were assessed by calculating pixel 
differences between 2 consecutive z-stacks gathered ≈48 seconds apart. Pixel differences are 
calculated as a percentage change from 1 z-stack to the next. These values are then averaged 
across all z-stacks gathered to give a motility index value representing 15-minutes of recording 
(Figure 4.3A/C). Statistical analysis revealed no difference in process motility between sham 
(50.99%±21.09) and BCAS groups (55.52%±14.95) 1-week following surgery (p=0.421) 
(Figure 4.3A). As an additional measure of process motility, process coverage was calculated 
(Figure 4.3B/D). Process coverage refers to the percentage of the total imaging field that is 
contacted by microglial processes during a 15-minute recording. No significant difference in 
process coverage was identified between sham (68.83%±4.23) and BCAS (67.69%±4.46) 
mice, 1-week following surgery (p=0.0.39) (Figure 4.3B). 
Overall, these data indicate that microglial process dynamics are unaltered within 






Figure 4.3 Microglial surveillance functions are unaltered within Cx3Cr1eGFP/+ mice 
following BCAS. (A) Microglial motility measured over a consecutive 15-minute imaging 
period, was found to be unaltered following BCAS surgery. (B) Microglial process coverage 
was assessed over the same 15-minute imaging period and was also found to be unaltered 1-
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week following BCAS surgery. Data presented as median±IQR. (C) Images to demonstrate 
dynamic microglial process movement. T1 (green) is a 2D summated version of the first 3D z-
stack acquired. T2 (red) represents a z-stack gathered ≈48 seconds later, with T1+T2 showing 
a merge of the 2 images. The hashed square represents the inserts (i) that are shown below, 
with the white arrowhead highlighting an example of process retraction. (D) Representative 
images of a summated projection of all z-stacks gathered over the 15-minute imaging period 
to enable total process coverage to be calculated with Cx3Cr1eGFP/+ sham and Cx3Cr1eGFP/+ 
BCAS mice. Scale bar 50µm.  
 
4.3.4 Microglial density is unaltered following BCAS within 
Cx3Cr1eGFP/+ mice 
The lack of any phenotypical changes within microglial cells was surprising given the clear 
microglial response following BCAS observed within chapter 3. Multiphoton microscopy, in 
our hands, is restricted to the upper layers of the cortex. Therefore, to determine if the lack of 
microglial response was due to a cortical resistance, more widespread microglial counts were 
carried out 3-months following BCAS surgery. Cx3Cr1eGFP/+DAPI+ve cell counts were carried 
out, post mortem, within the corpus callosum and hippocampus CA1, due to the fact that these 
regions had previously shown a strong microglial response following BCAS (Figure 4.4). A 
larger region of interest was also used to quantify microglia within the cortex, to determine if 
the muted cortical response is limited to superficial regions (<200m). Statistical analysis 
revealed no significant differences between microglial numbers within the cortex (p=1.00), 
corpus callosum (p=1.00) or hippocampus CA1 region (p=0.252) of BCAS mice (cortex: 
13.31±3.26, corpus callosum: 12.47±2.94, CA1: 11.93±2.0) in comparison to shams (cortex: 
12.62±2.12, corpus callosum: 12.02±2.67, CA1: 11.12±1.59) 3-months following surgery 
(Figure 4.4A/B/C). The percentage area of Cx3Cr1 florescence per cell was also calculated to 
give an indication of microglial structural changes 3-months following BCAS. The area of 
Cx3Cr1 expression per cell was not significantly different within the cortex (p=0.47), corpus 
callosum (p=0.30), or hippocampal CA1 region (p=0.61) of BCAS mice (cortex: 0.73±0.3, 
corpus callosum: 0.43±0.16, CA1: 0.86±0.52) when compared to shams (cortex: 0.85±0.09, 
corpus callosum: 0.49±0.12, CA1: 0.92±0.17) (Figure 4.4D/E/F). 
Taken together these data show no evidence of microglial expansion, within Cx3Cr1eGFP/+ 






Figure 4.4 Microglial density is unaltered 3-months following BCAS in Cx3Cr1eGFP/+ 
mice. Cx3Cr1eGFP/+ cell counts per 0.1mm2 were found to be unaltered 3-months following 
BCAS surgery within the somatosensory cortex (A), corpus callosum (B) and the hippocampal 
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CA1 region (C). As an indication of altered microglial structure, the area of Cx3Cr1eGFP/+ 
florescence per cell was calculated and found to be unaltered 3-months following BCAS within 
the somatosensory cortex (D), corpus callosum (E), and the hippocampal CA1 region (F). Data 
presented as median±IQR. (G) Representative images of Cx3Cr1eGFP/+/DAPI staining within 
Cx3Cr1eGFP/+ sham and Cx3Cr1eGFP/+ BCAS mice 3-months following surgery within the 
somatosensory cortex (Cx), corpus callosum (CC), and hippocampal CA1 region (CA1). 
Regions of interest for cell counts are represented by the dotted white lines. Scale bar 50µm. 
 
4.3.5 Neurovascular coupling responses are unaltered following 
BCAS within Cx3Cr1eGFP/+ mice 
Vascular haemodynamic responses are crucial to help match blood flow to energy 
consumption within the brain. Previous studies have demonstrated a significant impairment in 
neurovascular coupling responses following BCAS (Duncombe, Kitamura, et al., 2017). The 
next aim therefore was to test neurovascular coupling responses within Cx3Cr1eGFP/+ mice 
following 3-months of BCAS. Laser speckle imaging was used to detect blood flow changes 
within the barrel cortex following unilateral whisker stimulation (Figure 4.5). No significant 
difference in blood flow response to whisker stimulation was detected within BCAS mice 
(22.47±16.48) when compared to shams (18.06±14.49), 3-months following surgery 
(p=0.606) (Figure 4.5A).  
Overall, these data indicate that neurovascular coupling responses are unaltered within 






Figure 4.5 Neurovascular coupling responses are unaltered following BCAS within 
Cx3Cr1eGFP/+ mice. (A) Blood flow responses within the barrel cortex following whisker 
stimulation were found to be unaltered following BCAS surgery. Data presented as 
median±IQR. (B) Representative images displaying blood flow recordings before, during, and 
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after whisker stimulation within both Cx3Cr1eGFP/+ sham and Cx3Cr1eGFP/+ BCAS mice. 
Accompanied by images of CBF, as measured by laser speckle, at baseline and during 
whisker stimulation. The box on each image indicates the region measured within the 
somatosensory cortex.  
 
4.3.6 Spatial memory is impaired following BCAS within 
Cx3Cr1eGFP/+ mice 
The next aim of the study was to assess spatial learning and memory, within Cx3Cr1eGFP/+ 
mice following 3-months of BCAS. As in chapter 3, the Barnes maze was used to test visuo-
spatial learning and memory over a 2-week period. Spatial learning was assessed over 6 
consecutive days, with the time taken for mice to locate and enter the escape chamber (escape 
latency) used as a measure of learning (Figure 4.6). Statistical analysis, over all 6 trainings 
days, reported an overall main effect of time (F(5,45) = 20.260, p<0.001) indicating learning 
across training days. However, no effect of group (p=0.187) or significant interaction 
(p=0.792) were identified (Figure 4.6A). As an additional measure of spatial learning 
movement distance per trial was compared, once again an overall main effect of time was 
identified (F(5,45) = 9.962, p<0.001) with no significant group differences (p=0.472) or 
interactions (p=0.777) (Figure 4.6B). Thus, indicating that spatial learning was unaffected 
following BCAS within Cx3Cr1eGFP/+ mice. To ensure that movement speed was not 
influencing results, average speed per trial was assessed and compared between groups. An 
overall main effect of time was observed (F(5,45) = 7.811, p<0.001) with no main effect of group 
(p=0.104) or interaction (p=0.284), indicating that movement speed was comparable between 
groups and therefore had no impact on learning (Figure 4.6C).  
Following the spatial learning task, a reference memory probe trial was conducted, in which 
the escape chamber was removed, and the percentage of time spent within the quadrant 
previously home to the escape chamber was measured (Figure 4.6D). The probe trial was 
conducted 72-hours following the last training day to allow longer-term spatial memory to be 
assessed. Statistical analysis revealed no significant difference in the time spent within the 
target zone of Cx3Cr1eGFP/+ sham (69.17%±25) when compared to BCAS mice (95%±56.7) (U 
= 15, p>0.05). To confirm that target quadrant times did indeed reflect a preference for that 
quadrant, time spent within all 4 quadrants were compared. Within Cx3Cr1eGFP/+ sham mice, a 
significant difference between time spent within each quadrant was identified (2(3) = 11.945, 
p<0.01), with post hoc analysis revealing a significant increase in time spent within the target 
zone compared to all other zones (clockwise; p<0.05, opposite; p<0.05, counter-clockwise 
 
 161 
p<0.05) (Figure 4.6D). Within Cx3Cr1eGFP/+ BCAS mice, however, no significant difference 
between time spent within each quadrant was reported (p=0.224) indicating no significant 





Figure 4.6 Spatial memory, but not learning, is impaired following BCAS within 
Cx3Cr1eGFP/+ mice. (A) An overall effect of time demonstrates learning within both groups. 
Escape latency was found to be comparable across the 6 training days, indicating no spatial 
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learning impairment following BCAS. (B) Movement distance throughout each trial revealed a 
similar pattern to escape latency, with an overall effect of time and no group differences. (C) 
Although movement speed was found to be significantly affected by time, with no group 
differences identified. Data presented as mean±SEM. (D) Sham mice demonstrated a 
preference for the target quadrant indicating an intact memory of the target hole location. 
BCAS mice showed no preference for any quadrant. Data presented as median±IQR. *p<0.05. 
(E) Representative movement traces during day 1 and 6 of the training period taken from 
Cx3Cr1eGFP/+ sham and Cx3Cr1eGFP/+ BCAS groups. Stars indicate target hole. (F) Trace and 
occupancy plots gathered during probe trails of Cx3Cr1eGFP/+ sham and Cx3Cr1eGFP/+ BCAS 
mice. Stars indicate target hole; brighter colours indicate increased time spent in that area 
(occupancy plot only).  
To test cognitive flexibility, an additional reversal training segment was completed within 
the Barnes maze following the reference memory probe (Figure 4.7). The reversal training 
phase, completed over 3 consecutive days, required mice to learn that their escape chamber 
had been relocated, 1800, to the other side of the maze. Across the 3 reversal training days an 
overall main effect of time was observed (F(2,18) = 33.737, p<0.001) indicting learning within 
both groups (Figure 4.7A). No overall group effect was reported (p=0.303) as well as no 
significant interaction (p=0.649) indicating a comparable performance across both groups 
(Figure 4.7A). A similar pattern was also observed with movement distance, which was shown 
to be significantly reduced over time (F(1.2,10.796) = 22.910, p<0.001), with no significant group 
differences (p=0.233) or interactions (p=0.310) (Figure 4.7B). Movement speed was also 
found to be effected overall by time (F(1.28,11.49) = 5.448, p<0.05) with no significant group 
effects (p=0.738) or interactions identified (p=0.678) (Figure 4.7C). Thus, indicating that 
reversal learning was unaffected following chronic BCAS within Cx3Cr1eGFP/+ mice. 
To assess adaptive memory, a reversal memory probe was carried out 72-hours following 
the final reversal training day (Figure 4.7D). A comparison between time spent within the 
target quadrant revealed no significant difference between Cx3Cr1eGFP/+ BCAS mice 
(36.67%±45) when compared to shams (48.33%±19.6) (U = 14, p>0.05). To confirm that 
target quadrant times did indeed reflect a preference for that quadrant, time spent within all 4 
quadrants were compared (Figure 4.7D). Within Cx3Cr1eGFP/+ sham mice a significant 
difference in the time spent within each of the 4 quadrants was identified (2(3) = 8.069, 
p<0.05), with post hoc analysis demonstrating a preference for the target quadrant over all 
others (clockwise p<0.05, opposite p<0.05, counter-clockwise p<0.05) (Figure 4.7D). 
Likewise, Cx3Cr1eGFP/+ BCAS showed a significant difference between the time spent within 
each quadrant (2(3) = 10.188, p<0.05). However, post hoc analysis demonstrated a preference 
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for the target zone over the clockwise (p<0.05) and counter-clockwise (p<0.05) zones but not 
the opposite zone (p=0.273) (Figure 4.7D). Therefore, no clear preference for the target zone 
was identified indicating impaired reversal memory within Cx3Cr1eGFP/+ BCAS following 3-
months of BCAS.  
In conclusion these data illustrate impairments in visuo-spatial memory, but not learning, 




Figure 4.7 Reversal memory, but not learning, is impaired following BCAS within 
Cx3Cr1eGFP/+ mice. (A) An overall effect of time demonstrates learning within both groups. 
 
   164 
Escape latency was found to be comparable across the 3 reversal training days indicating no 
spatial learning impairment following BCAS. (B) Movement distance throughout each trial 
revealed a similar pattern to escape latency with an overall effect of time and no group 
differences. (C) Although movement speed was found to be significantly affected by time, no 
group differences were identified. Data presented as mean±SEM. (D) Sham mice 
demonstrated a preference for the target quadrant, indicating an intact memory of the target 
hole location. BCAS mice showed a target zone preference when compared to clockwise and 
counter-clockwise but not opposite quadrants, indicating no preference for the target zone and 
therefore impaired adaptive memory. Data presented as median±IQR. *p<0.05. (E) 
Representative movement traces during day 1 and 3 of the reversal training period taken from 
Cx3Cr1eGFP/+ sham and Cx3Cr1eGFP/+ BCAS groups. Stars indicate target hole. (F) Trace and 
occupancy plots gathered during probe trails of Cx3Cr1eGFP/+ sham and Cx3Cr1eGFP/+ BCAS 
mice. Stars indicate target hole; brighter colours indicate increased time spent in that area 
(occupancy plot only).  
 
4.3.7 Microglial density remains unaltered following BCAS 
within Cx3Cr1eGFP/+App23 mice 
Previous studies using co-morbid constructs of App23 and BCAS show exacerbated 
cerebrovascular pathology associated with more severe functional and cognitive outcomes 
(Shang J Fau - Yamashita et al., 2016). The effect of a co-morbid App23 and BCAS construct 
on microglial populations, however, has not been extensively analysed. The next aim of the 
study, therefore, was to carry out a detailed phenotypical analysis of microglia within 
Cx3Cr1eGFP/+App23 mice following sham/BCAS surgery.  
The first aim was to evaluate microglial density within Cx3Cr1eGFP/+App23 mice following 
3-months of sham/BCAS surgery. Cx3Cr1eGFP/+DAPI+ve cell counts were carried out within the 
cortex, corpus callosum, and hippocampal CA1 region (Figure 4.8). Statistical analysis 
revealed no significant differences between microglial numbers within the cortex (p=0.916), 
corpus callosum (p=0.713) or hippocampus CA1 region (p=0.598) of BCAS mice (cortex: 
14.35±4.43, corpus callosum: 12.46±4.23, CA1: 12.29±1.78) in comparison to shams (cortex: 
13.95±3.16, corpus callosum: 13.40±3.83, CA1: 12.00±2.64) (Figure 4.8A/B/C). Percentage 
area of Cx3Cr1 eGFP florescence per cell was also calculated as an indication of altered 
structure. The area of Cx3Cr1 expression per cell was found to be unaltered within the cortex 
(p=0.834), corpus callosum (p=0.916) and hippocampal CA1 region (p=0.189) of BCAS mice 
(cortex: 0.74±0.25, corpus callosum: 0.455±0.12, CA1: 0.81±0.105) when compared to shams 






Figure 4.8 Microglial density is unaltered 3-months following BCAS within 
Cx3Cr1eGFP/+App23 mice. Cx3Cr1eGFP/+ cell counts per 0.1mm2 within Cx3Cr1eGFP/+App23 mice 
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were found to be unaltered 3-months following BCAS surgery within the somatosensory cortex 
(A), corpus callosum (B), and the hippocampal CA1 region (C). As an indication of altered 
microglial structure, the area of Cx3Cr1eGFP/+ florescence per cell was calculated and found to 
be unaltered 3-months following BCAS within the somatosensory cortex (D), corpus callosum 
(E) and the hippocampal CA1 region (F). Data presented as median±IQR. (G) Representative 
images of Cx3Cr1eGFP/+DAPI staining within Cx3Cr1eGFP/+App23 sham and BCAS mice, taken 
from the somatosensory cortex (Cx), hippocampal CA1 region (CA1), and corpus callosum 
(cc), 3-months following surgery. Scale bar 50µm. 
 
To assess the effect on microglial populations of increased amyloid alone, microglial 
counts within Cx3Cr1eGFP/+App23 sham mice were compared to Cx3Cr1eGFP/+ shams (Figure 
4.9). No significant alterations in microglial numbers were identified within the cortex 
(p=0.114), corpus callosum (p=0.277) or hippocampal CA1 region (p=0.236) of 
Cx3Cr1eGFP/+App23 sham mice (cortex: 13.95±3.16, corpus callosum: 13.40±3.83, 
hippocampal CA1: 12.00±2.64) in comparison to Cx3Cr1eGFP/+ shams (cortex: 12.62±2.12, 
corpus callosum: 12.02±2.67, hippocampal CA1: 11.12±1.59) (Figure 4.9A/B/C). Cx3Cr1 
eGFP expression per cell quantification also revealed no significant differences within the 
corpus callosum (p=0.114) or hippocampal CA1 region (p=0.541) of  Cx3Cr1eGFP/+App23 sham 
mice (corpus callosum: 0.43±0.09, hippocampal CA1: 0.86±0.09) in comparison to 
Cx3Cr1eGFP/+ shams (corpus callosum: 0.49±0.12, hippocampal CA1: 0.92±0.17) (Figure 
4.9E/F).Within the cortex however, Cx3Cr1eGFP/+App23 sham mice showed a significant 
reduction in Cx3Cr1eGFP expression per cell (0.72±0.10) when compared to Cx3Cr1eGFP/+ shams 
(0.85±0.09, p<0.05), indicating a reduced in microglial size (Figure 4.9D).  
Together these data show no evidence of microglial expansion within Cx3Cr1eGFP/+ sham 






Figure 4.9 Microglial density is unaltered within Cx3Cr1eGFP/+ mice in response to APP 
overexpression alone. Cx3Cr1eGFP/+ cell counts per 0.1mm2 within Cx3Cr1eGFP/+App23 sham 
mice were found to be comparable to Cx3Cr1eGFP/+ shams within the somatosensory cortex (A), 
corpus callosum (B) and the hippocampal CA1 region (C). As an indication of altered microglial 
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structure, the area of Cx3Cr1eGFP/+ florescence per cell was calculated and found to be 
unaltered in Cx3Cr1eGFP/+App23 sham when compared to Cx3Cr1eGFP/+ sham mice within the 
corpus callosum (E) and the hippocampal CA1 region (F). Cx3Cr1eGFP/+ florescence per cell, 
however, was found to be reduced within Cx3Cr1eGFP/+App23 sham mice when compared to 
Cx3Cr1eGFP/+ shams (D). Data presented as median±IQR. *p<0.05. (G) Representative images 
of Cx3Cr1eGFP/+DAPI staining within Cx3Cr1eGFP/+App23 sham and Cx3Cr1eGFP/+ sham mice, 
within the somatosensory cortex (Cx), hippocampal CA1 region (CA1), and corpus callosum 
(cc), 3-months following surgery. Scale bar 50µm. 
 
4.3.8 Neurovascular coupling responses are impaired following 
BCAS within Cx3Cr1eGFP/+App23 mice 
Having previously demonstrated that BCAS had no impact on neurovascular coupling 
responses 3-months following surgery within Cx3Cr1eGFP/+ mice, the next aim was to determine 
if deficits were apparent when BCAS was coupled to increased amyloid. Neurovascular 
coupling following whisker stimulation was measured within Cx3Cr1eGFP/+veApp23 
sham/BCAS mice 3-months following surgery (Figure 4.10A). Blood flow responses 
following stimulation were found to be significantly reduced within BCAS mice (10.69±6.99) 
in comparison to shams (22.77±16.9, p<0.01) (Figure 4.10A), indicating impaired 
neurovascular coupling responses. To determine if this impairment is mediated solely by 
increased amyloid, neurovascular coupling measurements from Cx3Cr1eGFP/+App23 sham mice 
were compared to Cx3Cr1eGFP/+ shams (Figure 4.10B). No significant difference between blood 
flow response to stimulation was identified (p=0.277) indicating comparable responses within 
Cx3Cr1eGFP/+App23 sham (22.77±16.9) and Cx3Cr1eGFP/+ sham mice (18.06±14.49) (Figure 
4.10B).  
Overall, these data illustrate that BCAS coupled to increased amyloid leads to 
neurovascular coupling deficits, which are not apparent when mice are subjected to BCAS or 





Figure 4.10 Neurovascular coupling responses are significantly impaired within 
Cx3Cr1eGFP/+ App23 mice following BCAS. (A) Blood flow responses within the barrel cortex 
following whisker stimulation were found to be significantly reduced within Cx3Cr1eGFP/+App23 
BCAS mice in comparison to Cx3Cr1eGFP/+App23 shams. **p<0.01. (B) Neurovascular coupling 
responses were found to be comparable between Cx3Cr1eGFP/+ sham and Cx3Cr1eGFP/+App23 
sham mice. Data presented as median±IQR (C) Representative images displaying blood flow 
recordings before, during, and after whisker stimulation within Cx3Cr1eGFP/+ sham mice, as well 
as Cx3Cr1eGFP/+ App23 sham and BCAS mice. Accompanied by images of CBF, as measured 
by laser speckle, at baseline and during whisker stimulation. The box on each image indicates 
the region measured within the somatosensory cortex. 
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4.3.9 Microglial structure and process motility are unaffected 
within Cx3Cr1eGFP/+App23 mice following BCAS 
Having demonstrated neurovascular coupling impairments within Cx3Cr1eGFP/+App23 mice 
following 3-months of BCAS, in the absence of microglial expansion, we wondered whether 
microglia may still play a role in this dysfunction through altered function. A switch to a more 
activated pro-inflammatory microglial phenotype could, in the absence of expansion, still be 
a mechanism by which the neuro-glial-vascular unit becomes dysfunctional. To investigate 
this, multiphoton microscopy was utilised to assess microglial structure and process dynamics 
1-week following sham/BCAS surgery in Cx3Cr1eGFP/+App23 mice (Figure 4.11). No 
significant differences were identified for soma area (p=0.27), volume (p=0.29) or sphericity 
(p=0.51) within Cx3Cr1eGFP/+App23 BCAS mice (area: 2439m2±70, volume: 8444m3±304, 
sphericity: 0.82±0.01) when compared to Cx3Cr1eGFP/+App23 shams (area: 2607m2±100, 






Figure 4.11 Microglial structure is unaltered within Cx3Cr1eGFP/+App23 mice following 
BCAS. Microglial structure was analysed using reconstructed z-stacks taken from the cerebral 
cortex via multiphoton microscopy. Soma area (A), volume (B) and sphericity (C) were found 
to unaltered following BCAS surgery. Data presented as Mean±SEM. (D) Representative 
images of 2D summated stacks generated from the 3D z-stacks used for structural analysis. 
Scale bar 50µm. 
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Process motility and coverage were also found to be unaltered, 1-week following surgery, 
within Cx3Cr1eGFP/+App23 BCAS mice (motility: 56.65±15.51, coverage: 69.18±13.41) when 
compared to Cx3Cr1eGFP/+App23 sham mice (motility: 54.73±4.0, coverage: 70.80±2.08) 
(p=0.343 and p=1.00 respectively) (Figure 4.12A/B).  
Taken together, these data demonstrate an absence of both microglial structural and 




Figure 4.12 Microglial surveillance functions are unaltered within Cx3Cr1eGFP/+App23 
mice following BCAS. (A) Microglial motility measured over a consecutive 15-minute imaging 
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period, was found to be unaltered within Cx3Cr1eGFP/+App23 mice 1-week following BCAS 
surgery. (B) Microglial process coverage was assessed over the same 15-minute imaging 
period and was also found to be unaltered 1-week following BCAS surgery. Data presented 
as median±IQR. (C) Images to demonstrate dynamic microglial process movement. T1 (green) 
is a 2D summated version of the first 3D z-stack acquired. T2 (red) represents a z-stack 
gathered ≈48 seconds later, with T1+T2 showing a merge of the 2 images. The hashed square 
represents the inserts (i) that are shown below, with the white arrowhead highlighting an 
example of process retraction. (D) Representative images of a summated projection of all z-
stacks gathered over the 15-minute imaging period to enable total process coverage to be 
calculated within Cx3Cr1eGFP/+ App23 sham and Cx3Cr1eGFP/+ App23 BCAS mice. Scale bar 
50µm.  
 
4.3.10 Spatial learning and memory are impaired within 
Cx3Cr1eGFP/+App23 mice, with no additional BCAS mediated 
deficit 
Having demonstrated spatial memory, but not learning, impairments within Cx3Cr1eGFP/+ 
mice following 3-months of BCAS, the next aim was to determine if additional deficits were 
apparent when BCAS was coupled to increased amyloid. The Barnes maze was carried out on 
Cx3Cr1eGFP/+App23 mice 3-months following sham/BCAS surgery (Figure 4.13). During the 
training phase, an overall effect of time was observed (F(5,60) = 4.415, p<0.01) indicating a 
degree of learning across the 6 training days. No significant group (F(1,12) = 0.110, p=0.745) or 
interaction effects (F(5,60) = 0.440, p=0.819) were identified (Figure 4.13A). Movement 
distance demonstrated the same trend with an overall effect of time (F(2.66,31.93) = 5.555, p<0.01) 
with no significant effects of group (F(1,12) = 0.000, p=0.997) or interaction (F(2.66,31.93) = 1.385, 
p=0.266) (Figure 4.13B). Analysis of movement speed throughout the training days revealed 
no significant effects of time (F(2.71,32.50) = 1.815, p=0.168), group (F(1,12) = 0.236, p=0.636) or 
interactions (F(2.71,32.50) = 0.990, p=0.403) (Figure 4.13C). 
Overall, these data demonstrate learning within each group with no effect of BCAS surgery. 
The learning profile across the 6 training days, however, was very flat and not the usual steep 
learning profile that is apparent within sham mice (Figure 4.6A). To determine if increased 
amyloid alone resulted in an impairment in spatial learning, the learning profiles of 
Cx3Cr1eGFP/+App23 sham mice were compared to Cx3Cr1eGFP/+ shams (Figure 4.13E). Analysis 
of the learning slope across the 6 training days revealed a significant increase in 
Cx3Cr1eGFP/+App23 sham mice (-23.26±28.0) when compared to Cx3Cr1eGFP/+ shams (-
33.96±6.9) (p<0.05) indicative of a slower rate of spatial learning (Figure 4.13E). Taken 
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together these data indicate impaired spatial learning within Cx3Cr1eGFP/+App23 mice, with no 
additional deficit apparent following BCAS.  
As a test of spatial memory, a probe trial was carried out within Cx3Cr1eGFP/+App23 sham 
and BCAS mice, 72-hours following the last training day (Figure 4.13D). Statistical analysis 
revealed no significant difference in the time spent within the target zone of Cx3Cr1eGFP/+App23 
sham (65%±56.67) when compared to BCAS mice (22.5%±66.25) (U = 17.5, p>0.05). To 
confirm that target quadrant times did indeed reflect a preference for that quadrant, time spent 
within all 4 quadrants were compared. Cx3Cr1eGFP/+App23 sham mice showed a significant 
difference in the time spent within each quadrant (2(3) = 8.492, p<0.05). Post hoc analysis 
revealed a target zone preference over the clockwise (p<0.05) and opposite (p<0.05) zones, 
but not the counter-clockwise zone (p=0.672) demonstrating no preference for the target 
quadrant (Figure 4.13D). Cx3Cr1eGFP/+App23 BCAS mice demonstrated no difference in the 






Figure 4.13 Spatial learning and memory are impaired within Cx3Cr1eGFP/+App23 mice, 
with no additional BCAS mediated deficit. (A) An overall effect of time demonstrates 
learning within both groups. Escape latency was found to be comparable across the 6 training 
days indicating no additional spatial learning deficit following BCAS. (B) Movement distance 
throughout each trial revealed a similar pattern to escape latency with an overall effect of time 
and no group differences. (C) Movement speed across the 6 training days revealed no 
significant overall effects of time or group as well as no interactions. Data presented as 
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mean±SEM. (D) Cx3Cr1eGFP/+App23 sham mice demonstrated a preference for the target 
quadrant over clockwise and opposite but not counter-clockwise zones, indicating no memory 
for the target hole. Cx3Cr1eGFP/+App23 BCAS mice showed no preference for any quadrant. 
Data presented as median±IQR. *p<0.05. (E) A significant increase in learning profile within 
Cx3Cr1eGFP/+App23 sham mice, indicative of a slower rate of spatial learning, was identified 
when compared to Cx3Cr1eGFP/+ shams. *p<0.05 (F) Representative movement traces during 
day 1 and 6 of the training period taken from Cx3Cr1eGFP/+App23 sham and Cx3Cr1eGFP/+App23 
BCAS groups. Stars indicate target hole. (G) Trace and occupancy plots gathered during 
probe trails of Cx3Cr1eGFP/+App23 sham and Cx3Cr1eGFP/+App23 BCAS mice. Stars indicate 
target hole; brighter colours indicate increased time spent within that area (occupancy plot 
only).  
 
Having demonstrated impairments in spatial memory within Cx3Cr1eGFP/+App23 mice the 
next aim was to assess cognitive flexibility (Figure 4.14). Cx3Cr1eGFP/+App23 sham and BCAS 
mice underwent reversal training across 3 consecutive days. Statistical analysis revealed an 
overall effect of time (F(2,24) = 4.290, p<0.05) with no significant effects of group (F(1,12) = 
0.369, p=0.56) or interaction (F(2,24) = 1.558, p=0.231) (Figure 4.14A). Movement distance 
displayed the same pattern with an overall effect of time (F(2,24) = 4.783, p<0.05), with no 
significant group (F(1,12) = 0.738, p=0.407) or interaction effect (F(2,24) = 0.360, p=0.701) 
(Figure 4.14B). Movement speed across reversal training reported no significant effects of 
time (F(2,24) = 0.324, p=0.727), group (F(1,12) = 0.000, p=1.000) or interactions (F(2,24) = 0.224, 
p=0.801) (Figure 4.14C).  
As with the training phase, although an improvement in escape latency and movement 
distance over time was apparent, the learning prolife appeared flatter in comparison to 
Cx3Cr1eGFP/+ sham mice (Figure 4.7). Therefore, learning profiles of Cx3Cr1eGFP/+App23 sham 
and Cx3Cr1eGFP/+sham mice were compared. Cx3Cr1eGFP/+App23 sham mice displayed a 
significant reduced learning slope over the reversal training phase (-0.28±14.13) when 
compared to Cx3Cr1eGFP/+ sham mice (-36.95±17.94) (p<0.05) (Figure 4.14E).  
Adaptive memory was then assessed with a reversal probe completed 72-hours following 
the final reversal training day (Figure 4.14D). Statistical analysis revealed no significant 
difference in the time spent within the target zone of Cx3Cr1eGFP/+App23 sham (25%±63.33) 
when compared to BCAS mice (35.83%±35.83) (U = 20, p>0.05). When time spent within the 
target quadrant was compared to the other 3 quadrants, both Cx3Cr1eGFP/+App23 sham and 
BCAS mice showed no significant difference in the time spent within each quadrant (2(3) = 
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1.000, p=0.80, and 2(3) = 5.722, p=0.13 respectively), indicating no memory for the target 
zone (Figure 4.14D).  
Taken together these data illustrate an impairment in spatial learning and memory as well 
as cognitive flexibility and adaptive memory within Cx3Cr1eGFP/+App23 mice, with no 




Figure 4.14 Cognitive flexibility and adaptive memory are impaired within 
Cx3Cr1eGFP/+App23 mice, with no additional BCAS mediated deficit. (A) An overall effect 
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of time demonstrates learning within both groups. Escape latency was found to be comparable 
across the 3 reversal training days indicating no additional deficit following BCAS. (B) 
Movement distance throughout each trial revealed a similar pattern to escape latency with an 
overall effect of time and no group differences. (C) Movement speed across the 3 reversal 
training days revealed no significant overall effects of time or group as well as no interactions. 
Data presented as mean±SEM. (D) Cx3Cr1eGFP/+App23 sham and BCAS mice showed no 
preference for any quadrant during probe trials, indicative of impaired adaptive memory. Data 
presented as median±IQR. (E) A significant increase in learning profile within 
Cx3Cr1eGFP/+App23 sham mice, indicative of a slower rate of cognitive flexibility, was identified 
when compared to Cx3Cr1eGFP/+ shams. Data presented as median±IQR. *p<0.05 (F) 
Representative movement traces during day 1 and 3 of the reversal training period taken from 
Cx3Cr1eGFP/+App23 sham and Cx3Cr1eGFP/+App23 BCAS groups. Stars indicate target hole. (G) 
Trace and occupancy plots gathered during probe trails of Cx3Cr1eGFP/+App23 sham and 
Cx3Cr1eGFP/+App23 BCAS mice. Stars indicate target hole; brighter colours indicate increased 
time spent in that area (occupancy plot only).  
 
4.3.11 eGFP insertion leads to reduced Cx3Cr1 receptor 
expression within Cx3Cr1eGFP/+ mice 
 
The data presented within the chapter thus far has demonstrated an absence of microglial 
response, in terms of structure, expansion and function, following both BCAS and BCAS 
coupled with increased amyloid. A lack of microglial response is surprising, particularly given 
the significant microglial response observed following BCAS within chapter 3. Through the 
generation of the Cx3Cr1eGFP/+ microglial reporter mouse, 1 copy of the Cx3Cr1 receptor is 
replaced with the gene encoding green florescent protein (eGFP). The Cx3Cr1 receptor allows 
for neuronal-microglial communication and its signalling is suggested to be responsible for 
sustaining normal microglial activity (Biber, Neumann H Fau - Inoue, Inoue K Fau - Boddeke, 
& Boddeke, 2007; U.-K. Hanisch & H. Kettenmann, 2007). Therefore, the next aim was to 
determine if the loss of Cx3Cr1 receptor signalling could be an explanation for the lack of 
microglial response observed following BCAS. Flow cytometry was used to isolate microglial 
cells from Cx3Cr1eGFP/+ and wild-type C57BL/6J mice. Cx3Cr1 receptor expression was then 
quantified through qPCR and compared between groups (Figure 4.15). Statistical analysis 
revealed a significant, ≈5-fold, reduction in Cx3Cr1 receptor expression within Cx3Cr1eGFP/+ 
mice (0.22±0.07) when compared to wild-type C56BL/6J mice (1.08±0.38) (t(4) = 3.131, 
p<0.05) (Figure 4.15).  
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Overall, these data demonstrate that Cx3Cr1 receptor expression is significantly reduced 




Figure 4.15 Cx3Cr1 receptor expression is significantly reduced within Cx3Cr1eGFP/+ 
mice. Cx3Cr1 receptor expression within microglial cells was found to be significantly reduced, 
≈5-fold, within Cx3Cr1eGFP/+ mice in comparison to wild-type C57BL/6J mice. Data presented a 
mean±SEM. *p<0.05.  
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4.4 Discussion 
The present study set out to investigate structural and functional alterations within 
microglial cells following BCAS, and to discover how these may change when coupled with 
a model of amyloidosis. The results show, following BCAS alone, no alterations within 
microglial structure, function, or density alongside unimpaired neurovascular coupling 
responses and visuospatial learning. Spatial memory, however, was found to be impaired 
following BCAS despite the absence of a clear microglial response. When BCAS was coupled 
to a model of amyloidosis, microglial structure, function, and density were once again found 
to be unaltered. In contrast, neurovascular coupling responses were found to be impaired when 
BCAS and increased amyloid were present together. Visuospatial learning and memory, 
however, were found to be impaired within App23 mice alone, with no additional deficits 
apparent following BCAS surgery. Cx3Cr1 receptor heterozygous mice were used for all 
experiments, with qPCR analysis revealing a ≈5-fold reduction in Cx3Cr1 receptor expression. 
The interruption of normal Cx3Cr1 receptor signalling, therefore, could be an explanation as to 
the lack of microglial responses observed here following BCAS, even in the presence of 
increased amyloid. 
 
4.4.1 Microglial density is unaltered following BCAS within 
Cx3Cr1eGFP/+ mice 
To allow microglia to be readily visualised the Cx3Cr1eGFP/+ transgenic mouse line, in which 
one allele of the Cx3Cr1R gene is replaced with the gene encoding enhanced green fluorescent 
protein (eGFP), was used. This insertion results in the expression of eGFP within Cx3Cr1+ 
cells, which include microglia, dendritic cells, and activated endothelial cells (Jung S, 2000). 
The original aim was to use this microglial reporter line to allow dynamic microglial 
mechanisms to be evaluated following BCAS. Initial investigations however, demonstrated an 
absence of microglial expansion following both short-term and chronic BCAS.  
These results are surprising given the substantial microglial proliferative response observed 
in chapter 3. In the present study, however, 0.18mm micro-coils were applied to the left and 
right common carotid arteries, resulting in a CBF reduction of ≈30%. This contrasts with the 
BCAS procedure within chapter 3, that used a mixed-coil approach achieving a slightly more 
severe blood flow reduction of ≈50%. Microglial density in the present study, was also 
assessed at a more chronic 3-month time-point following surgery, in contrast to the 6-week 
evaluation that was carried out previously. Despite these experimental differences, the lack of 
microglial expansion was still unexpected as previous experiments, using the same milder 
BCAS model, consistently report white matter microglial expansion following BCAS 
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(Coltman et al., 2011; Duncombe, Kitamura, et al., 2017; Fowler et al., 2017; Holland et al., 
2015; Kitamura et al., 2017; Manso et al., 2017; Reimer et al., 2011). A key difference between 
the present study and the previous BCAS literature is the use of the Cx3Cr1eGFP/+ transgenic 
mouse line. Therefore, the loss of 1 gene encoding the Cx3Cr1 receptor could be impacting on 
microglial responses following BCAS.   
Despite heterozygous Cx3Cr1 receptor mice being routinely used for multiphoton 
experiments, with the assumption of no adverse microglial effects, signalling between the 
chemokine receptor Cx3Cr1 and its sole ligand Cx3CL1 (Fractalkine) has been identified as a 
prominent regulator of microglial activation (Jeffrey K. Harrison et al., 1998; Nishiyori et al., 
1998). Studies on the consequence of a total loss of Cx3Cr1 receptor expression are mixed. 
Initially, no evidence of altered phenotype was observed in either CNS or peripheral immune 
responses (Jung, Aliberti, et al., 2000). However, additional investigations reported the 
activation of microglia towards a neurotoxic profile in the absence of Cx3Cr1 receptor 
signalling (Cardona et al., 2006; Fumagalli, Perego C Fau - Ortolano, Ortolano F Fau - De 
Simoni, & De Simoni, 2013). One study suggested that deficiency is protective against 
ischemic stroke (Tang Z Fau - Gan et al., 2014), whereas others have shown that the 
downregulation of Cx3CL1 by neurons leads to microglial neurotoxicity after ischemic stroke 
(He, Ren, Guo, & Deng, 2019). Mixed neuron-glial cultures, prepared from Cx3Cr1 KO mice 
stimulated with LPS, also showed reduced microglial activation with the lessened release of 
the pro-inflammatory cytokines TNF-alpha, NO, and superoxide from microglial cells 
(Mattison et al., 2013). 
Heterozygous Cx3Cr1eGFP/+ mice, in contrast, have been considered to have normal 
microglial behaviours following eGFP insertion and therefore are widely used in 
neuroimaging studies (Nimmerjahn et al., 2005; Wieghofer et al., 2015). For example, it has 
been  reported that infarctions within Cx3Cr1eGFP/+ mice were similar to wild-type controls after 
MCAO (Fumagalli et al., 2013). However, there is now growing evidence to suggest, under 
certain experimental conditions, that Cx3Cr1 receptor heterozygosity leads to abnormal 
microglial responses (Poniatowski et al., 2017; Wieghofer et al., 2015). In support of our 
findings, research in a model of ischemic preconditioning (IPC), demonstrated that microglial 
expansion following IPC was prevented within Cx3Cr1 receptor heterozygous mice (A. A.-O. 
McDonough et al., 2019). Pharmacological inhibition of Cx3Cr1 receptor signalling, within a 
rat model of hypertension, was also found to prevent microglial activation, reduced pro-
inflammatory cytokines, and restore systolic blood pressure (Ho et al., 2020). A role for 
fractalkine signalling in microglial proliferation has also been demonstrated in cultured human 
microglia (Hatori, Nagai A Fau - Heisel, Heisel R Fau - Ryu, Ryu Jk Fau - Kim, & Kim, 2002). 
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Furthermore, in a model of ischemia stroke, neuronal autophagy was shown to result in 
decreased neuronal Cx3CL1 expression leading to microglial activation (He et al., 2019).  
Such findings are interesting given the fact that Cx3Cl1-Cx3Cr1 signalling has been 
proposed as a constitutive signalling with a calming influence limiting microglial activation 
(Cardona et al., 2006). However, the evidence for such a role comes from Cx3Cr1 knockout 
experiments and therefore it could be the case that reducing, but not completely blocking, 
Cx3CL1-Cx3Cr1 signalling is having an alternative effect of microglial responses. Additional 
studies within Cx3Cr1 heterozygous mice assessing Cx3CL1-Cx3Cr1 signalling under normal 
and disease conditions, therefore, would be required to prove such a theory.  
Taken together, the evidence from previous studies alongside our own findings suggests 
that fractalkine signalling is an important pathway by which microglial proliferation and 
activation can be initiated in response to certain stimuli, and that even small perturbations in 
receptor levels has the potential to attenuate microglial responses. 
 
4.4.2 Microglial structure and surveillance functions are 
unaltered following BCAS within Cx3Cr1eGFP/+ mice 
The advancement of microglial reporter lines alongside neuroimaging studies have allowed 
single microglial cells to be tracked over-time in both homeostatic and pathological conditions. 
Such investigations have allowed microglial structural transformations to be observed and 
tracked within changing environments. Under normal homeostatic conditions, microglia adopt 
a characteristic morphology, consisting of a small spherical cell soma surrounded by highly 
ramified flopodia-like processes. (Nimmerjahn et al., 2005). In the presence of damage or 
infection, homeostatic microglia undergo dynamic structural changes, ultimately forming an 
amoeboid-like appearance (M. A.-O. Kluge et al., 2017; Stence et al., 2001). Amoeboid-like 
microglial confirmations are indicative of an activated microglial state and are associated with 
the upregulation of inflammatory related markers such as CD68 and MHC11 (Kettenmann et 
al., 2011; Lartey et al., 2014). Multiphoton imaging has allowed such morphological changes, 
within individual microglial cells, to be quantified. Structural parameters, such as soma size 
and sphericity, can accurately distinguish between activated and resting microglial 
populations, as amoeboid conformations are associated with the increased release of pro-
inflammatory cytokines  (B. M. Davis et al., 2017; Kozlowski & Weimer, 2012).  
To date detailed phenotypical evaluations of microglial structure have not been carried out 
within the context of BCAS. Therefore, in the present study, the aim was to determine if 
microglial conformational changes could be identified following short-term BCAS. Such an 
observation would help build on the pathogenic understanding of the previous chapter, by 
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illustrating the presence of microglial activation alongside extensive proliferation in response 
to BCAS.  
Cx3Cr1eGFP/+ mice were used to allow microglial cells within the cerebral cortex to be readily 
visualised via multiphoton microscopy. Previous neuroimaging studies have demonstrated that 
in response to various insults such as ischemic stroke, Aβ deposition (Lull & Block, 2010) and 
probe implantation (Kozai, Vazquez, Weaver, Kim, & Cui, 2012), microglial conformationally 
change to more amoeboid forms leading to neuroinflammation. In the present study, cortical 
z-stacks were acquired to allow the structural evaluation of individual microglial cells, in vivo, 
1-week following BCAS surgery. Soma area, volume and sphericity were found to be 
unaltered following BCAS. This result is difficult to contextualise due to the previous 
observation of a lack of BCAS mediated microglial expansion within Cx3Cr1eGFP/+ mice. One 
explanation is that no structural alterations are occurring following BCAS since Cx3Cr1 
receptor heterozygosity is preventing the microglial response. Alternatively, it could be the 
case that 1-week of BCAS does not lead to such structural changes and is not associated with 
microglial activation. Previous work using a photothrombotic occlusion model used 
multiphoton microscopy and Cx3Cr1eGFP/+ mice to demonstrate increased microglial soma size, 
indicative of microglial activation within both the peri-infarct and sites of secondary 
neurodegeneration (Kluge et al., 2018). Microglial structural changes observed within the peri-
infarct region and sites of secondary neurodegeneration also showed increased expression of 
markers associated with microglial activation such as CD68 and CD11b (M. A.-O. Kluge et 
al., 2017). However, these observations are in the context of more severe blood flow 
reductions. Therefore, without a clear wild-type comparison, it is difficult to determine if 
microglial structural changes are occurring following short-term BCAS. In the previous 
chapter microglial area per cell was found to be increased through immunohistochemical 
staining of Iba-1. However, such an evaluation is limited and does not compare to the accuracy 
of the structural evaluation methods used here. It would therefore be necessary for additional 
experiments to be conducted to help elucidate microglial structural changes following BCAS 
in the absence of Cx3Cr1 receptor heterozygosity. Cx3Cr1 receptor antibodies are available 
which would allow microglial structure within wild-type mice to be compared to Cx3Cr1eGFP/+ 
mice through structural evaluation of z-stacks taken from thick cortical tissue sections. Such a 
comparison would help determine if microglial structure is altered following BCAS and 
whether such changes are prevented by Cx3Cr1 heterozygosity.  
In conjunction with morphological changes, microglial process dynamics have also been 
shown to infer altered phenotypic state following insult. In homeostatic ‘resting’ states, 
microglial processes are highly dynamic and function to sample their local environment, 
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including making contact with other cells within their vicinity (Nimmerjahn et al., 2005). 
Rapid extension and retraction of process has been shown to be an important step in the 
sequence of structural changes leading to microglial activation (Stence et al., 2001). Microglial 
process movement has also been shown to reflect response to areas of damage. For example,  
following a laser ablation injury, microglial processes were found to extend towards the 
injured area (Davalos et al., 2005). The absence of microglial process movement towards areas 
of injury can also reflect dysfunctional responses. For example, in an experimental stroke 
model, process extension to areas of laser injury was found to be impaired within sites of 
secondary neurodegeneration (Kluge et al., 2018). To date microglial process dynamics have 
not been evaluated within the context of BCAS. In present study repeated z-stacks of the 
cerebral cortex were gather, over 15 consecutive minutes, to allow microglial process 
dynamics to be evaluated 1-week following BCAS surgery. Process motility as well as 
coverage were found to be unaffected following BCAS surgery. As with structural changes, it 
is once again difficult to draw conclusive conclusions from these findings due to the confound 
of Cx3Cr1 receptor heterozygosity influencing normal microglial responses. Previous studies 
have demonstrated that the re-localisation of the purinergic P2Y12 receptor from microglial 
processes to the soma may be a predictor of non-responsive microglial processes (Kluge et al., 
2018). A comparison between microglial P2Y12 receptor localisation within wild-type and 
Cx3Cr1eGFP/+ mice could help elucidate process motility changes following BCAS and 
determine if such changes are affected due to Cx3Cr1 receptor heterozygosity.  
 
4.4.3 BCAS elicits significant and sustained reductions in 
cerebral blood flow within Cx3Cr1eGFP/+ mice 
In the present study BCAS surgery was found to induce mild, sustained reductions in CBF. 
Laser speckle imaging revealed a modest ≈26% reduction in CBF at 24-hours which 
progressed to ≈30% at 3-months. Such blood flow reductions, following milder BCAS 
surgery, are in agreement with the 30-40% reductions previously reported within wild-type 
mice (Maki et al., 2011; McQueen et al., 2014; Nishio et al., 2010; Shibata et al., 2004). 
The results demonstrate comparable blood flow reductions between wild-type and 
Cx3Cr1eGFP/+ mice following BCAS surgery. Thus, indicating that any downstream effects of 





4.4.4 Neurovascular coupling response are unaltered following 
BCAS within Cx3Cr1eGFP/+ mice 
Neurovascular coupling is a crucial mechanism by which components of the neuro-glial-
vascular unit communicate to match local blood flow to neuronal activity, allowing perfusion 
to satisfy metabolic demands. In human patients reduced vascular function is associated with 
cognitive impairment as well as progression from mild cognitive impairment to dementia 
(Buratti et al., 2015; Viticchi et al., 2012). Previous work in aged mice demonstrated that 
neurovascular coupling impairments were associated with increased astrogliosis, loss of 
astrocytic end-feet as well as increased microglial numbers (Duncombe, Lennen, et al., 2017). 
In the present study neurovascular coupling responses, within the somatosensory cortex 
following whisker stimulation, were found to be unaltered following BCAS surgery within 
Cx3Cr1eGFP/+ mice. These results are in direct contradiction with wild-type data which shows a 
≈20% reduction in blood flow responses to stimulation following BCAS surgery (Duncombe, 
Kitamura, et al., 2017). Thus, inferring that Cx3Cr1 receptor heterozygosity is conferring 
protection against BCAS mediated neurovascular coupling impairments.  
Astrocytes, and more specifically end-feet connections to blood vessels, have been 
identified as key components of the neurovascular coupling signalling cascade (Bazargani & 
Attwell, 2016). Previous BCAS studies have demonstrated that astrogliosis occurs subsequent 
to microglial alterations (Holland et al., 2015). It has also been shown that the release of 
microglial factors is a key mechanism by which astrogliosis can be stimulated (Liddelow et 
al., 2017). Therefore, following BCAS, astrocytes may become reactive in response to 
microglial expansion and activation. Thus, one explanation for preserved neurovascular 
coupling, within Cx3Cr1 receptor heterozygous mice, is that the attenuation of microglial 
responses prevents the activation of astrocytes. In the absence of astrocyte proliferation and 
activation, end-feet connections remain intact and preserve haemodynamic functions. To 
confirm this theory, additional immunohistochemical investigations, using markers for 
reactive astrocytes (GFAP) and astrocytic end-feet (AQP4), would be required to determine if 
astrogliosis and end-feet retraction is absent following BCAS within Cx3Cr1eGFP/+ mice.  
 
4.4.5 Spatial memory is impaired within Cx3Cr1eGFP/+ mice 
following BCAS 
In the present study, the Barnes maze test of visuo-spatial learning and memory was 
performed 3-months following sham/BCAS surgery. Spatial learning was found to be 
unaffected following BCAS within Cx3Cr1eGFP/+ mice, however, in contrast spatial memory 
was found to be significantly impaired. The same effects were also observed within the 
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reversal phase, with no impairment in reversal learning but a clear deficit in adaptive spatial 
memory. In chapter 3 we reported clear evidence demonstrating that microglial expansion is a 
key factor driving white matter damage and spatial learning impairments, following BCAS. 
Furthermore, it was demonstrated that the blockade of microglial proliferation, through 
GW2580 treatment, was able to protect against spatial learning impairments following BCAS 
but was unable to rescue spatial memory deficiencies. In the present study, we observed a lack 
of microglial expansion within Cx3Cr1eGFP/+ mice in response to BCAS, which was associated 
with impaired spatial memory but not learning. These findings provide additional evidence to 
suggest that microglial expansion is a key factor driving spatial learning, but not memory 
impairments, following BCAS.  
It therefore seems apparent that Cx3Cr1 receptor heterozygosity protects against BCAS 
mediated impairments in spatial learning through the prevention of microglial expansion. In 
support of our findings, reduced expression of Cx3Cr1 through siRNA targeting within a BCAS 
model was shown to attenuate microglial activation, white matter lesions and cognitive deficits 
(Liu et al., 2015). Furthermore, in an animal model of global cerebral ischemia, treatment with 
an antibody against the Cx3Cr1 receptor was found to inhibit microglial activation leading to 
the alleviation of cognitive impairment, neuronal loss and myelin deficits (Du et al., 2020). In 
contrast to our findings, research conducted within Cx3Cr1 receptor heterozygous mice, 
without an additional insult, reported intact spatial learning but deficient spatial memory as 
assessed via the hidden-platform water maze task. Cognitive deficits within Cx3Cr1 receptor 
heterozygous mice were found to correlate with a significant reduction in synaptic plasticity 
and hippocampal neurogenesis, despite unaltered microglial populations (Rogers et al., 2011). 
In the present study however, we found that spatial learning and memory was intact within 
Cx3Cr1eGFP/+ sham mice. This may be a reflection of the different behavioural paradigms used, 
with the water maze being known to elicit much stronger stress responses than the Barnes 
maze (Pompl et al., 1999). It could therefore be the case that excessive stress can elicit spatial 
memory deficits, within Cx3Cr1eGFP/+ mice, which are not apparent in the less stressful context 
of the Barnes maze.  
Taken together these data would indicate that rescued spatial learning following BCAS is 
due to a lack of microglial response within Cx3Cr1 receptor heterozygous mice. It is important 
to note however, that the present study assessed spatial learning and memory within a milder 
BCAS model, at a more chronic timepoint then that reported within chapter 3.  
Spatial memory, however, was found to remain impaired following BCAS. These 
observations further strengthen the theory that spatial memory deficits following BCAS are 
independent of microglial expansion. It would be important, however, to further confirm this 
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association by assessing white matter damage within Cx3Cr1 heterozygous mice following 
BCAS. As, within chapter 3, improvements in spatial learning were found to strongly correlate 
to reduced microglial numbers and reduced white matter damage following GW2580 
treatment.  
 
4.4.6 Microglial density remains unaltered following BCAS 
within Cx3Cr1eGFP/+App23 mice 
Having demonstrated a lack of microglial responses within Cx3Cr1eGFP/+ mice following 
BCAS, the next aim was to determine if this effect is still apparent under co-morbid conditions. 
BCAS was carried out on App23 transgenic mice to create an additional challenge leading to 
a more significant insult. Previous research into aged App23 mice showed a clear increase in 
microglial related gene expression over-time, with a progressive increase in markers 
associated with microglial activation such as CD68 (Janssen et al., 2017). In the present study 
microglial structure and function were assessed within Cx3Cr1eGFP/+App23 mice following 
short-term BCAS with a broader examination of microglial expansion conducted, more 
chronically, 3-months following surgery. Under all the conditions by which microglia were 
assessed within Cx3Cr1eGFP/+App23 mice, with and without BCAS surgery, no apparent 
differences were detected. These findings directly contradict previous research which 
demonstrated that BCAS within App23 mice led to an exaggerated microglial response, 
identified by increased cell numbers in both white and grey matter regions in comparison to 
App23 shams (Zhai Y Fau - Yamashita, Yamashita T Fau - Nakano, Nakano Y Fau - Sun, Sun 
Z Fau - Shang, et al., 2016). A lack of altered microglial process dynamics also contradicts 
work conducted within the 5xFAD model of AD, which reported hyper-motile process 
movement within Cx3Cr1eGFP/+ mice (Gyoneva, Swanger, Zhang, Weinshenker, & Traynelis, 
2016). Although, the 5xFAD mouse line is a more aggressive model of amyloid accumulation 
and all motility changes were observed in close proximity to cortical beta-amyloid plaques.  
In the present study therefore, we have shown an absence of microglial responses within 
Cx3Cr1eGFP/+ mice, not only in the presence of increased amyloid, but also in the co-morbid 
situation of increased amyloid and BCAS.  
 
4.4.7 Impaired neurovascular coupling responses following 
BCAS within Cx3Cr1eGFP/+App23 mice  
As discussed previously, neurovascular coupling deficiencies within Cx3Cr1eGFP/+ mice 
were found to be unimpaired following BCAS. Here, however, neurovascular coupling 
deficiencies were detected within Cx3Cr1eGFP/+App23 mice, 3-months following BCAS 
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surgery. Cx3Cr1eGFP/+App23 sham mice, however, displayed normal neurovascular coupling 
responses, thus indicating that a co-morbid situation was required to trigger impairments.  
Previous investigations have demonstrated that App23 mice develop cerebral amyloid 
angiopathy (CAA) progressively, from 8 months, with substantial deposits from 14-21 months 
(Calhoun et al., 1999; D. T. Winkler et al., 2001). Multiphoton imaging studies have 
demonstrated that CAA can form tight banded structures around vessels, creating an 
exoskeleton-like structure, acting to physically restrict hemodynamic responses as well as 
displace astrocytic end-feet which are crucial for neurovascular coupling (Kimbrough, Robel, 
Roberson, & Sontheimer, 2015). However, the present study was conducted with mice aged 
12-months old and therefore substantial CAA deposits are yet to form. Interestingly, work 
within our group has previously shown, in models of amyloidosis, that BCAS surgery causes 
a redistribution of amyloid aggregates from the parenchyma to the vessels (Salvadores et al., 
2017). This evidence, therefore, could explain why neurovascular coupling deficits are only 
apparent in Cx3Cr1eGFP/+App23 mice when subjected to BCAS. In the present study, BCAS 
could be exacerbating vascular amyloid accumulation leading to increased CAA formation, 
resulting in impairments in neurovascular coupling responses either directly by physically 
restricting vessels and dislodging astrocytic end-feet or indirectly through the onset of 
inflammation. To prove such a theory additional experiments would be required using amyloid 
markers such as methoxy-XO4 and multiphoton microscopy to track the onset of CAA within 
the somatosensory cortex of mice following BCAS surgery. Such dynamic imaging 
approaches would allow hemodynamic responses following whisker stimulation to be 
conducted in vivo in real time alongside CAA assessment of the same vessels. Thus, potentially 
providing in vivo real time assessments of blood vessels longitudinally as CAA deposits form 
following BCAS surgery. Alternatively, in vivo multiphoton experiments have demonstrated 
that Aβ peptides themselves can act on cerebral arteries to cause localised constriction, through 
the release of reactive oxygen species (Niwa et al., 2001). These localised constriction events, 
therefore, alongside BCAS mediated endothelial stress, could coincide to lead to impairments 
in neurovascular coupling responses. Additional experiments, however, would be required to 
confirm the presence of Aβ peptides in the vicinity of poorly responding cerebral arteries to 




4.4.8 Impaired spatial learning and memory within 
Cx3Cr1eGFP/+App23 mice, with no clear additional BCAS 
mediated impairment 
Neurodegenerative diseases such as AD, are characterised by spatial memory deficits 
(Kaskie & Storandt, 1995). Previous studies, using the App23 mouse line, have demonstrated 
significant impairments in spatial learning and memory, as measured by the Barnes maze, at 
12-months of age (Prut et al., 2007). It has also been demonstrated that severe BCAS leads to 
more significant memory impairments within APPswe/PS1 mice, which is associated with 
increased microglial dysfunction (Maude Bordeleau, Ayman ElAli, & Serge Rivest, 2016). 
Therefore, the aim was to determine if Cx3Cr1 receptor heterozygosity could rescue the 
cognitive impairments previously identified within App23 mice at 12-months of age, and to 
determine if this benefit would extend to a co-morbid situation. Within, both training and 
reversal phases both Cx3Cr1eGFP/+App23 sham and BCAS groups showed a degree of learning. 
However, when learning profiles were compared to Cx3Cr1eGFP/+ sham mice, 
Cx3Cr1eGFP/+App23 sham mice demonstrated a significantly impaired rate of learning. Training 
and reversal probes highlighted significantly impaired spatial memory in both 
Cx3Cr1eGFP/+App23 sham and BCAS groups.  
Within Cx3Cr1eGFP/+App23 mice we have demonstrated a lack of microglial response 
following BCAS surgery, however spatial learning and memory deficits were still identified 
with no apparent additional BCAS mediated deficit. These data indicate that spatial learning 
deficits, within Cx3Cr1eGFP/+App23 mice, are not mediated by white matter microglial 
expansion, as was determined to be the cause in chapter 3. Previous studies within App23 
transgenic mice have demonstrated hippocampal loss of cell bodies adjacent to Aβ peptide 
deposits at 12-months of age (Sturchler-Pierrat et al., 1997). Studies have also reported 
hippocampal CA1 neuronal loss (Calhoun Me Fau - Wiederhold et al., 1998) and altered 
synaptic function within aged App23 mice (Roder et al., 2003). It is therefore likely that 
neuronal damage and altered synaptic signalling within the hippocampus underlie cognitive 
deficits, within Cx3Cr1eGFP/+App23 mice, independent of microglial expansion and activation.  
 
4.4.9 Study limitations and future directions 
One limitation of the present study was the lack of pathological insight. For example, an 
assessment of white matter damage would have been advantageous to help further strengthen 
the link established within chapter 3, that the blockade of white matter expansion prevents 
white matter damage and cognitive impairment following BCAS. The current study is also 
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lacking any detailed information regarding the soluble and insoluble burden of Aβ. Evidence 
of the relocation of Aβ from the parenchyma to cerebral vessels following BCAS has 
previously been reported in another amyloidosis model (Salvadores et al., 2017). If such a 
change were apparent in the present study, this could provide mechanistic insight to explain 
neurovascular coupling deficiencies within App23 mice following BCAS. 
The study also lacks a more detailed evaluation of microglial activation. Although, 
structural analysis demonstrated no change, indicative of a homeostatic state, this evaluation 
was only completed 1-week following BCAS surgery. Therefore, information regarding 
microglial activation state at the more chronic 3-month time-point was not generated. In our 
present cranial window set up, window clarity cannot be guaranteed at such timepoints due to 
excessive regrowth. Microglial activation, at chronic time-points, could however be assessed 
using immunohistochemical markers such as Lamp2 or CD68, or alternatively through qPCR 
evaluation of genes associated with activation such as the pro-inflammatory cytokines TNF-α 
and IL-1β.  
A fundamental issue with the study design was the lack of adequate wild-type mice to 
enable comparisons to be directly made to outcomes within Cx3Cr1eGFP/+ mice. This, however, 
was out of our control as the original aim of this study was to track microglial responses 
following BCAS, with the notion that the widely used Cx3Cr1eGFP/+ mouse line had normally 
functioning microglia. We were, however, able to make comparisons to previously published 
data which was gathered within comparable aged mice with the similar durations of BCAS 
surgery. Therefore, the addition of such comparisons to wild-type data helped elucidate key 
differences in functional and cognitive outcomes following BCAS surgery within Cx3Cr1eGFP/+ 
mice. Future studies, however, could make use of the newly developed transgenic microglial 
mouse lines which achieve microglial visualisation without a loss of Cx1Cr1 receptor 
expression (Miron & Priller, 2020). A comparison between BCAS mediated microglial 
changes within Cx3Cr1eGFP/+ mice and reporter lines without Cx1Cr1 receptor targeting would 
help clearly demonstrate the role of Cx1Cr1 receptor signalling in such responses. 
In the present study microglial process dynamics were assessed, in vivo, under the 
anaesthetic isoflurane. Recent evidence has emerged, however, suggesting that microglial 
behaviour, with reference to process dynamics, can be influenced differentially depending on 
the anaesthetic used. For example, both acute and chronic cranial window preparations found 
that isoflurane increased the length of surveillant microglial processes when compared to 
awake mice (Sun et al., 2019). The effect of arousal state therefore, appears to have a 
significant impact on process motility, with awake mice showing reduced process motility in 
comparison to anaesthetised mice (Stowell et al., 2019). It is therefore important in future 
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studies to employ multiphoton set-ups that can be performed within awake mice, to ensure that 
anaesthetic effects do not cloud true pathological differences.   
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4.5 Conclusion 
In the present study, within Cx3Cr1eGFP/+ mice, microglial were shown to be unchanged 
alongside intact neurovascular coupling and spatial learning following BCAS. The 
replacement of 1 copy of the Cx3Cr1 receptor was found to lead to a ≈5-fold reduction in 
receptor expression. Thus, suggesting that fractalkine signalling may be an important pathway 
by which microglial proliferation and activation can be initiated following BCAS. The 
addition of amyloidosis, as a comorbidity, led to neurovascular coupling and spatial learning 
and memory deficits despite the absence of microglial expansion. Indicating that the presence 
of increased amyloid alone triggers other neuro-glial-vascular unit changes leading to damage 
and dysfunction, independent of microglial expansion. The present study therefore highlights, 
the Cx3CL1-Cx3Cr1 signalling pathway as a key potential mechanism by which microglial 






Investigating dynamic alterations within the 
cerebrovasculature in response to BCAS with the use 
of intravital imaging 
 
  
5.1 Introduction  
The development of intravital multiphoton imaging approaches within chapter 4 provided 
a unique opportunity within the laboratory to evaluate, in vivo, dynamic microglial processes 
in the context of VCI. These technologies have been scarcely used in the field of VCI, and 
therefore the aim of the present study was to use multiphoton microscopy to allow dynamic 
changes within the cerebrovasculature to be assessed following BCAS.  
There is increasing evidence from epidemiological, clinical and experimental studies to 
suggest that cerebrovascular damage and dysfunction play a fundamental role in the 
pathogenesis of many types of dementia (Toth et al., 2017). Furthermore, endothelial 
dysfunction has been highlighted as an initiating mechanism driving downstream pathological 
processes, including microvascular inflammation, contributing to the onset and progression of 
VCI (Poggesi A Fau - Pasi et al., 2016; J. M. Wardlaw et al., 2013).  
The endothelium dynamically regulates the inflammatory response within the brain 
through control of vascular permeability to peripheral macromolecules and leukocytes (Videm 
& Albrigtsen, 2008). In response to an array of different compounds, endothelial cells can 
become activated leading to increased surface expression of adhesion molecules (Videm & 
Albrigtsen, 2008). Adhesion molecules interact with leukocytes travelling within the blood 
stream triggering down-stream proinflammatory signalling cascades (Schnoor et al., 2015). 
The shedding and circulation of these adhesion molecules, following endothelial activation, 
may therefore reflect endothelial dysfunction and/or microvascular inflammation (Poggesi et 
al., 2016). In support of this, increased soluble ICAM-1 levels ,within human patients, have 
been observed in alongside lacunar infarcts and WMH (Han et al., 2009; Hassan et al., 2003), 
with longitudinal MRI studies also showing an association between increased ICAM-1 levels 
and WMH progression (Markus et al., 2005).  
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A role for endothelial dysfunction and microvascular inflammation has also been 
demonstrated within animal models of BCAS. Microarray analysis conducted 3-days 
following BCAS revealed alterations within endothelial related genes alongside increased pro-
inflammatory associated genes (Reimer et al., 2011). ICAM-1 expression was also shown to 
be significantly increased subcortically at 3-months following BCAS, which was associated 
with poorer cognitive outcomes (Kitamura et al., 2017).  
Alongside roles in vascular permeability and inflammation, the endothelium has also been 
proposed to facilitate the transport and clearance of waste products from the brain. Perivascular 
spaces are compartments that form around the surface of blood vessels within the brain (Jeffrey 
J. Iliff et al., 2013b). A key role of these spaces is to facilitate the exchange of brain interstitial 
fluid (ISF) and cerebral spinal fluid (CSF), which allows the clearance of interstitial solutes 
and waste products from the brain parenchyma, in a process known as paravascular drainage 
(Abbott, 2004; Cserr Hf Fau - Ostrach & Ostrach, 1974; S. Yamada et al., 1991). Vascular 
pulsation, generated through spontaneous arteriole smooth muscle contractions, has been 
proposed as the predominant driving force facilitating paravascular drainage pathways 
(MacGregor Sharp et al., 2020). Such mechanisms are therefore fundamental to the clearance 
of potentially harmful waste products from the brain (Jeffrey J. Iliff et al., 2013b). However, 
the function of pulsatory mechanisms in the context of BCAS has never been studied. 
Therefore, the aim of the present study was to use multiphoton microscopy to access 













5.1.1 Hypothesis  
This study tests the hypothesis that BCAS causes vascular dysfunction resulting in 
endothelial cell activation and impaired vascular pulsation leading to the onset of neuro-glial-
vascular damage through downstream signalling to the immune system.   
 
5.1.2 Aims 
Using a model of BCAS within wild-type C57BL/6J mice, alongside intravital multiphoton 
microscopy, the studies aimed to: 
1. Assess temporal changes in CBF following 4-weeks of BCAS 
2. Assess RBC velocity, within leptomeningeal veins and arteries, following 4-weeks 
of BCAS 
3. Assess changes in vascular pulsation in response to 4-weeks of BCAS 
4. Determine if leukocyte trafficking behaviours, within leptomeningeal veins and 
arteries, are altered in response to 4-weeks of BCAS 
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5.2 Materials and Methods 
 
5.2.1 Experimental mice 
Adult male C57BL/6J mice were used for all experiments and were group housed on a 12-
hour light and dark cycle with ab libitum access to food and water. For the studies described 
in this chapter, 2 cohorts of mice were used. Initially a cohort of 6 C57BL/6J mice were used 
to ensure that RBC velocity could be accurately measured via multiphoton microscopy in our 
hands. For all remaining experiments, a second cohort of 18 mice were used. At the start of 
the experiment all mice were coded and randomly assigned to different experimental groups, 
to ensure that all investigators were blinded to surgical status for the duration of experiments 
and analysis. Mice were separated into sham (n=8) and BCAS groups (n=10) randomly. 
Details of group numbers and exclusions can be found in the relevant methods sections below, 
alternatively an overall summary can be found within Table 5.1. 
 
Table 5.1 Number of mice within each experimental group with details of exclusions
 
5.2.2 Bilateral common carotid artery stenosis  
Bilateral common carotid artery stenosis (BCAS) surgery was performed according the 
method previously described (Section 2.2). For the present study, a milder form of BCAS was 
achieved through the application of 0.18mm diameter micro-coils to both the left and right 
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common carotid arteries. As a control for all experiments sham mice underwent an identical 
procedure with the only exception being the application of micro-coils. All mice recovered 
well following surgery and therefore no mice were excluded due to poor health. 
 
5.2.3 Craniotomy and cranial window surgery in preparation for 
multiphoton microscopy 
Cranial window surgery was carried out 4-weeks prior to multiphoton microscopy 
according to the method outlined within Section 2.4. Strict exclusion criteria were applied to 
minimise any effect of cranial window implantation on the neuro-inflammatory response 
(detailed in Section 2.4). According to these criteria 1 sham mouse was excluded due to a 
cranial window detachment (Table 5.1) 
 
5.2.4 Laser speckle imaging to measure cortical cerebral blood 
flow 
Laser speckle imaging was used to assess CBF within sham and BCAS mice following 
surgery as previously described in Section 2.3. For the present study, scalp opening, and 
retraction was not necessary as imaging could be performed directly through the cranial 
window. Blood flow was analysed at baseline, 24-hours, 1-week, and 1-month following 
surgery. A total of 3 BCAS mice were excluded from the study due to no obvious blood flow 
reductions 1-week following BCAS surgery (Table 5.1). 
 
5.2.5 Multiphoton microscopy 
Multiphoton microscopy was carried out using the set-up and parameters detailed within 
Section 2.5. Approximately 30-minutes prior to imaging, mice receive a tail vein injection of 
100µl fluorescein isothiocyanate (FITC)-dextran (15mg/ml) to allow the cerebral vasculature 
to be visualised (Table 2.2). Multiphoton imaging was performed 4-weeks following 
sham/BCAS surgery and 8-weeks following cranial window surgery. 
  
5.2.6 In vivo cerebral RBC velocity measurement via line scan 
analysis 
The assessment of RBC velocity was carried out using line scans and assessed according 
to the method outlined in Section 2.5.3. RBC velocity was assessed within 5 veins and 5 
arteries per mouse. The values for each vessel type were averaged and presented as 
median±interquartile range. Strict exclusion criteria were applied, such that any linescan 
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recording whose quality was not sufficient to give accurate readings of RBC velocity were 
excluded (detailed within Section 2.5.3). Based on these criteria 5 veins and 6 arteries were 
excluded from sham mice and 3 veins and 2 arteries were excluded from BCAS mice.  
 
5.2.7 In vivo vascular pulsation measurement via line scan 
analysis 
Cerebral vascular pulsatility was evaluated with the use of multiphoton microscopy as 
detailed within Section 2.5.4. Briefly, the pulsatility of individual vessels was determined by 
positioning linescans orthogonal to the vessel’s axis. To calculate dynamic vessel width 
changes over time, vessel width (µm) within each region was plotted against time (ms). Vessel 
wall pulsatility (µm per ms) was calculated from the resulting graphs as the absolute value of 
area under the diameter-time plot, integrated to the running average calculated across the entire 
3600ms sampling time. To calculate the total number of dynamic vessel pulses (pulsation 
frequency) across the sampling time, the total number of peaks were also calculated from the 
same diameter-time plots. 
 
5.2.8 In vivo assessment of leukocyte trafficking behaviours 
The in vivo assessment of leukocyte trafficking behaviours was carried out according to 
method outlined within Section 2.5.5. Leukocyte rolling and adhesion were assessed, and 
values summated to calculate leukocyte trafficking per 100µm per minute. Leukocyte 
trafficking was calculated within 5 secondary leptomeningeal veins and 5 secondary 
leptomeningeal arteries per mouse and values were averaged. Due to the positioning of the 
cranial window, 1 sham mouse only had 3 secondary veins visible and therefore assessed. In 
terms of secondary arteries only 3/5 were visible in 1 sham animal and 4/5 for 1 BCAS mouse.  
 
5.2.9 Statistical analysis 
Statistical analysis was performed using SPSS (v22, IBM Corp.) and Prism (v8, GraphPad 
Software Inc, La Jolla, USA) software packages. Repeated measures one-way ANOVA’s were 
used to assess CBF differences as well as RBC velocity within veins and arteries over-time. 
Independent samples Mann-Whitney U tests were used to analyse sham and BCAS differences 
in RBC velocity, vein/artery widths used for RBC assessment, pulsation area, pulsation 
frequency, widths of vessels used for pulsation assessments, and leukocyte trafficking.  
Correlations were analysed using the Spearman’s ranked correlation coefficient. For 
parametric statistical tests, data is presented as mean ± standard error of the mean (SEM) and 
for nonparametric testing data is presented as median ± interquartile range (IQR) (specified in 
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relevant figure legend). Vessel wall pulsatility (µm per ms) was calculated as the absolute 
value of area under a plot of vessel diameter versus time, integrated to the running average 
calculated across the entire 3600ms sampling time. To calculate the total number of dynamic 
vessel pulses (pulsation frequency) across the sampling time, the total number of peaks were 
also calculated from the same diameter-time plots. All statistical analysis was completed 
within SPSS, apart from vascular pulsation assessments, which were analysed using Prism 
software. Statistical significance was determined at p<0.05.   
 
5.2.10 Experimental contributions 
The majority of experiments and analysis detailed within this chapter were conducted by 
myself. The studies, however, were also supported by Dr Juraj Koudelka and Professor Karen 
Horsburgh. I performed multiphoton imaging and completed all the data analysis presented. 
Dr Juraj Koudelka performed cranial window surgery and operated the software for image 
capture during multiphoton imaging sessions. Professor Karen Horsburgh carried out sham 
and BCAS surgery on all mice.   
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5.3 Results 
 
5.3.1 Cerebral blood flow is significantly and persistently 
reduced following BCAS 
Results to date have demonstrated a robust, predominantly microglial, inflammatory 
response following BCAS leading to white matter damage and cognitive impairments. The 
mechanisms by which BCAS stimulates neuroinflammatory responses, however, remain 
largely unknown. In the present study we employed a mild BCAS model and selected a 
timepoint following surgery at which pathological damage and cognitive impairments are not 
yet present. The aim was to try and uncover early mechanisms by which BCAS stimulates the 
activation and proliferation of microglial cells leading to neuroinflammation, white matter 
damage and spatial learning impairments.  
Initially laser speckle imaging was employed to confirm mild CBF reductions following 
BCAS surgery, as well as to allow the exclusion of any mice that show resistance to BCAS 
surgery (Figure 2.2). Laser speckle analysis was conducted directly through the cranial 
window at baseline, 24-hours, 1-week, and 4-weeks following surgery (Figure 5.1). BCAS 
surgery elicited a ≈30% reduction in CBF, which decreased further to a ≈50% reduction at 1-
week, finally stabilising at a ≈30% reduction by 4-weeks following surgery. Sham mice 
demonstrated stable CBF values across the same period (Figure 5.1A). Statistical analysis 
revealed a significant overall effect of time (F(1.5,10.7) = 16.057, p<0.01), group (F(1,7) = 13.851, 
p<0.01) as well as a significant time-group interaction (F(1.5,10.7) = 11.926, p<0.01) (Figure 
5.1A). Bonferroni post hoc analysis revealed that BCAS surgery elicited a significant 
reduction in blood flow at 24-hours (Sham; 103.02%±4.7, BCAS; 69.50%±8.6, p<0.05), 1-
week (Sham; 95.06%±6.0, BCAS; 50.84%±7.1, p<0.01) and 4-weeks (Sham; 101.96%±5.5, 
BCAS; 70.61%±7.7, p<0.05) following surgery when compared to shams (Figure 5.1A). 
Overall, these data show a modest reduction in CBF following BCAS surgery which is 






Figure 5.1 BCAS induces a sustained reduction in CBF. (A) BCAS surgery reduced 
CBF by ≈30%, with sham mice showing stable blood flow over the same period. Data 
presented as Mean±SEM. *p<0.05, **p<0.01. (B) Representative images displaying laser 
speckle imaging of the cerebral vasculature within sham and BCAS mice at baseline, 24-
hours, 1-week, and 1-month following surgery. Blue colours represent low and red high blood 
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5.3.2 RBC velocity can be accurately and reliable measured in 
vivo via multiphoton microscopy 
Laser speckle imaging allows superficial cortical blood flow responses to be tracked 
following BCAS surgery, however this method only generates an overview of blood flow 
changes and provides no information regarding more subtle changes to the cerebral 
vasculature. Here, multiphoton microscopy was applied to allow individual vessels to be 
analysed following BCAS allowing a more detailed evaluation of BCAS mediated vascular 
flow changes.  
The first aim was to assess red blood cell (RBC) velocity within individual leptomeningeal 
veins and arteries of the cortex to determine if BCAS surgery leads to altered blood flow within 
individual vessels. As this method was new to the group, it was important to first optimise 
multiphoton imaging protocols to allow RBC velocity to be calculated accurately and reliably. 
To image the cerebral vasculature, in vivo, mice were fitted with cranial windows 4-weeks 
prior to imaging to allow any procedural inflammation to resolve. The cerebral vasculature 
was then visualised through the introduction of a FITC-dextran tracer via the tail vein. Veins 
and arteries were distinguished based on structure as well as direction of blood flow, with 
veins having convergent, and arteries divergent, flow. To image RBCs flowing through 
individual vessels, high speed line scans were captured. The slope of each RBC within the line 
scan image was calculated to generate a RBC velocity value for each vessel (Figure 5.2). RBC 
velocity values were gathered for leptomeningeal veins (8.61±3.85) (Figure 5.2A) and arteries 
(12.04±5.49) (Figure 5.2B) and were found to fall within the range of values previously 
reported within the literature (Veins: 3.9-9.2mm/s, Arteries: 8.4-23mm/s) (Figure 5.2C). 
Having demonstrated the accuracy of the imaging setup, the reproducibility of the method was 
then tested by longitudinal RBC velocity measurements, of the same vessels, at baseline, 1-
week, and 6-weeks (Figure 5.2D). No significant differences were identified between values 
gathered across imaging sessions within veins (F(2,10) = 1.150, p=0.36) or arteries (F(2,8) = 
0.985, p=0.42) (Figure 5.2D). 
Overall, these data demonstrate that RBC velocity can be accurately and reliably measured, 






Figure 5.2 RBC velocity measurements align with previously published data. Line 
scanning was used to measure RBC velocity within leptomeningeal veins and arteries. Line 
scans were gathered from 2 veins and 2 arteries per mouse and values were averaged to give 
a RBC velocity value (mm per second). RBC velocity was found to be 9.2±4.5 mm/s in veins 
(A), and 12.0±5.5 mm/s in arteries (B). Values presented as median±interquartile range. (C) 
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Values published within the literature using multiphoton microscopy and line scanning 
methods to assess RBC velocity. (D) Repeated measurements of the same veins and arteries 
across multiple imaging sessions were found to be consistent. Values presented as mean±
SEM.  
 
5.3.3 RBC velocity is significantly reduced following BCAS 
Having demonstrated the accuracy and reliability of in vivo RBC velocity measurements, 
the next aim was to investigate the impact of BCAS on these measures. Following the 4-week 
rest period after cranial window implantation, mice underwent sham/BCAS surgery and RBC 
velocity was assessed 1-month later (Figure 5.3). Line scan analysis within leptomeningeal 
veins revealed a significant reduction in RBC velocity within BCAS mice (4.44±7.49) when 
compared to shams (10.47±6.75) (U=8.00, p<0.05) (Figure 5.3A). The same effect was also 
observed within leptomeningeal arteries, with BCAS mice showing significantly reduced RBC 
velocity values (12.24±4.66) when compared to shams (19.13±6.52) (U=4.00, p<0.01) (Figure 
5.3B). To ensure that these findings could not be attributed to differences in the size of vessel 
analysed, average vessel width was compared between sham and BCAS mice (Figure 5.3C/D). 
Statistical analysis revealed no significant differences between vessel widths of veins and 
arteries imaged from sham (veins: 58.78µm±29.95, arteries: 37.94µm±9.49) and BCAS mice 
(veins: 60.24µm±14.74, arteries: 39.57µm±6.04) (veins: U=25.00, p=1.00, arteries: U=33.00, 






Figure 5.3 RBC velocity is significantly reduced following BCAS. RBC velocity was 
found to be significantly reduced within leptomeningeal veins (A) and arteries (B) following 
BCAS surgery. The vessel widths of both veins (C) and arteries (D) assessed for RBC velocity 
were found to be comparable between sham and BCAS groups. Data presented as median±
interquartile range. *p<0.05, **p<0.01. Representative images of leptomeningeal veins (E) and 
arteries (F) line scans taken from sham and BCAS mice 1-month following surgery. White lines 
indicate the position of the linescan. Scale bar 50µm. 
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As RBC velocity and laser speckle imaging measures had been completed within the same 
animals, the values were compared to assess the relationship between superficial blood flow 
changes and those occurring at the single vessel level (Figure 5.4). Veins RBC velocity was 
found to positively correlate to CBF measures at 1-month following surgery (rs(7) = 0.733, 
p<0.05) (Figure 5.4A). Thus, indicating that the most severe blood flow reductions following 
BCAS, as measured by laser speckle analysis, are associated with the slowest RBC velocities 
within secondary leptomeningeal veins. Artery RBC velocity was then compared to 1-month 
laser speckle blood flow (Figure 5.4B). Statistical analysis revealed a trend for a positive 
correlation between artery RBC velocity and superficial blood flow measurements (rs(7) = 
0.650, p=0.058) (Figure 5.4B). 
Overall, these data demonstrate that BCAS induced reductions in superficial cortical flow 
are also reflected in significantly reduced RBC velocity within secondary leptomeningeal 
veins and arteries found deeper within the cortex. 
 
 
Figure 5.4 RBC velocity is positively correlated to superficial CBF measurements 
within leptomeningeal veins. (A) RBC velocity was positively correlated to superficial cortical 
blood flow within leptomeningeal veins. (B) A trend for a correlation between RBC velocity and 
superficial cortical blood flow was identified within leptomeningeal arteries. Data presented as 
Mean. 
 
5.3.4 Arterial pulsation is significantly impaired following BCAS 
Having demonstrated that BCAS leads to blood flow reductions within individual vessels 
of the leptomeningeal cortical vasculature, the next aim was to determine if vascular function 
was also impaired. Vascular pulsation is a mechanism proposed to be fundamental to 
paravascular CSF-ISF exchange, which is a crucial process facilitating waste clearance from 
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the brain (Jeffrey J. Iliff et al., 2013a). To investigate the effect of BCAS surgery on vascular 
pulsation, multiphoton microscopy was utilised to allow the pulsatility of individual vessels to 
be determined. Vascular pulsation was measured at multiple levels of the vascular tree 
encompassing leptomeningeal veins, ascending veins, leptomeningeal arteries, and penetrating 
arteries. Line scans were carried out across the width of each vessel to determine pulsation 
area as well as the frequency of pulsation (Figure 5.5). The area of vascular pulsation was 
found to be significantly reduced within the leptomeningeal arteries of BCAS mice 
(433.2±206.7) when compared to shams (654.2±350.8) (U=6.00, p<0.05) (Figure 5.5A). 
Vascular pulsation, however, was found to be unaffected within leptomeningeal veins 
(p=0.45), ascending veins (p=0.18) and penetrating arteries (p=0.18) following BCAS surgery 
(Figure 5.5A). The frequency of vascular pulsation was also analysed as the number of width 
changes (peaks) per second (Figure 5.5B). The frequency of pulsation was found to be 
significantly increased within the leptomeningeal arteries of BCAS mice (23.2±3.6) in 
comparison to shams (19.3±3.6) (U=41.00, p<0.05) (Figure 5.5B). However, no significant 
differences in pulsation frequency were identified within leptomeningeal veins (p=1.00), 
ascending veins (p=0.53) or penetrating arteries (p=0.07) following BCAS surgery (Figure 
5.5B). To confirm that pulsation effects following BCAS were not due to differences in the 
width of vessels analysed, vessel widths for all vessel assessed, within sham and BCAS mice 
were measured and compared (Figure 5.5E). No significant differences between sham and 
BCAS groups were identified for vessel widths sampled from leptomeningeal arteries 
(p=0.90), penetrating arteries (p=0.53), leptomeningeal veins (0.53) or ascending veins (0.23) 
(Figure 5.5E).  
Taken together these data demonstrate a vascular pulsation deficit, specifically within 
secondary leptomeningeal arteries, following BCAS surgery. 
 
 




Figure 5.5 Arterial pulsation is significantly impaired following BCAS surgery. (A) 
The area of vascular pulsation was found to be significantly impaired within secondary 
leptomeningeal arteries following BCAS surgery. Leptomeningeal veins, ascending veins, and 
penetrating arteries were found to be unaltered. (B) The frequency of vascular pulsation was 
found to be significantly increased within leptomeningeal arteries of BCAS mice in comparison 
to shams. Frequency was found to be unaltered within the other vessels analysed. 
 
 209 
Representative plots of vessel width changes over-time within a leptomeningeal artery taken 
from both sham (C) and BCAS mice (D). Red denotes the area under the curve which is used 
as a measure of pulsation (E) The width of vessels analysed for all vessel types were found 
to be comparable between sham and BCAS groups. Data presented as median±interquartile 
range. *p<0.05. 
 
5.3.5 Leukocyte trafficking is significantly increased following 
BCAS 
Having demonstrated that BCAS leads to altered blood flow and pulsation within the 
cerebral vasculature, the next aim was to determine if there was any evidence of endothelial 
cell activation following surgery. Endothelial cells can become activated in response to a wide 
range of signalling molecules leading to increased surface expression of adhesion molecules 
such as ICAM-1 and VCAM-1. Adhesion molecules act to contact peripheral immune cells 
within the circulation causing leukocytes to roll along the endothelial surface until enough 
physical bonds are formed to facilitate adherence (Videm & Albrigtsen, 2008). Such leukocyte 
trafficking behaviours lead to the onset of inflammatory signalling cascades and in some 
circumstance’s extravasation of immune cells into the brain (Schnoor et al., 2015). To 
determine if leukocyte behaviours, associated with endothelial activation, were altered 
following BCAS, time-lapse recordings were carried out in vivo via multiphoton microscopy 
(Figure 5.6).  
Leukocyte trafficking was found to be significantly increased within the leptomeningeal 
veins of BCAS mice (0.24±1.62) when compared to shams (0±0.21) (U=40.00, p<0.05) 
(Figure 5.6A). The percentage of leptomeningeal veins analysed that showed leukocyte 
trafficking was also quantified for sham and BCAS groups. The frequency of leukocyte 
trafficking was found to be significantly increased within BCAS mice (40±40) when compared 
to shams (0±20) (Figure 5.6B). Leukocyte trafficking within leptomeningeal arteries, however, 
was found to be extremely rare with behaviours only evident in 2 of the 70 arteries analysed 
across both sham and BCAS groups (Data not shown). To confirm that the cells seen travelling 
through the vasculature were indeed leukocytes, we injected acridine orange which is a 
florescent dye that specifically binds to cells containing DNA and therefore will not bind to 
RBCs. Acridine orange staining confirmed that these cells are indeed nucleic and therefore 
strongly indicates that we are observing leukocyte behaviours in vivo (Figure 5.6C). 
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Figure 5.6 Leukocyte trafficking is significantly increased within leptomeningeal 
veins following BCAS. (A) The number of leukocytes trafficking, within secondary 
leptomeningeal veins, was found to be significantly increased within BCAS mice in comparison 
to shams. (B) The frequency of leukocyte trafficking events was also found to be significantly 
increased within leptomeningeal veins following BCAS surgery. Data presented as median±
interquartile range. *p<0.05. Leukocyte trafficking within leptomeningeal arteries was observed 
to be extremely rare, data not shown. (C) Acridine orange staining confirming that the black 
loss of signal spheres observed contain a nucleus. White arrowhead denotes a leukocyte 
within the leptomeningeal vein. A sequence of images to display an example of leukocyte 
rolling (D) and adhesion (E). White arrows indicate a leukocyte of interest and are positioned 
in the same location within every image, numbers above the image represent time in seconds. 
 
As measures of RBC velocity had also been carried out within the same secondary 
leptomeningeal veins as measured here, the relationship between RBC velocity and leukocyte 
trafficking was assessed (Figure 5.7). Statistical analysis revealed a significant negative 
correlation between RBC velocity and leukocyte trafficking (rs(15) = -0.652, p<0.01) (Figure 
5.7). Thus, indicating that as RBC velocity within leptomeningeal veins decreases the number 
of leukocytes trafficking along the endothelial cell wall increases.  
In conclusion these data show evidence of increased leukocyte trafficking, indicative of 




Figure 5.7 RBC velocity is negatively correlated to leukocyte trafficking. As RBC 
velocity within leptomeningeal veins decreases the number of leukocytes trafficking along the 
endothelial cell wall increases. Individual vessel data presented from both sham and BCAS 
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5.4 Discussion 
The present study set out to utilise newly established intravital multiphoton imaging 
approaches to investigate dynamic alterations within the cerebral vasculature in response to 
BCAS. The results demonstrate that BCAS results in reduced RBC velocity alongside 
impaired arterial pulsation, and increased leukocyte trafficking. Taken together these findings 
highlight alterations in vascular mechanisms, in response to BCAS, that could lead to 
pathological damage and functional impairments.  
 
5.4.1 BCAS mediated cortical blood flow reductions can be 
detected globally as well as at the single vessel resolution 
In the present study laser speckle imaging was once again used to assess superficial CBF 
changes following BCAS. BCAS surgery was found to reduce blood flow by ≈30% at 24-
hours, dipping to ≈50% at 1-week before stabilising at ≈30%, 1 month following surgery. Such 
blood flow reductions are in agreement with previous studies using the milder BCAS model 
including the study detailed in chapter 4 (Maki et al., 2011; McQueen et al., 2014; Nishio et 
al., 2010; Shibata et al., 2004). In the present study, however, laser speckle imaging was 
conducted directly through the cranial window, whereas previous studies had imaged through 
the intact skull. It is therefore, reassuring that comparable values were generated lending 
support to the accuracy of the laser speckle imaging set up.  
The BCAS model has been shown across numerous investigations within our laboratory 
and others to elicit a robust and reliable reduction of CBF to the forebrain (Holland et al., 2015; 
Manso et al., 2017; McQueen et al., 2014; Reimer et al., 2011; Shibata et al., 2004). However, 
the effect of mild BCAS on the speed of RBC velocity within individual blood vessels of the 
cortex, had not previously been investigated. Therefore, multiphoton microscopy was 
employed to allow the speed of RBC velocity to be determined, in vivo, via line scan imaging. 
BCAS surgery was shown to significantly reduce the speed of RBC velocity within 
leptomeningeal veins and arteries. These changes are in agreement with previously published 
work using the mixed coil BCAS model (Yata et al., 2014). Furthermore, reduced blood flow 
velocity, within human patients, was shown to be associated with increasing age as well as 
increased white matter lesion burden (Joanna M. Wardlaw et al., 2011). 
In the present study, the extent of RBC velocity reductions following BCAS were 
significant, with decreases of ≈47% within leptomeningeal veins and ≈39% within 
leptomeningeal arteries following surgery. As first order vessels have been shown to have a 
faster RBC velocity than those more distal to the primary vessel (T. N. Kim et al., 2012), 
primary vessels were tracked to branch points to ensure that only secondary vessels were 
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analysed. This helped to ensure that the same level of the vascular tree was being analysed 
across mice and surgery groups, thus helping to limit speed variations. Care was also taken to 
position linescans away from vessel branch points to help limit the influence of turbulent blood 
flow on velocity measures.  
BCAS is achieved through the application of micro-coils to both the common carotid 
arteries delivering blood to the brain. Here we have identified that blood flow is affected within 
both leptomeningeal veins and arteries. Giving evidence to suggest that blood flow speeds are 
affected throughout the vascular tree following BCAS. Thus, lending support to the theory that 
blood flow is reduced throughout the brain and not preserved through compensatory 
mechanisms. 
 
5.4.2 BCAS leads to impaired arterial pulsation 
Vascular pulsation is a mechanism proposed to be fundamental to paravascular cerebral 
spinal fluid-interstitial fluid exchange, such clearance pathways function to remove harmful 
waste products, such as Aβ, from the brain (Carare, Hawkes Ca Fau - Jeffrey, Jeffrey M Fau - 
Kalaria, Kalaria Rn Fau - Weller, & Weller, 2013; Jeffrey J. Iliff et al., 2013b; Laman & 
Weller, 2013). 
Dysfunctional waste clearance could result in harmful metabolic by-products or 
neuroinflammatory molecules being present within the brain for extended periods of time. The 
accumulation of such harmful molecules could contribute to prolonged neuroinflammatory 
environments leading to damage and dysfunction. In the present study we made use of high 
temporal resolution in vivo multiphoton line scanning to allow the assessment of vascular 
pulsation within an array of components of the vascular tree. Vascular pulsation was found to 
be significantly reduced within leptomeningeal arteries, with no BCAS related changes 
observed in the other vessels analysed. Thus, indicating a specific susceptibility within the 
leptomeningeal arteries. Interestingly, although vascular pulsation within leptomeningeal 
arteries was found to impaired, the frequency at which these vessels were pulsing was shown 
to be increased following BCAS. This is likely an attempt to compensate for the lack of 
pulsatory drive through an increase in pulsatory frequency. This compensatory mechanism, 
however, was shown to be insufficient to rescue pulsation deficiencies following BCAS.  
Previous research into paravascular clearance pathways in response to BCAS, 
demonstrated significantly impaired waste clearance mechanisms (Appendix Figure 1). In 
agreement with these findings, impaired glymphatic influx alongside impaired arterial 
pulsation, were also identified following 30-minutes of unilateral ligation of the internal 
carotid artery (J. J. Iliff et al., 2013). However, the pulsation deficit was identified specifically 
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within penetrating arteries following unilateral ligation, in contrast to the leptomeningeal 
artery deficit identified here following BCAS surgery. This difference most likely reflects the 
source of insult, as BCAS is specifically restricted to the common carotid arteries whereas 
unilateral ligation impacts the internal carotid artery. Taken together these data demonstrate 
that arterial pulsation is a predominant driver of CSF-ISF exchange. Therefore, reductions in 
arterial pulsation, as a result of cerebrovascular disease, has the potential to impair waste 
clearance mechanisms allowing the build-up of toxic molecules, such as Aβ, within the aged 
brain (Hawkes, Jayakody N Fau - Johnston, Johnston Da Fau - Bechmann, Bechmann I Fau - 
Carare, & Carare, 2014). In support of this, mechanical compliance of human posterior 
cerebral arteries was shown be impaired within aged patients, which was associated with 
elastin loss and impaired responses to changes in pressure (Fonck et al., 2009). Interestingly, 
human population-based studies have also demonstrated a link between common carotid 
arterial stiffness and the occurrence of cerebral microbleeds (Ding et al., 2015). Such 
microbleeds are also identified following prolonged (6-month) BCAS in mice and therefore 
pulsatory deficiencies could potentially be the underlying cause (Holland et al., 2015).  
It is important to note however, that in the present set up we are unable to rule out the 
contribution of cardiac derived vascular pulsations. Historically, perivascular drainage was 
assumed to be driven solely by the cardiac rhythm as drainage was found to cease upon cardiac 
arrest (Weller, Djuanda E Fau - Yow, Yow Hy Fau - Carare, & Carare, 2009). Mathematic 
modelling and in vivo multiphoton experiments, however, demonstrate that cardiac pulsation 
would not provide sufficient motive force and that spontaneous vasomotor contraction and 
relaxation of smooths muscle cells is likely the primary driver of perivascular drainage (Aldea, 
Weller, Wilcock, Carare, & Richardson, 2019; Diem et al., 2017; van Veluw et al., 2020). 
Overall, these data demonstrate that arterial pulsation is specifically impaired following 
BCAS, which could lead to detrimental inflammatory responses through impaired waste 
clearance mechanisms, leading to the build-up of toxic molecules.   
 
5.4.3 BCAS leads to increased leukocyte trafficking, indicative of 
endothelial activation 
Endothelial activation can occur in response to an array of stimuli leading the increased 
surface expression of adhesion molecules (Videm & Albrigtsen, 2008). Adhesion molecules 
on the surface of activated endothelial cells act to interact with leukocytes travelling within 
the blood stream. Such endothelial-leukocyte interactions trigger down-stream 
proinflammatory signalling cascades, as well as in some cases leukocyte transmigration into 
the brain (Schnoor et al., 2015). 
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In the present study leukocyte trafficking was assessed within leptomeningeal veins and 
arteries of mice following 1-month of BCAS. A significant increase in the number and 
frequency of leukocytes trafficking was observed within leptomeningeal veins following 
BCAS surgery. This finding is in agreement with previous research in models of BCAS and 
cerebral ischemia which report a significant increase in leukocyte trafficking following CBF 
reductions (Kataoka, Kim Sw Fau - Plesnila, & Plesnila, 2004; Yata et al., 2014). A key 
difference between the current study and the past literature is the timing of observations 
following CBF reductions. Yata et al report a steady reduction in leukocyte trafficking from 1 
day to 2-weeks following BCAS. Therefore, in our milder BCAS model it is likely that 
leukocyte trafficking behaviours occur later following CBF reductions, allowing trafficking to 
be still observable 1-month following surgery.  
In the present study we identified very little evidence of leukocyte trafficking within the 
leptomeningeal veins of sham mice. Which is in agreement with previous research that found, 
under normal conditions, leukocyte trafficking within leptomeningeal veins to be extremely 
rare or even entirely absent (Kataoka et al., 2004; Yata et al., 2014). Leukocyte trafficking 
within leptomeningeal arteries was also found to be at extremely low levels within both sham 
and BCAS mice. These findings are in agreement with the previous literature (Kataoka et al., 
2004; Yata et al., 2014) and is consistent with the widely regarded notion that post capillary 
venules are the primary site of vascular permeability in response to inflammation (dela Paz & 
D’Amore, 2009). An observation which has been attributed to the fact that the venous 
vasculature possess a slower flow rate, thinner walls and fewer tight junctions in comparison 
to their arterial counterparts and therefore is better suited to the dynamics of leukocyte 
trafficking (dela Paz & D’Amore, 2009).  
The studies detailed within chapters 3 and 4 have clearly demonstrated that endogenous 
brain microglia are key drivers of neuroinflammation and white matter damage following 
BCAS. However, the signalling mechanisms by which microglia become activated and 
proliferate in response to BCAS remain unclear. Within the present study leptomeningeal 
veins were shown to have increased leukocyte trafficking following BCAS, indicating 
increased endothelial activation. In response to certain stimuli, such as severe cerebral 
hypoperfusion, leukocytes have been shown to cross the BBB leading to neuroinflammation, 
neuro-glial-vascular unit disruption and the onset of white matter pathology (Huang et al., 
2010; Yata et al., 2014). Leukocyte adhesion to the endothelial wall alone, without 
extravasation into the brain, has also been shown to lead to downstream signalling facilitating 
the recruitment and activation of microglial cells (H. Wang et al., 2015). In support of this 
connection, microglial cultures exposed to endothelial cell media, following hypoxic 
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challenge, showed a switch to an amoeboid conformation associated with the release of pro-
inflammatory molecules, inhibited migration and phagocytosis as well as increased neuronal 
toxicity (Xing, Li, Deng, Ning, & Lo, 2018). As additional evidence for a link between 
endothelial activation and microglial activation, aged blood was found to impair hippocampal 
neural precursor activity and activate microglia via increased endothelial VCAM1 expression 
(Yousef et al., 2019). Interestingly, recent evidence has demonstrated that microglial 
dynamically interact with vessels, through the extension of processes to occupy areas void of 
astrocytic end-feet, through Cx3Cr1 signalling mechanisms (Mondo et al., 2020). This new 
evidence further elucidates endothelial-microglial cross talk and could help explain the lack 
of microglial responses observed within Cx3Cr1 receptor heterozygous mice following BCAS, 
as described in chapter 4.  
Previous studies have demonstrated impaired clearance mechanisms in response to BCAS 
(Appendix Figure 1) which is likely the result of impairments in arterial pulsation that were 
identified here. Impaired waste clearance from the brain could lead to the prolonged presence 
of harmful metabolites, reactive oxygen species as well as neuroinflammatory mediators 
(Jeffrey J. Iliff et al., 2013b). These molecules have the potential themselves to activate 
microglial cells and could trigger neuroinflammatory responses following BCAS.  
The present study, therefore, demonstrates evidence of endothelial activation and impaired 
arterial pulsation following BCAS. This data is significant as it adds support to the growing 
body of human evidence challenging the view that reduced blood flow post-stenosis is the only 
major contributor to VCI (Alhusaini et al., 2018; Aribisala et al., 2014; Shi et al., 2020; Joanna 
M. Wardlaw et al., 2017). Thus, highting that reduced CBF is just one of the consequences 
following BCAS surgery, and that additional vascular mechanisms, such as impaired pulsation 
and endothelial activation, could also be significantly contributing to downstream 
mechanisms.  
 
5.4.4 Study limitations and future directions 
In the present study leukocyte trafficking was found to be significantly increased following 
BCAS, indicating an increase in endothelial activation. It would, however, be important in 
future experiments to confirm this finding through the assessment of adhesion molecule 
expression. In the current study an attempt was made to assess ICAM-1 expression through 
multiphoton microscopy with the use of a PE-conjugated antibody. If successful this would 
have allowed the speed of RBC velocity, pulsation, leukocyte trafficking and ICAM-1 
expression to all be determined within the same vessel. Early imaging sessions however, 
demonstrated that ICAM-1 florescence was significantly influenced by the clarity of the 
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cranial window, with increased laser power resulting in increased ICAM-1 signal (data not 
shown). As a result, ICAM-1 expression was not quantified within the present study. Previous 
BCAS studies, however, demonstrated a significant increase in ICAM-1 expression, 
subcortically, over-time following surgery (Kitamura et al., 2017). Though, this analysis was 
not restricted to blood vessels and was also not conducted within the cortex, which is the region 
in which leukocyte trafficking was assessed in the present study. In future studies, endothelial 
activation could be assessed within the cerebral cortex through immunohistochemical staining 
with ICAM-1/VCAM-1 alongside a vascular marker such as collagen IV. Increased co-
localisation of markers following 1-month of BCAS would strengthen evidence for increased 
endothelial activation following BCAS.  
In previous studies it has been shown that leukocyte plugging can occur, following BCAS, 
which leads to the cessation of blood flow through individual capillaries (Yata et al., 2014). 
This is a phenomenon that was not assessed within the present study, however given the 
significant increase in leukocyte trafficking within leptomeningeal veins, following BCAS 
surgery, it is likely that such events are occurring here post-BCAS. It would therefore be 
interesting in future studies to analyse these behaviours as leukocyte plugging leads to a 
complete cessation in blood flow and therefore could be a mechanism by which BCAS could 
mediated ischemic conditions within these areas. Such changes could serve as an important 
explanation as to why sub-regional vulnerability is evident within the BCAS model, which has 
shown specific white matter and thalamic susceptibility.  
A limitation of the present study is the lack of direct evidence demonstrating endothelial-
microglial crosstalk following BCAS. In future studies multiphoton microscopy could be used 
to monitor microglial-endothelial interactions following BCAS. For example, structural z-
stacks could be carried out, longitudinally across multiple imaging sessions, within areas of 
reduced RBC velocity following surgery. Such images would allow for 3D reconstructions to 
be generated allowing endothelial-microglial contact to be assessed chronically, as well as the 
structural evaluation of microglial cells to help provide a temporal profile of phenotypical 
changes during the progression of cerebral hypoperfusion. Alongside this, microglial and 
endothelial cells could be isolated via FACS at multiple timepoints following BCAS surgery 
and analysed through RNA sequencing methods (Swartzlander et al., 2018). Such an in-depth 
analysis at multiple stages following BCAS would help elucidate the order of responses and 
help identify signalling mechanisms by which endothelial cells could stimulate microglial 
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5.5 Conclusion 
The present study demonstrates that reduced CBF is just one of the consequences following 
BCAS surgery, and that additional vascular mechanisms, such pulsatory dysfunction and 
endothelial activation, are likely to be key contributors to downstream neuroinflammation, 
white matter damage and cognitive dysfunction. Reduced CBF, impaired vascular pulsation, 
and endothelial dysfunction have all been implicated in the pathogenesis of human VCI. The 
present evidence, therefore, highlights BCAS surgery in mice as an accurate model for the 









6.1    CSF1R as a target for therapeutic intervention 
The approaches currently used for dementia treatment can only temporarily relieve 
symptoms, with no therapeutic options available that have the ability to halt or reverse disease 
progression (Dong, Li, Cheng, & Hou, 2019). Evidence from human post mortem studies 
demonstrates that the vast majority, up to 75%, of old aged dementia cases show mixed 
pathology, thus highlighting the need for multi-faceted therapeutic approaches (Pathological 
correlates of late-onset dementia in a multicentre, community-based population in England 
and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and 
Ageing Study (MRC CFAS), 2001). Despite such evidence, the primary focus for the 
development of disease altering dementia treatment has been concerned with the removal of 
Aβ aggregates, with such treatments found to be largely unsuccessful at clinical trial. The 
ineffectiveness of amyloid targeted treatments likely reflects the need for therapeutic 
approaches that target all aspects of mixed dementia syndromes. A theory which is further 
strengthened by the fact that neuroinflammation, synapse loss, and neurofibrillary tau tangles 
more accurately correlate to cognitive decline (Gray, Kinghorn, & Woodling, 2020; Ismail et 
al., 2020; Nelson et al., 2012). 
Pharmacological approaches targeting inflammation have been considered for the 
treatment of dementia. The first indication that anti-inflammatory drugs may have a potentially 
beneficial impact, came from observations within a rheumatoid arthritis cohort that reported 
an unexpectedly low dementia prevalence (McGeer Pl Fau - McGeer, McGeer E Fau - Rogers, 
Rogers J Fau - Sibley, & Sibley, 1990). Further support for such a link came from the 
Rotterdam study which demonstrated, within middle age and elderly people, a considerable 
reduction in AD risk when anti-inflammatory drugs were taken for at least 2-years (in t' Veld 
et al., 2001). Non-steroidal anti-inflammatory drugs, however, have not always been shown to 
have a beneficial impact (Imbimbo, Solfrizzi, & Panza, 2010). Such negative findings likely 
reflect the heterogenous nature of dementia, the significance of intervention timing within 
disease progression, as well as the fact that these approaches are broad spectrum and therefore 
do not specifically target the key inflammatory mediators and mechanisms. Despite 
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compelling evidence for the role of microglial proliferation and activation in dementia onset 
and progression, microglial specific treatments are yet to be tested in human patients.  
The experiments presented within the first chapter of this thesis utilised a pharmacological 
approach to investigate the role of microglial proliferation, in the development of white matter 
damage and cognitive impairment, following BCAS surgery. The results demonstrate that 
microglial proliferation is fundamental to white matter damage and cognitive impairment 
following BCAS, as blocking microglial proliferation was found to reverse these effects. Such 
findings are promising, given that GW2580 treatment only blocks microglial proliferation, and 
does not deplete the existing microglia population even at high doses (Adrian Olmos-Alonso 
et al., 2016b). Therefore, providing a distinct advantage over microglial ablation approaches, 
as residual microglial will still be able to fulfil crucial homeostatic functions following 
treatment.  
An important consideration, however, is the fact that human CSF1R mutations lead to a 
autosomal dominant condition known as hereditary diffuse leukoencephalopathy with 
spheroids, which is characterised by white matter damage as well as behavioural and cognitive 
abnormalities (Rademakers et al., 2011). CSF1R human mutations are found within the 
tyrosine kinase domain of the receptor (Rademakers et al., 2011), which is the same target by 
which GW2580 elicits its mode of action. These findings highlight the need for more 
comprehensive study of GW2580 treatment, as duration as well as developmental timing of 
treatment could be crucial to avoid potentially detrimental effects.  
An additional consideration regarding GW2580 treatment, is the current lack of 
understanding concerning the phenotypic state of residual microglial cells following treatment. 
As these cells may still be activated following BCAS and thus could potentially alter the 
capacity of microglia to carry out normal homeostatic functions. As mentioned, previously, 
following the completion of this study, bulk RNA sequencing has been carried out within the 
white matter to access the inflammatory environment following BCAS and GW2580 
treatment. RNA sequencing analysis demonstrated reduced expression of genes associated 
with inflammatory signalling such as Tlr2, Tlr4, Tlr13, Itgam, Ccl6, and Ccl9 within BCAS 
mice following GW2580 treatment. Additionally, microglial and endothelial-enriched genes 
set were found to be significantly increased following BCAS and subsequently reduced 
following GW2580 treatment. Implicating microglial proliferation in the signalling of 
endothelial related pathways following BCAS. Minor changes were also reported within 
oligodendrocyte progenitor cell and astrocytic-enriched gene sets following BCAS, however 
these were found to be unaffected following GW2580 treatment. Previous studies have also 
suggested that GW2580 treatment leads to an overall shift of inflammatory profile from pro- 
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to anti-inflammatory (Gomez-Nicola et al., 2013; A. Olmos-Alonso et al., 2016). Such 
findings therefore demonstrate that alongside a block of microglial proliferation, GW2580 is 
able to reduce pro-inflammatory signalling which likely implicates all of the components of 
the neuro-glial-vascular-unit. Such mechanisms, however, still lack the cell specific 
information needed to help determine exactly how residual microglial cells are behaving 
following GW2580 treatment. Furthermore, when microglial heterogeneity is considered, the 
true effects of microglial action within the context of BCAS remains to be fully elucidated.   
 
6.2    Microglial heterogeneity 
An important overall consideration for the role of microglial proliferation and activation in 
the context of VCI is the emerging evidence for intra- and inter-regional microglial 
heterogeneity within the brain. The emergence of single cell RNA sequencing techniques has 
provided unprecedented access to the genetic encoding that is occurring within individual 
cells. Studies analysing microglia isolated from cortical tissue biopsies taken from epileptic 
and MS patients, as well as cancer-free marginal tissue, demonstrated 14 distinct microglial 
subpopulations. These subpopulations were found to represent disease associated, pro-
inflammatory, and homeostatic microglial clusters (Olah et al., 2018). Such approaches have 
also been applied to mice which helped to further demonstrate the sophisticated nature of 
microglial heterogeneity, through the identification of specific time, region, and context 
dependent microglial subpopulations (Hammond et al., 2019; Masuda et al., 2019). It will 
therefore be necessary in future studies for such approaches to be applied to the study of VCI 
to help further elucidate the spectrum of microglial changes, as well as the specific effects of 
drug modifying treatments. Such cell specific heterogeneity may also help to explain regional 
vulnerabilities evident in disease, such as the white matter vulnerability observed within VCI.  
 
6.3    Cx3Cr1eGFP reporter mice: A reliable model to assess 
microglial function in health and disease? 
The aim of chapter 2 was to use the Cx3Cr1eGFP microglial reporter line, alongside intravital 
imaging, to help further elucidate the role of microglia in disease progression following BCAS. 
The experimental findings, however, found Cx3Cr1 receptor signalling to be an important 
mediator of microglial proliferation and activation in response to BCAS. As demonstrated by 
a lack of proliferative, structural, or functional changes within microglial cells following 
BCAS surgery, which was associated with intact neurovascular coupling responses and spatial 
learning. These results therefore indicate that perturbation of Cx3Cr1 receptor signalling, 
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through the replacement of one gene copy with eGFP, is sufficient to significantly alter 
microglial responses following BCAS surgery.  
Such findings are significant on two grounds. Firstly, Cx3Cr1eGFP microglial reporter mice 
display abnormal responses under certain disease conditions and therefore should be used with 
caution in future experiments. Secondary, this is the first evidence to implicate Cx3Cr1 receptor 
signalling in the pathogenesis of VCI.  
Cx3CL1 (fractalkine) is a chemokine that has been shown to regulate microglial activation 
through binding to its only receptor, Cx3Cr1R. Cx3CL1 is constitutively expressed by normal 
neurons and binds to the Cx3Cr1R which is exclusively expressed on microglial cells. The 
fractalkine signalling system therefore represents a direct line of communication between 
neuron and microglial cells (J. K. Harrison et al., 1998). The traditional view of fractalkine 
signalling was that it functions to inhibit microglial activity (J. K. Harrison et al., 1998). A 
view point that came from evidence demonstrating that neuronal damage leads to a reduced 
fractalkine level in the immediate hours following injury, thus reducing Cx3Cr1R signalling 
that resulted in the recruitment and activation of microglia (Desforges, Hebron, Algarzae, 
Lonskaya, & Moussa, 2012). More recently, however, alterations within Cx3Cr1R signalling 
has been reported to sequester microglial responses leading to beneficial effects in various 
disease conditions (Ho et al., 2020; A. McDonough et al., 2019). Such findings mirror our 
own, with a supressed microglial proliferative response within Cx3Cr1eGFP/+ mice following 
BCAS. Thus, highlighting that fractalkine signalling has an important role to play in the 
activation of microglia, which may be pro or anti-inflammatory in nature depending on the 
stimulus.  
Having demonstrated that the removal of 1 Cx3Cr1R gene copy is sufficient to alter normal 
Cx3Cr1R signalling, Cx3Cr1eGFP microglial reporter mice should be used with caution in future 
experiments. The fact that Cx3Cr1eGFP reporter mice are the most routinely used microglial 
reporter line (Wieghofer et al., 2015) is therefore concerning, as results should be readdressed 
in the context of potential abnormal microglial responses. 
 
6.4    Co-morbid models: Essential for the discovery of clinically 
relevant mechanisms? 
Within chapter 4 the addition of amyloidosis, as a co-morbidity alongside BCAS surgery, 
was found to lead to no alterations in structural, functional, or proliferative microglial 
responses within Cx3Cr1eGFP mice. Spatial learning and memory, however, was found to be 
impaired within Cx3Cr1eGFPApp23 mice. Furthermore, neurovascular coupling was found to be 
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impaired within Cx3Cr1eGFPApp23 mice following BCAS, indicating the presence of additional 
harmful mechanisms outside the role of microglia.  
Given the increasing evidence to suggest a significant overlap between dementia syndrome 
pathologies (Toledo et al., 2013), the need for accurate models of mixed dementia grows. 
Although, disease models such as BCAS can provide a fundamental understanding of key 
pathogenic mechanisms that lead to damage and impairment, the true nature of these events 
may in fact be very different in the face of multiple co-morbidities. For example, within 
chapter 4, neurovascular coupling was found to be impaired within Cx3Cr1eGFP/+App23 mice 
following BCAS, despite a lacking microglial response. In studies within wild-type C57BL/6J 
mice, neurovascular coupling impairments are found to be significantly correlated to 
microglial expansion following BCAS, implicating a causative role of microglia in such 
dysfunction (Duncombe, Kitamura, et al., 2017). These results therefore indicate an alternative 
mechanism of neurovascular coupling impairment following BCAS when amyloidosis is 
present as a co-morbidity. In future research therefore, more consideration should be made to 
mixed models of dementia to allow the study of pathogenic mechanisms in more clinically 
relevant models.  
 
6.5    BCAS: A more accurate model of human VCI than originally 
anticipated  
The BCAS model has been extensively studied and shown to recapitulate pathological 
features relevant to the study of human VCI (Duncombe, Kitamura, et al., 2017). Due to the 
physical nature of the BCAS surgery, to date these downstream effects have almost exclusively 
been attributed to chronic reductions in CBF. Cerebral hypoperfusion is undoubtable a key 
contributing factor to downstream pathology within the BCAS model. However, within 
chapter 5, arterial pulsation was found to be significantly impaired following BCAS surgery. 
This provided the first clear evidence to suggest that BCAS is more than simply a model of 
cerebral hypoperfusion, and therefore, downstream damage and dysfunction is not wholly the 
result of reduced CBF. Vascular pulsation has been proposed to be a key mediator of waste 
clearance from the brain (Jeffrey J. Iliff et al., 2013b). Such findings are significant as they 
highlight additional mechanism by which BCAS can significantly contribute to damage and 
disease progression. Such as through the aberrant clearance of potentially harmful waste 
products from the brain. Given that there is also clinical evidence to suggest pulsatory 
impairments associated with advanced age (Fonck et al., 2009), impaired pulsation leading to 
dysfunctional clearance pathways could represent a key pathogenic mechanism within VCI 
and dementia that requires additional research.  
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6.6    Final Conclusions 
In conclusion the data presented within this thesis highlights microglia as fundamental 
mediators of downstream white matter damage and cognitive impairment following BCAS. 
The effectiveness of GW2580 treatment demonstrates the value of such tools to the discovery 
of key pathogenic mechanisms, as well as highlighting microglial proliferation as a therapeutic 
target for the treatment of VCI. Additionally, the lack of microglial responses within 
Cx3Cr1eGFP/+ mice highlights Cx3CL1-Cx3Cr1 signalling as a potentially crucial pathway for the 
regulation of microglial responses, following BCAS surgery. Furthermore, studies have 
demonstrated that BCAS surgery is an accurate model of human VCI, with evidence of 
reduced CBF, deficient pulsation, and endothelial dysfunction. Future studies should, 
therefore, consider all BCAS mediated vascular changes when investigating pathogenic 




Figure 6.1 Graphical illustration of the main thesis findings. Image created with 
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Appendix Figure 1 Impaired paravascular drainage following BCAS. Poster generated 
and presented by Dr Mosi Li, demonstrates impairments in paravascular drainage pathways 
following BCAS which is associated with impaired arterial pulsation.  
